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CHAPTER 1
INTRODUCTION
Background
In patients with (insulin-dependent) diabetes mellitus (IDDM) , the development of
1
nephropathy, hallmarked by the presence of proteinuria in excess of 0.5 g/day, is a serious
complication. Diabetic nephropathy (DN) leads to progressive deterioration  in kidney
function. Moreover, DN is associated with a highly increased incidence of cardiovascular
disease. Renal failure and cardiovascular disease are in fact competing risks in these
patients, making renal replacement therapy only necessary in those who survive
cardiovascular complications. The natural course of DN has changed over the last decades.
Early and aggressive treatment has been shown to retard renal function loss and, in
particular, to improve survival in these patients. Despite the large progress in the treatment
of DN, its etiology is yet incompletely understood and it is not possible to prevent this
complication. There is evidence that both hereditary, as well as metabolic and
haemodynamic factors contribute to its pathogenesis. Knowledge of these factors will
identify patients at risk for developing nephropathy. The concept of microalbuminuria, i.e.
a urinary albumin excretion rate between 20 and 200 µg/min or 30 to 300 mg/day,  as an
early clinical sign of diabetic renal involvement, has greatly improved our understanding
of the natural course of diabetic renal disease and has enabled the development of early
intervention and prevention strategies.
This thesis aims to evaluate the influence of norepinephrine (NE) and the growth-
hormone insulin-like growth factor-I (GH-IGF-I) axis on renal function. Both substances
belong to hormonal systems that control renal function in opposite directions: NE causes
renal vasoconstriction, whereas stimulation of the GH-IGF-I-system induces renal
vasodilation. The early stages of diabetic renal involvement are characterised by imbal-
ances in glomerular vasodilatation and vasoconstriction. Against this background, the
possible role of these hormonal factors in DN is investigated.
This chapter outlines the epidemiology, the functional stages, the pathogenesis and
the therapeutic aspects of renal disease in IDDM. Several aspects of the pathogenesis of
DN are more extensively overviewed in sections on the effects of NE and the GH-IGF-I-
system on kidney function. Abnormalities in sodium and volume homeostasis in IDDM,
and the role of 11$-hydroxysteroid dehydrogenase (11$-HSD) in protecting the mineral-
ocorticoid receptor from activation by cortisol is briefly recapitulated.
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Epidemiology of diabetic renal disease
In the early cohorts of IDDM patients, diagnosed between 1933 to 1959, the
cumulative incidence of nephropathy amounted to 41-43% after 25 years of diabetes
duration [1,2]. In these cohorts, nephropathy was associated with a 10-year mortality rate
of 50 to 77% [1,2]. Comparing the 25 years cumulative incidence of nephropathy in
IDDM diagnosed between 1933-1942 and 1953-1962, a remarkable decrease was noted
from 41% to 27% [3]. A very spectacular decline up to 28%, 8.9% and 5.8% in IDDM
patients diagnosed between 1961-1965, 1966-1970, and 1971-1975 has been reported in
metabolically wellcontrolled Swedish patients [4], but in Danish cohorts a 35% incidence
is still observed [5]. 
 Survival in IDDM with proteinuria has improved dramatically. In Denmark, IDDM
patients with onset of proteinuria between 1957 and 1973 had a mortality rate that was 40
times higher than in patients without proteinuria [6]. After onset of proteinuria, the 8 years
survival rate of such patients was only 48%. In comparison, 8 years survival in IDDM
patients with onset of proteinuria between 1974-1978 and 1979-1983 had increased to
82% and 87%, respectively [7,8].
The decline of incidence in overt proteinuria and cardiovascular mortality has been
attributed to both improved blood pressure regulation and metabolic control [3-5]. In the
older epidemiological studies [1,2,6], arterial hypertension was not treated since it was not
recognised to have prognostic significance. Glycaemia could also not be strictly controlled
since home-based blood glucose and glycosylated haemoglobin measurements were not
yet available [9]. Remarkably, the peak incidence in proteinuria (10 to 15 years after the
onset of IDDM) has remained unchanged over the last decades [1-6]. 
It is noteworthy that there is also a decline in the incidence of progression from
microalbuminuria to overt proteinuria in IDDM. Previously, 80 to 90% of microalbumi-
nuric IDDM patients progressed to overt nephropathy [10,11]. Recent estimates revealed
that during the last 10 to 15 years only 30% of microalbuminuric patients progressed to
clinical proteinuria [12-16]. This suggests that better metabolic control and blood pressure
regulation are currently achieved in many microalbuminuric IDDM patients. The Diabetes
Control and Complication Trial (DCCT) indeed showed that intensive insulin treatment
reduces the progression of microalbuminuria in IDDM [17,18]. Furthermore, several trials
unequivocally demonstrated that early treatment with antihypertensive drugs can arrest or
delay the progression of microalbuminuria in normotensive microalbuminuric IDDM [19-
22]. Only 10% of microalbuminuric patients treated with ACE-inhibitors developed overt
proteinuria over an 8 years period, which is remarkably different from the 40% incidence
of microalbuminuria in patients not treated with ACE-inhibition [22]. Longer follow-up
will clarify whether intensive insulin treatment [17,18] and early ACE-inhibition treatment
[19-22] will really prevent or only postpone DN. From an optimistic point of view, the
aforementioned estimates suggest a decline in incidence and prevalence of nephropathy in
the next decades. 
Functional stages of diabetic renal involvementIntroduction 5
Table 1. Functional stages of diabetic renal involvement
       GFR   Ualb.V   MAP
Stage 1 Hyperfunction          88      = (8)     =      Nephromegaly
*
Stage 2 Silent phase          8/=     =(8)     =      Early histological changes
*
Stage 3 Microalbuminuria      =       8(88)   =(8)  Albumin excretion 20-200 µg/min 
** **
          (30-300 mg/day)
Stage 4 Nephropathy           9          88        8       Dipstick positive (albuminuria > 
        200 µg/min, proteinuria>500 mg/day)
Stage 5 End stage renal failure 99        88        88      Dialysis support or transplantation
GFR: glomerular filtration rate, Ualb.V urinary albumin excretion rate, MAP: mean arterial
pressure. * can be present during poor metabolic control, ** aggravates during exercise.
The renal changes in IDDM patients are classically divided into 5 functional stages
[23] (Table 1). An increased kidney size due to glomerular enlargement and tubular
hypertrophy and hyperplasia (renal hypertrophy/hyperplasia), with concomitant increases
in glomerular filtration rate (GFR) and renal blood flow (glomerular hyperfiltration/
hyperperfusion) are typical for stage 1 diabetic renal involvement. Transient increases in
urinary albumin excretion can be seen at diagnosis of IDDM and often reverse after
institution of insulin therapy. Physical exercise testing is associated with abnormal
albumin excretion rates at this stage of renal involvement. In a subset of patients, renal
hyperfunction persist for years, especially during poor metabolic control.
Stage 2 is characterised by early histologic alterations such as glomerular basement
membrane (GBM) thickening and mesangial expansion, that are generally present after 2
years of disease duration. Except for the aforementioned exercise provocation, albumin
excretion rate is normal, so that the glomerular filtration barrier against the loss of
macromolecules is assumed to be intact. However, some studies have found an increased
urinary excretion of the much larger and neutrally charged IgG in normoalbuminuric
IDDM patients [24]. In the context of an intact GBM this finding is not well understood.
GFR is either normal or elevated, comparable to stage 1 involvement. There are no
reliable methods to diagnose this stage of renal involvement and the early histologic
abnormalities have been found to correlate poorly with future progression to DN [25].
Also, the increase in urinary albumin excretion induced by exercise lacks any predictive
value on the future development of nephropathy.
Stage 3 diabetic renal involvement, also designated as incipient diabetic nephropath-
y, is characterised by a persistently raised albumin excretion rate (micro-albuminuria),
which typically develops after 5 to 15 years of diabetes duration in a subset of IDDM
patients. The raised albumin excretion is ascribed to an early impairment of the glomerular
filtration barrier against the loss of macromolecules. A decrease in the negatively charged
heparan sulfate proteoglycan (HS-PG) of the GBM is one of the biochemical alterations
that is likely to be responsible for the increased loss of albumin, but haemodynamic factors
may be involved as well [26]. GFR is remarkably unaltered or may be elevated inChapter 1 6
subgroups of patients. Blood pressure may still be below the normal range, although slight
increases in night and day-time blood pressure have been reported with 24-hour
ambulatory blood measurements [27]. Exercise causes an exaggerated blood pressure rise,
further indicating abnormalities in blood pressure regulation at this stage of renal
involvement.
The clinical hallmark of stage 4 involvement is the presence overt proteinuria in
excess of 0.5 g/day. Arterial hypertension is almost always present and contributes impor-
tantly to the loss of kidney function [28]. Unless arterial hypertension is treated, GFR
declines at a rate of approximately 1 ml/min per month. Besides more outspoken thicken-
ing of the GBM and mesangial expansion due to increased formation of extracellular
matrix, histologic examination now shows arteriolar hyalinosis and an increased number
of sclerosed glomeruli, appearing in a diffuse and nodular pattern, as first described by
Kimmelstiel and Wilson [29]. The progressive nature of nephropathy results in generalised
glomerulosclerosis ultimately leading to end-stage renal disease. Stage 5 diabetic renal
involvement represents end stage renal failure requiring dialysis or renal transplantation.
Microalbuminuria: a predictor of DN and cardiovascular disease
Under normal circumstances small amounts of albumin pass through the glomerular
filtration membrane. Most of the filtered albumin undergoes tubular reabsorption, so that
the final urinary albumin excretion rate is very low [30]. With the introduction of sensitive
assays in the early seventies it became possible to detect urinary albumin at these low
concentrations [31,32]. It was soon established that elevations in urinary albumin
excretion (microalbuminuria) were typically present in the years preceding DN [10,11].
Moreover, it has been established that the presence of microalbuminuria carried an
increased risk on cardiovascular complications [33,34]. These findings led to the concept
that microalbuminuria represents the incipient stage of diabetic renal disease [23,35-39].
The association with cardiovascular complications suggested that the presence of
microalbuminuria could also be an indicator of generalised vascular damage [37]. At
present, microalbuminuria is the first detectable clinical sign of an increased risk of DN
and of cardiovascular disease in IDDM [36,38,39].
Despite the great advance to measure proteinuria at low levels with assays that have
low coefficients of variation [31], measurement of urinary albumin excretion rate is
complicated by a large biological variability [38-40]. Day-to-day variation in albuminuria
is as high as 30-50%, and there is considerable chance that a random urine sample will
show supra normal values. Thirty-eight % of patients with IDDM experience sporadic
episodes of microalbuminuria without developing persistent microalbuminuria [41].
Recent diagnosis, worsened metabolic control, systemic illness, urinary tract infection and
physical exercise are potential confounding factors that temporarily raise albumin
excretion [10,38,39]. While single urine measurements suffice for screening purposes,
there is general agreement that multiple urine collections are required to diagnose
microalbuminuria reliably [36,38,39,42]. An albumin/creatinine ratio in a random or early
morning urine sample of >3.5 mg/mmol is highly predictable for the presence of
microalbuminuria [38,40], although a lower cut-off level of 2.5 mg/mmol has been
proposed for firstly voided morning urine [39]. For definite evaluation ofIntroduction 7
microalbuminuria, three timed overnight urine collections can be used to avoid the effects
of daytime physical activities, but 2-4 hour daytime or 24 hour urine collections also give
reliable results [43]. Using overnight or timed day-time urine collections, albumin
excretion is expressed in µg/min and microalbuminuria is defined as levels between 20
µg/min and 200 µg/min [36,38,39]. In 24 hour urine collections an albumin excretion rate
between 30 to 300 mg/day indicates microalbuminuria. The lower level of 20 µg/min (or
30 mg/day) is clearly above the upper normal limit of 10 to 12 µg/min found in healthy
subjects [38,39,44]), but the cut-off level of 20 µg/min has been chosen because of its
predictive value to discriminate patients at risk to develop nephropathy [36,38,39]. Thus
there is a grey area between 10 and 20 µg/min (15-30 mg/day). The upper value of 200
µg/min (300 mg/day) corresponds to a total protein excretion of 0.5 g per day.
If microalbuminuria is correctly diagnosed, 30% of these patients will progress to
overt proteinuria in 10 years [12-16,19-22,36,38]. A normal albumin excretion rate
excludes progression to nephropathy with a 99.5% chance [41]. It has been reported that
patients with an albumin excretion rate between 70 to 200 µg/day are particularly likely to
progress, whilst patients with a lower albumin excretion rate between 20 to 70 µg/day are
more likely to remain stable [12,42]. Thus, microalbuminuria is a very sensitive but not
specific measure to identify patients at risk of progression to nephropathy. 
The increased risk of cardiovascular morbidity and mortality in microalbuminuric
IDDM patients indicates that elevations in urinary albumin excretion have much broader
consequences than representing a risk marker for the development of nephropathy
[33,35,37-39]. This has been brought into a wider perspective by demonstrating that
microalbuminuria also predicts early mortality in non-insulin dependent diabetes mellitus
(NIDDM) as well as in the general population [45-47]. Apart from other well established
risk factors, microalbuminuria appears to be a powerful indicator of cardiovascular disease
[48]. The association between microalbuminuria and ischaemic heart disease is intriguing,
and may be part of the metabolic syndrome of which alterations in blood pressure
regulation are an important component [49]. The clear association between elevations in
blood pressure and microalbuminuria in patients with IDDM as well as in patients with
essential hypertension, and the fact that albumin excretion acutely falls after blood
pressure lowering, support a haemodynamic basis in the genesis of micro-albuminuria
[9,42,50]. On the other hand, an atherogenic lipoprotein profile [51,52], increased plasma
concentrations  of clotting factors and decreased fibrinolysis [51,54], endothelial dysfunc-
tion [53-55] and insulin resistance [56] are other manifestations of the metabolic syndrome
that have been documented in microalbuminuric IDDM patients.
Pathogenesis of diabetic renal disease
The pathogenesis of structural and functional abnormalities in DN is likely to be
multifactorial (Table 2). In this section metabolic and haemodynamic abnormalities thatChapter 1 8
Table 2. Mechanisms and factors implicated in the pathogenesis of diabetic nephropathy
1. Metabolic consequences of hyperglycaemia:
  Features: microcirculatory changes, glomerular basement membrane (GBM) thickening,
decreased heparan-sulfate-proteoglycan content of GBM, mesangial cell proliferation and
extracellular matrix production
Possible pathways: 
- upregulation of diacylglycerol (DAG) and protein kinase-C (PKC)
- nonenzymatic glycosylation: production advanced glycosylation products (AGE’s),
- polyol pathway: sorbitol accumulation, altered cellular redox state
Implicated intrarenal growth factors and cytokines:
- angiotensin II, endothelin, insulin-like growth factor I 
- platelet-derived growth factor-$, vascular endothelial growth factor,
- transforming growth factor-$ and other cytokines as IL-1$, IL-6, IL-8, TNF, IFN-( 
2. Altered renal haemodynamics: 
Features: increases in glomerular blood flow, intraglomerular pressure, filtration surface 
Mechanisms: diminished arteriolar resistance, imbalances in afferent/efferent tone,
 mesangial dysfunction 
Contributing factors: 
- hyperglycaemia and insulin 
- activated growth-hormone-insulin-like-growth-factor-I-axis
- hyperglucagonaemia 
- inadequate suppressed renin-angiotensin II system, increased angiotensin II reactivity
- altered sympathetic tone, increased norepinephrine reactivity 
- increased induction of nitric oxide versus disturbed endothelial function
- abnormal prostaglandin metabolism, increased levels of atrial natriuretic factor,
  upregulation of kinins 
- augmented tubular sodium reabsorption, increases in total exchangeable sodium and
  extracellular volume
3. Elevated lipid levels: glomerular lipid accumulation in glomerulosclerosis resembling
    atherosclerosis
4. Genetic Predisposition: genes involved yet unknown, only polymorphism in the ACE-gene
   identified as a marker of progression 
are considered to be implicated in the pathogenesis of DN are outlined. Furthermore, alter-
ations in lipoprotein metabolism and genetic factors that may influence the development
of DN are briefly described. Particular attention is paid to the renal effects of NE and the
GH-IGF-I-system.
Metabolic factors
Chronic hyperglycaemia is an inevitable consequence of IDDM and may induce
alterations in many cellular and molecular functions. The metabolic theories address
mechanisms by which elevated blood glucose levels may be causally involved in the
development of microvascular complications. 
First, the injurious effects of hyperglycaemia could be mediated via its effects on the
microcirculation. Elevated blood glucose levels induce arteriolar vasodilatation, increaseIntroduction 9
blood flow and raise hydrostatic pressure, impair vasoregulation and thereby fail to protect
target organs from increases in blood pressure. By such effects on the microcirculation,
particularly on capillary pressure, hyperglycaemia may be responsible for leakage of
plasma proteins and deposition of proteins in the walls of arterioles and capillaries and
thus induce damage to the kidneys [57,58]. 
A second pathway stresses the direct role for blood glucose to induce structural
glomerular abnormalities. Under experimental conditions, glucose has been demonstrated
to cause GBM thickening and mesangial cell proliferation [59,60], to increase extracellular
matrix production and synthesis of type IV collagen [61,62], and to decrease GBM density
of the negatively charged HSPG [63]. These effects may in part be mediated by the
expression of a matrix-producing cytokin, transforming-growth-factor-$ (TGF-$) [64].
More recently, it has been shown that upregulation of intracellular signal transduction via
stimulation of diacylglycerol (DAG) and protein kinase C (PKC), as present in diabetic
patients, can raise TGF-$ and other growth factors, like vascular endothelial growth
factor, angiotensin II and endothelin [65]. Interestingly, inhibition of this system by an
orally active PKC-$ isoform inhibitor has been shown to reverse the expression of TGF-$,
to decrease the production of type IV and VI collagen and to restore haemodynamic
abnormalities in diabetic rats [66]. These findings are in favour of an important role of the
PKC-transduction system through which elevated levels of blood glucose may be involved
in the pathogenesis of DN.
Third, hyperglycaemia is also associated with an increased non-enzymatic
glycosylation of long-lived proteins that may undergo Amadori rearrangement and thereby
lead to the irreversible formation of advanced glycosylation endproducts (AGE’s). AGE’s
have been demonstrated to induce mesangial expansion and increase type IV collagen
synthesis [67-69]. These effects may be mediated via specific AGE receptors [69], and are
prevented by neutralising antibodies or by aminoguanidine in experimental diabetes
[69,70]. 
Finally, hyperglycaemia causes an increased substrate delivery into the polyol path-
way that results in the accumulation of sorbitol and changes the cytosolic redox state. In
the polyol pathway, glucose is reduced to sorbitol by the enzyme aldose-reductase and
sorbitol is oxidised to fructose by the enzyme sorbitol dehydrogenase (Figure 1). Under
conditions of hyperglycaemia increased amounts of sorbitol are produced, as for instance
documented in diabetic kidneys. The accumulation of this compound has been proposed
to cause damage of renal tissue [71]. Another consequence of increased substrate delivery
into the polyol pathway is the accumulation of NADP  and NADH, leading to an increased
+
cytosolic cell ratio of free NADH/NAD  [72]. Such changes in redox state are also present
+
in hypoxic tissues. Since vasodilation and increased blood flow are characteristic early
vascular responses of tissue hypoxia and are also seen during hyperglycaemia, the so-
called pseudohypoxia theory argues that an altered cytosolic redox state may be involved
in the haemodynamic alterations and subsequent microvascular complications of IDDM
[72].D-GLUCOSE
NADPH
6PG 
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G6PDH 
6PGDH
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Figure 1. Reduction of glucose to sorbitol and oxidation of sorbitol to fructose in the sorbitol pathway.
Reduction of glucose to sorbitol by aldose reductase (AR) is coupled to oxidation of NADPH to
NADP . NADP  is reduced to NADPH by the hexose monophosphate pathway. Oxidation of sorbitol
+ +
to fructose by sorbitol dehydrogenase (SDH) is coupled to reduction of NAD  to NADH. The cytosolic
+
ratio of free NADH/NAD  is in equilibrium with lactate and pyruvate. G6P: glucose-6-phosphate;
+
6PG: 6-phosphogluconaat, and R5P: ribulose-5-phosphate.
Renal haemodynamic factors 
Elevations in GFR have long been recognised in patients with IDDM and can persist
for many years after the onset of diabetes [73-75]. The early stages of experimental
diabetes are also characterised by a state of glomerular hyperfiltration. Its possible
pathogenetic role became apparent when glomerular hyperfiltration, consequently to
experimental renal ablation, was found to induce glomerulosclerosis [76]. In a similar
way, a chronic increase in single nephron glomerular filtration (SNGFR) was associated
with the development of glomerulosclerosis and renal function loss in diabetic rats [77].
According to the equation GFR= kf(˛Pc-˛B), net hydraulic pressure (“Pc), net
oncotic pressure (“B), filtration surface area and hydraulic permeability (kf) determine
glomerular ultrafiltration [30]. Since GFR changes linearly with glomerular blood flow
under conditions of pressure equilibrium in the rat [30] and is highly correlated with
effective renal plasma flow (ERPF) in man [78], renal blood flow is considered a determi-
nant of GFR. Theoretically, a change in any of these factors could be involved in diabetic
hyperfiltration. Using the micropuncture technique, increases in glomerular blood flow,
intraglomerular pressure and ultrafiltration coefficient have been documented in
hyperfiltering diabetic rats [79-81]. Of these factors, the rise in intraglomerular capillary
pressure was shown to play a key role as pharmacological amelioration of intraglomerular
hypertension with ACE-inhibitors could be prevent glomerulosclerosis in these animals
[82-83]. The rise intraglomerular capillary pressure in diabetes has been attributed to
imbalances in afferent and efferent glomerular arteriolar tone, and to an increase in
systemic arterial pressure [80,81]. A diminished glomerular afferent tone and an increased
glomerular efferent constriction are vascular abnormalities that have been implicated in
the glomerular hypertension associated with diabetes [80,81]. 
The original assumption that intraglomerular hypertension directly causes glomeru-
lar damage appears to be an oversimplification since later studies have shown that
haemodynamic and non-haemodynamic factors are involved in the process ofIntroduction 11
glomerulosclerosis [84-87]. Nevertheless, an important role is still attributed to glomerular
hypertension, either as an initiator or as a conditional factor in a cascade of cellular events
that leads to glomerular damage. Several mechanisms have been proposed. First, chronic
pressure overloading of the capillary endothelial cell layer may lead to cell detachment,
GBM denudation, collagen exposure and consequently to platelet aggregation, fibrin
accumulation and intracapillary microthrombosis. Second, capillary dilation may disrupt
the attachment of podocytes to the GBM with the subsequent formation of subendothelial
deposits. Third, continuous stretching may induce mesangial cell proliferation and
extracellular matrix production by stimulating cytokin expression [85-87]. As a result,
either of these mechanisms may impair the glomerular filtration barrier and enhance
glomerular protein passage, which, in turn, might be toxic and accelerate glomerular
damage [88]. In a similar way, glomerular  accumulation of atherogenic lipoproteins could
contribute to the process of glomerulosclerosis [89]. 
The neurohumoral stimulus for the hyperfiltration phenomenon in diabetes is
unknown, although many factors could play a contributory role [81]. Moderate hypergly-
caemia increases GFR [90,91] and chronical lowering of blood glucose reduces GFR in
hyperfiltering IDDM patients [92]. The effect of glucose on GFR may result from a
decrease in afferent glomerular arteriolar tone, mediated via the tubulo-glomerular
feedback (TGF) loop [90,91]. Insulin at doses that raise its plasma level 4 to 8 fold acutely
elevates ERPF [93,94], and its vasodilating properties are probably mediated via nitric
oxide that directly affects glomerular arteriolar tone and mesangial function [95]. Another
relevant action of insulin is an increased tubular sodium reabsorption, leading to increases
in total exchangeable sodium and extracellular volume, which have been implicated in
diabetic glomerular hyperfiltration [96,97]. Alterations in contra-regulatory hormones, GH
and glucagon, which are well known renal vasodilators [98-100], could also play a role
since these hormones are often elevated during suboptimal metabolic control [101-104].
It is possible that intrarenal accumulation of  IGF-I, as part of the GH-IGF-I-system, may
induce the early functional and morphological renal changes in diabetes [105]. Renal
haemodynamics in diabetes may also depend on alterations in neurohormonal systems that
regulate glomerular tone, such as the renin- angiotensin-aldosterone-system (RAAS) and
the sympathetic nervous system (SNS) [81]. The presence of diabetes obviously affects the
SNS, although various changes have been reported [106]. Furthermore, systemic blood
pressure responses to pressor agents like angiotensin II and NE are increased in diabetes
mellitus [107-110]. Among other factors, vasoactive substances, such as prostaglandins,
nitric oxide, kinins and atrial natriuretic peptide, have also been implicated in diabetic
glomerular hyperfiltration [81]. Currently, none of these factors has been found to fully
account for the increase in GFR in IDDM patients. For instance, exogenous infusions of
glucose, insulin, GH, IGF-I and glucagon all increase GFR, but not to levels as generally
encountered in diabetic hyperfiltration.
Although animal studies provided an experimental basis for an increased GFR and
elevated intraglomerular pressure as pathogenetic factors involved in the development of
DN, it should be stressed that there are caveats in extrapolating these data to the human
situation. First, glomerular pressure cannot be measured in man and it is thus unknown
whether glomerular hyperfiltration in human IDDM is accompanied by an increase in
intraglomerular pressure. The only indirect proof stems from fingernail micropunctureChapter 1 12
studies that demonstrated capillary hypertension in human IDDM, but no differences were
found between normo- and microalbuminuric patients [111]. Second, it is clinically
difficult to measure glomerular hyperfiltration in IDDM patients. Many clinical studies
defined glomerular hyperfiltration as a GFR above the upper normal limit of a control
population. Such an arbitrary definition does not discriminate subtle intrarenal
haemodynamic abnormalities in apparently normofiltering patients and has, therefore, the
disadvantage to underestimate the hyperfiltration phenomenon. This could explain why
some [112], but not all [113,114] clinical observations found an elevated GFR to be impli-
cated in DN. Finally, in man renal insufficiency is an uncommon consequence of long-
standing glomerular hyperfiltration per se, since subjects with one kidney [115-117] and
patients with acromegaly [118,119] are not at high risk of renal failure. This strongly
suggests that glomerular hyperfiltration alone does not result in important glomerular
injury in humans. 
Lipoproteins 
Higher serum levels of low-density lipoprotein (LDL) cholesterol, apolipoprotein B,
triglycerides and lipoprotein (a), and lower levels of high-density lipoprotein (HDL)
cholesterol have been observed in IDDM patients with nephropathy and even in patients
with microalbuminuria [51,52,120-122]. Such atherogenic lipoprotein changes are likely
to explain in part the increased cardiovascular risk in these patients. There exists much
controversy whether lipoprotein abnormalities are also involved in the pathogenesis of DN
[123]. An independent association between elevated LDL cholesterol levels and progres-
sion of microalbuminuria [124] and overt nephropathy [125] has been observed. This
suggests a pathophysiological role of hyperlipidaemia analogous to atherosclerosis.
Indeed, the lipid depositions and mesangial cell proliferation of glomerulosclerotic lesions
show a remarkable resemblance with the lipid filled monocytes and vascular smooth
muscle cell proliferation in atherosclerotic plaques. Furthermore, experimental studies
showed hypercholesterolaemia to aggravate glomerulosclerosis, which was prevented by
cholesterol lowering therapy [126,127]. However, clinical support for the benefit of
cholesterol lowering therapy on progression of nephropathy is lacking. Short-term
simvastatin treatment did not decrease albuminuria in IDDM with nephropathy [128].
Lovastatin, another HMG CoA reductase inhibitor, attenuated the rate of renal function
loss in NIDDM patients with nephropathy, but the lack of intergroup comparison in this
study has been criticised [129].
Genetic factors
The fact that only a proportion of IDDM patients eventually develop overt proteinur-
ia and that this complication has a peak incidence 10 to 15 years after the onset of
diabetes, supports the notion that specific susceptibility factors are involved in the
pathogenesis of DN [1-3,5]. The observation that DN clusters in affected families further
strengthens the involvement of genetic factors [130-132]. IDDM siblings belonging to
families with a first-degree relative suffering from nephropathy have a life long risk of
70% to develop nephropathy, whereas this risk is only 20% when there is no family
history of DN [132], and it has been suggested that one or two major genes determineIntroduction 13
susceptibility to DN. Since a familial predisposition to essential hypertension is associated
with an increased risk of DN [133-135], candidate genes have been sought among loci
involved in the regulation of blood pressure. 
Recent attention has been given to polymorphisms in genes encoding for RAAS
components. In this respect, the ACE gene polymorphism seems to be of relevance. This
polymorphism consists of an 287 basepair insertion (I) or deletion (D) of intron 16 of the
ACE gene. The DD genotype has been shown to be associated with an increased
cardiovascular risk in non-diabetic populations [136,137], in non-insulin-dependent
diabetic (NIDDM) patients [138,139] and in IDDM patients with nephropathy [140]. DD
homozygotes have elevated serum [141] and tissue ACE levels [142], causing an increased
vascular conversion of angiotensin I to angiotensin II [143] and an increased pressor
response to angiotensin I [144]. It is, therefore, hypothesised that increased angiotensin II
formation is involved in the increased cardiovascular risk in conjunction with the DD
genotype. The issue whether the DD genotype is also associated with DN is controversial.
Some cross-sectional studies showed the DD genotype to be more prevalent among IDDM
and NIDDM patients with nephropathy [145,146], while in other reports no association of
the ACE gene polymorphism with DN could be demonstrated [147-149]. Recently it was
shown that in IDDM patients treated with an ACE inhibitor, the rate of decline in GFR is
greater in patients with the DD genotype compared to patients with the ID or II genotype
[150,151] Similar findings have been reported in non-diabetic subjects with nephropathy
[152], and that study also demonstrated a less effective antiproteinuric effect of ACE
inhibition treatment in subjects with the DD genotype. Thus, the ACE gene polymorphism
is more likely to be a marker of progression of DN than a susceptibility factor for DN.
The number of candidate genes for DN is growing and evaluation of their putative
roles will require large numbers of subjects, including sib-pairs discordant for DN [132].
Renal effects of norepinephrine
After its release from the terminal nerve endings of the SNS, NE acts in an autocrine
fashion on local "-adrenoceptors,  while at the same time small amounts leak into the
circulation [153,154]. This spilled-over NE is not an inert circulating neurotransmitter, but
a hormonally active substance [155,156]. In the kidney, "-adrenoceptors are located along
the interlobular, afferent and efferent glomerular arterioles, mesangial cells and tubular
segments [157-159]. This distribution pattern suggests that NE may control glomerular
blood flow, glomerular capillary pressure and renal sodium handling [153,154]. Studies
on renal sympathetic nerves have shown that low frequency stimulation results in sodium
retention and renin release and high frequency stimulation in a fall in ERPF and some
decline in GFR [160,161]. Exogenous NE infusions markedly reduce ERPF without much
change in GFR in animals [162-165]. The NE-induced renal haemodynamic changes are
likely mediated via afferent and efferent glomerular arterioles [160-165]. These vessels are
the major sites of flow resistance in the kidney and importantly determine renal blood
flow, whereas they are also involved in the control of intraglomerular pressure [30].
Micropuncture studies in the rat have indeed documented that NE causes a fall in renal
blood flow by afferent and efferent glomerular vasoconstriction, and that NE evidently
increases intraglomerular pressure [162]. Interestingly, the prevailing blood pressure was
found to determine the glomerular vessel response. There was a predominant increase inChapter 1 14
efferent tone when blood pressure was kept unchanged, whereas both afferent and efferent
glomerular resistance increased when blood pressure was allowed to increase [162]. The
lack of change in GFR during NE infusion was explained by an increase in
intraglomerular pressure offsetting the fall in glomerular blood flow [162]. Although, the
precise intrarenal effects of NE are unknown in man, there are obvious similarities with
animal data. Indeed, intravenous infusions of NE lower ERPF but have little effect on
GFR [166, 167]. Consequently the filtration fraction (FF) rises which may reflect a change
in pressure profile along the arterioles. It is therefore plausible that NE also increases
intraglomerular pressure in man, as supported by the finding that NE augmented
proteinuria in nephrotic patients [168].
The diabetic state has variably been associated with an increased, unchanged, or
even a decreased SNS activity and/or vascular reactivity to NE [81,106]. These
inconsistencies may be attributed to differences in the species investigated, in blood
glucose and insulin levels, or in the vascular bed under study [81,106,169-171]. There is
only one study in kidney tissue taken from severely hyperglycaemic rats that has addressed
the putative role of NE in DN. In this study, afferent glomerular arteriolar responsiveness
was attenuated in experimental diabetes [165]. Most evidence, however, points towards an
increased vascular responsiveness in diabetes [81,106]. For instance, systemic blood
pressure responsiveness to exogenous NE has repeatedly been found to be exaggerated
diabetic patients [108-110]. Furthermore, the responsiveness to NE-induced
vasoconstriction of dorsal hand veins, which contain "-adrenoceptors like glomerular
arterioles, is increased in moderately hyperglycaemic microalbuminuric IDDM patients
[172]. These findings raise the possibility that glomerular vessels in IDDM are also
hyperresponsive to NE. Such an exaggerated renal responsiveness could, therefore,
contribute to the elevations in intraglomerular pressure and albumin excretion rate, and
thus play a pathogenesis role in DN [81,172,173]. However, no human study has evaluated
renal NE responses in IDDM, and has established whether NE has the ability to increase
microproteinuria.
The growth hormone-insulin-like growth factor-I system and kidney function 
IGF-I is a small peptide hormone (MW 7.6 kDa), which production is under
pituitary GH control [174]. The pituitary GH product of 21.5 kDa (191 amino acids) is
secreted in pulsatile fashion with approximately 13 surges per day and has a short half-life
of 20 minutes that is prolonged after binding to GH-binding protein. GH is a strong
secretagogue of IGF-I. GH simulates IGF-I gene transcription and increases IGF-I
synthesis in many tissues. Most IGF-I present in the circulation originates from the liver
[175]. IGF-I, in turn, inhibits pituitary GH release by a negative feedback mechanism. The
biological activity of IGF-I depends on the plasma levels of several binding proteins that
interfere with IGF-I receptor interaction, as well as on IGF-I receptor expression [174].
The IGF-I shares 70% homology with proinsulin and binds with high affinity to the IGF-I-
receptor and with lower affinity to the insulin receptor. The plasma levels of IGF-I range
from 10-125 nmol per liter, which is much higher than insulin with fasting levels in the
picomolar range. Excessive stimulation of the insulin receptor is, however, prevented by
the fact that more than 99% of IGF-I is bound to specific IGF-binding proteins (IGFBP),
and only a small amount of IGF-I is present its free form [174]. About 85% of IGF-I isIntroduction 15
bound to IGFBP-3 and forms a 150 kDa ternary complex after association with the acid-
labile subunit (ALS), that does not pass through the capillary barrier [176]. The binding
to IGFBP-3 has such a high affinity that competition between IGFBP’s and the IGF-I
receptor occurs. The 150 kDa complex can thus be viewed as a circulating IGF-I reservoir
[174]. Both cleavage by proteases and phosphorylation impair the formation of the ternary
complex, and enhance binding of IGF-I with its receptor. Another 20% of serum IGF-I is
found in smaller (±45 kDa) complexes, containing IGFBP-1, IGFBP-2, IGFBP-3 or
IGFBP-4, which can pass through capillary endothelial membranes and deliver IGF-I to
specific tissue-binding sites. 
In man, renal haemodynamic parameters covary with endogenous GH and IGF-I
levels. GFR and ERPF are elevated in acromegaly, decline after GH lowering treatment
with octreotide, and are decreased in GH deficiency [177-182]. GH stimulates renal
haemodynamics after a lag period allowing IGF-I levels to increase [183,184], whereas
rhIGF-I infusion induces an immediate rise in GFR and ERPF [185-187]. Thus, GH seems
to increase renal haemodynamics indirectly via stimulating IGF-I synthesis.
IGF-I receptors as well as mRNA encoding for the different IGFBP’s are expressed
in various structures of the kidney including glomerular arterioles [188]. In contrast, GH
receptors are not present on human glomerular vessels. Contradictory results have been
presented with respect to IGF-I production in human nephrons [174,188], and it is
unknown whether the GH receptor is expressed in other glomerular structures [174].
Based on micropuncture studies in the rat, rhIGF-I has been shown to decrease
efferent glomerular arteriolar resistance with a trend towards a reduction of afferent
arteriolar resistance [185]. Exogenous rhIGF-I does not increase glomerular capillary
pressure. The rises in SNGFR and in whole kidney GFR are fully accounted for by
increments in glomerular blood flow and in the filtration coefficient [185]. The IGF-I-
induced renal changes are likely mediated via nitric oxide (NO), because IGF-I has been
shown to increase NO synthesis in cultured vascular endothelial cells [189], and the NO
synthase inhibitor, N -nitro-l-arginine methyl ester, abolishes renal vasodilation by IGF-I
G
[190]. Moreover, IGF-I could also be involved in mesangial cell relaxation [191].
Several experimental studies indicate that an enhanced GH-IGF-I-axis could be
involved in diabetes-associated hyperfiltration and plays a pathogenetic role in the
development of glomerulosclerosis. Following unilateral nephrectomy in the rat, IGF-I has
been found to accumulate in hyperfiltering nephrons and the increase in SNGFR was
inhibited by anti-IGF-I-antibody administration [192]. It is of interest, that IGF-I has been
found to accumulate in kidneys of diabetic rats during the initial phases of renal enlarge-
ment and renal hyperperfusion [193]. Concomitant increases in renal IGF-I receptor
expression and receptor binding activity have also been documented in kidney tissue from
streptozotocin-induced diabetic rats [194]. This renal IGF-I accumulation has been shown
to be GH dependent since it is diminished in hypophysectomised diabetic rats and is in
part restored after GH replacement [195]. Thus, these findings suggest that renal IGF-I is
involved in renal hypertrophy and raise the possibility that GH is necessary for this effect.
A possible role of the GH-IGF-I-system in the development of glomerulosclerosis
is supported by observations in hGH-transgenic mice and in rats bearing GH-producing
tumours which develop albuminuria, mesangial cell proliferation and premature
glomerulosclerosis [196,197]. However, IGF-I alone may not be completely responsibleChapter 1 16
for GH-IGF-I-induced glomerulosclerosis, since mice transgenic for IGF-I do not develop
glomerulosclerosis [198]. These negative findings may be due to lower IGF-I levels in the
transgenic animals expressing IGF-I as compared to those expressing high levels of GH,
but it is also possible that concomitant elevations in GH are necessary for IGF-I to induce
glomerulosclerosis. Pituitary GH deficiency or GH lowering treatment with octreotide
indeed modified the renal alterations after streptozotocin-induced diabetes in rats, as
supported by inhibition of glomerular hypertrophy and lower albumin excretion rates in
these animals [199,200]. Of interest, high glucose levels increased IGF-I, IGF-I mRNA,
and IGF-I receptor expression in cultured mesangial cells, which, in conjunction with
raised TGF-$1 levels, enhanced extracellular matrix production [201]. Taken together, it
is possible that abnormalities in the GH-IGF-I-system can contribute to the development
of glomerulosclerosis in diabetes mellitus.
During poor metabolic control both glomerular hyperfiltration and elevated circulat-
ing GH levels have been documented [75,92,101-103]. However, no difference in diurnal
GH profile between normo- and hyperfiltering IDDM patients was observed [202].
Nevertheless, an exaggerated GH-responses to GH-releasing hormone has been shown in
hyperfiltering IDDM patients [203], indicating that glomerular hyperfiltration is indeed
related to abnormalities in GH-release. Despite high circulating GH-levels, serum IGF-I
levels are often low, again in relation to poor metabolic control [204]. This has been
ascribed to GH-resistance at the hepatic level [205,206]. Lower circulating IGF-I levels,
in turn, may contribute to GH-hypersecretion by insufficient inhibition at the pituitary.
This may cause an adverse sequence of events: GH may worsen metabolic control and
poor control may elevate GH-levels. Intensive insulin treatment, and more importantly,
restoration of hepatic insulinisation, have been shown to increase IGF-I levels [207,208]
and reverse GH-hypersecretion [102]. This indicates that in IDDM patients relative
insulinopenia may cause GH hypersecretion and lower the IGF-I level.
How can elevated GH and lower IGF-I levels be implicated in diabetic glomerular
hyperfiltration? The association of increased renal haemodynamics with abnormalities in
the GH-IGF-I system, as shown in diabetic rats, results from intrarenal IGF-I accumul-
ation, an increased IGF-I receptor expression and alterations in IGFBP’s [105,193-195,
199,200]. Such alterations covary with insulin levels since they are outspokenly present
during insulinopenia and partly prevented by insulin treatment [193,210]. Thus, despite
impaired (hepatic) IGF-I synthesis, poor metabolic control could in fact enhance renal
IGF-I accumulation. A maximally stimulated intrarenal IGF-I accumulation may,
therefore, explain why GH administration does not increase GFR and ERPF in poorly
controlled IDDM patients, whereas it augments GFR and ERPF in well-controlled IDDM
patients [99]. The mechanisms underlying renal IGF-I accumulation are not precisely
known, but are conceivably due to an increased trapping of IGF-I from the circulation
[195]. Local production of IGFBP’s, increased IGF-I receptor expression [193-195] and
increased IGFBP-3 protease activity that impairs the formation of the ternary complex
[211] could all be involved in intrarenal IGF-I accumulation in IDDM.
Sodium and volume homeostasis in IDDM and the role of 11$-hydroxysteroid
dehydrogenase Introduction 17
An increase in exchangeable sodium accompanied by extracellular volume expan-
sion is a well documented feature of diabetic patients and might contribute to elevations
in GFR, as well as to rises in blood pressure in association with microalbuminuria [96,110,
212-217]. The mechanisms responsible for this abnormal sodium retention are incom-
pletely understood. An enhanced renal tubular sodium reabsorption, possibly mediated by
insulin, may be involved [97]. In diabetic patients sodium excretion is attenuated follow-
ing head out water immersion [218] and saline infusion [219]. Elevated plasma levels of
sodium retaining hormones, like angiotensin II, aldosterone en NE, are not encountered in
IDDM and are unlikely to explain the tendency towards sodium retention
[212,213,216,220,221]. 
Mineralocorticosteroids play a central role in extracellular sodium and fluid
homeostasis. Interestingly, the mineralocorticoid receptor has equal affinity for cortisol
and aldosterone in vitro, but, in contrast, the renal tubules exclusively bind aldosterone in
vivo  [222-225]. Recently, it has become clear that the mineralocorticoid receptor is
protected from being activated by cortisol by the intracellular enzyme 11$-hydroxysteroid
dehydrogenase (11$-HSD) [224]. Two isoforms have been identified. 11$-HSD  is 1
present in the liver. This enzyme is NADH/NAD  dependent and catalyses the
+
interconversion between cortisol and cortisone. 11$-HSD  is expressed in the kidney and 2
unidirectionally catalyses the oxidation of cortisol to its inactive compound, cortisone.
This isoenzyme is NADP  dependent [225]. Thus, there is a link between cortisol metabo-
+
lism and the regulation  of volume and sodium homeostasis. For instance, genetic
mutations in 11$-HSD  that impair its activity cause hypokalaemic hypertension despite 2
undetectable aldosterone levels [226,227]. This so-called apparent mineralocorticoid
excess syndrome can also be acquired as a consequence of glycerrhethinic acid ingestion
[228]. 
It is unknown whether 11$-HSD activity is altered in IDDM. Changes in the
cortisol-cortisone shuttle towards cortisol could contribute to abnormal sodium retention
in IDDM. Alternatively, a shift towards cortisone could attenuate sodium retention.
Treatment of diabetic nephropathy
Arterial hypertension 
Arterial hypertension importantly contributes to the progression of proteinuria and
the loss of renal function in IDDM patients with nephropathy, and many studies have
demonstrated that blood pressure lowering reduces proteinuria and slows the rate of
decline in GFR [28,229-233]. Even slight elevations in blood pressure have been shown
to increase microalbuminuria in IDDM patients [9,39,42,112,234]. These findings have
resulted in  the recommendation to start antihypertensive treatment in microalbuminuric
IDDM patients when blood pressure values exceed 140/90 mmHg [235,236] or even
130/85 mmHg [238]. It is, however, controversial whether one specific class of
antihypertensive agent is more effective than another. $-blockers [229,230,232], periph-
eral vasodilators [229,230,302], diuretics [229,230,232] and ACE-inhibitors [231,233]
have all been shown to effectively retard the decline in GFR in patients with overt
nephropathy. Trials that compared the effectiveness of $-blockers and ACE inhibitors
have shown inconsistent results [238,239]. ACE-inhibition was found to be more effectiveChapter 1 18
than $-blockade, but in this study blood pressure reduction was better with the ACE-
inhibitor [238]. Another study could not demonstrate a benefit of ACE-inhibition over $-
blockade, but in that study baseline proteinuria was lower in the $-blocker group [239].
Similar studies in non-diabetic renal disease either showed an increased [240] or no
difference in effectiveness of ACE-inhibitors as compared to $-blockers [152]. Interest-
ingly, the latter study showed that the I/D polymorphism of the ACE gene was a
determinant of the renal protective outcome. 
There are theoretical advantages of ACE inhibitors that are attributable to additional
renoprotection as these agents have been documented to lower intraglomerular pressure in
animal studies [82,83]. Also, such a role for ACE inhibitors has been favoured in IDDM
patients with DN by demonstrating that captopril added to other antihypertensive
medications reduced the rate of renal function loss that could not be attributed to its blood
pressure lowering effects alone [241]. Furthermore, several meta-analyses comparing
ACE-inhibition treatment with other antihypertensive therapies pointed out that ACE-
inhibitors induced larger reductions in proteinuria beyond their blood pressure lowering
effect [242,243]. 
So, should drugs interfering with the RAAS such as ACE-inhibitors and angiotensin
II-antagonists be preferred, or will any rigorous blood pressure reduction, irrespective of
the choice of drug, be sufficient to treat DN? It is important to realise that a clinical trial
comparing the effects on renal failure and mortality of these drugs has never been
performed, but it is highly questionable whether such a study will ever be undertaken. The
lesson so far learned is that blood pressure should be rigidly lowered, since patients with
the largest blood pressure reduction will benefit the most [9]. ACE inhibitors have
unequivocally demonstrated to be effective and have gained an important place in the
treatment of DN [231,233,238,241]. As these drugs have also been shown to arrests or
delay progression of microalbuminuria [19-22], these patients should also be treated.
Addition of diuretics may be useful to oppose the abnormal sodium retention in IDDM
[213,244]. However, the potential advantage of $-blockers should not be overlooked
because of proven secondary prevention of cardiovascular disease in non-diabetic subjects.
Theoretically, calcium-antagonist may also have some advantages by modifying vascular
reactivity to various endogenous pressor agents [245].
Although hypertension has been recognised as important prognostic indicator of renal
function loss and blood pressure lowering therapy has proven renoprotective effectiveness,
many patients still progress to end stage renal disease [229-233,241,246, 247]. A number
of post-hoc analyses on clinical trials in patients with renal disease of various origin, showed
that apart from blood pressure lowering, the severity of proteinuria was correlated with a
worse prognosis with respect to long-term renal function [246,247]. Similar findings have
been reported in patients with DN, in whom a relative large initial fall in albumin excretion
after $-blockers [248] and ACE-inhibitors [249] predicted a slower rate of decline in GFR.
These studies suggest that clinical proteinuria is not only a marker of renal disease, but
could also be a pathogenetic factor in the process of glomerulosclerosis [250]. If it is true
that insufficient reduction in proteinuria and substantial residual proteinuria indicate a
poorer prognosis, a more aggressive antiproteinuric therapy may possibly increase long-
term renal function outcome in patients with renal disease. The advocated stringent blood
pressure targets [235-237] should then be individualised on the initial decline inIntroduction 19
proteinuria [251,252]. It is, however, unknown whether this is also true for protein
excretion rates in the microalbuminuric range.
Metabolic control
Although not being the primary objective, the  DCCT unequivocally showed that
intensive insulin treatment reduces the occurrence of microalbuminuria in IDDM patients
[17,18]. In short, 1441 IDDM patients were allocated to either intensive or conventional
insulin treatment. The goal of intensive therapy was to achieve near normal blood glucose
levels. The mean HbA1c level reached was 7.2%, which was approximately 2% lower than
that in the conventionally treated IDDM patients. Mean follow-up was 6.5 years (range 3
to 9 years). Most patients (n=1365) had a normal albumin excretion rate at baseline. In
these patients, the estimated 9 year cumulative incidence in persistent microalbuminuria was
10% and 26% in the intensive and conventional insulin treatment groups, respectively,
indicating a reduction in risk of development of microalbuminuria of 60%. In 6% and 15%
of these patients, respectively, microalbuminuria progressed to levels above 70 µg/min. In
all patients, including those with microalbuminuria at baseline, the calculated 9-year
cumulative incidence in clinical proteinuria was 3% and 7% with intensive and conventional
treatment, respectively. This indicates a risk reduction in the development of overt
nephropathy of 51% [17]. In a separate analysis of the 73 patients with microalbuminuria
at baseline, of which 38 were assigned to intensive therapy and 35 to conventional therapy,
no difference in progression to clinical proteinuria was seen, which occurred  in 8 patients
of each group [17]. 
The DCCT demonstrates that intensified insulin treatment reduces the risk of
development of microalbuminuria, and supports the role of hyperglycaemia in the
pathogenesis of incipient nephropathy [58-72]. Accordingly, a meta-analysis of 16 studies
showed that lowering blood glucose levels retarded progression urinary albumin excretion
in normo- and microalbuminuric IDDM patients [253]. It should be noted that the lack of
effect of intensive insulin therapy on the progression of microalbuminuria to overt
nephropathy in the DCCT [17], was also found in a British collaborative study [254].
Moreover, it is controversial whether improved metabolic control slows the rate of decline
in GFR in patients with established DN [255-257]. Some reports have suggested that
glycaemic control loses its significance as a risk factor in established nephropathy
[255,256], but these result have been challenged by the positive correlation between
HbA1c levels and the rate of decline in GFR in patients with clinical nephropathy [257].
It is conceivable that patients with overt DN will also benefit from strict metabolic control,
although this will not reverse established renal disease [258,259]. Obviously, substantial
longer observation periods are required to determine whether sustained blood glucose
lowering as achieved in the DCCT will prevent or delay renal failure over 10 to 20 years.
What degree of glycaemic control should be aimed for to minimise the risk of
complications? The major burden in managing IDDM patients to maintain blood glucose
in the normal range is the risk of hypoglycaemia is [260,261]. This is illustrated by the 3
fold increase in severe hypoglycaemic episodes as well as more nocturnal hypoglycaemia
and hypoglycaemia unawareness in the intensive insulin treated group of the DCCT
[16,17]. The investigators of the DCCT recommended HbA1c levels of 7 to 8% since suchChapter 1 20
a treatment goal would achieve a maximum benefitBto-risk ratio. Another report
postulated, in contrast, that no clinical benefit results from a decrease of the HbA1c level
below 8.1%, since only higher HbA1c levels were associated an exponential increase in
the risk of developing microalbuminuria [262]. These authors proposed the presence of a
glycaemic threshold for the risk of nephropathy. However, a post-hoc analysis of the
DCCT did not support the existence of a glycaemic threshold, but in fact showed a
curvilinear relationship between the HbA1c level and the logarithm of the risk of
microalbuminuria development [263]. Nonetheless, inherent to such a logarithmic relation,
the reduction in risk is greatest when the highest HbA1c values are reduced. Weighing this
risk of microalbuminuria against that of hypoglycaemia, and aware of the view that
elevated blood glucose levels alone do not cause nephropathy, but that haemodynamic and
genetic factors are also involved, it has been proposed that achievement of an HbA1c level
below 8.1% is a reasonable primary prevention strategy  [264]. It was argued that
continuous monitoring will identify those patients in whom, despite improved glycaemic
control, progression of microalbuminuria takes place. These patients might then benefit
from early aggressive blood pressure lowering therapy. 
Dietary intervention
Protein intake modulates renal function [265]. In humans, GFR and ERPF acutely
increase after an amino acid infusion and an oral protein load [265,266]. Experimental
studies have shown that a high dietary protein intake contributes to a rise in the intra-
glomerular pressure and GFR, and have documented that protein restriction ameliorates -
glomerular hypertension and hyperfiltration, and retards the progression of renal function
impairment [77,267]. These studies have led to the suggestion that protein restriction
could be of clinical benefit in IDDM patients with nephropathy. 
Only a few clinical studies addressed the effects of protein restriction in IDDM
patients with (incipient) nephropathy [234,268-271]. These studies demonstrated that a
low protein diet decreased albuminuria, but variably affected the rate of decline in GFR
which was either found to be unchanged [234,268,271] or indeed retarded by protein
restriction [269, 270]. A meta-analysis of these studies showed that the relative risk of
progression of albuminuria and decline in GFR was evidently lower in IDDM patients
using a low protein diet compared with patients consuming a usual-protein diet [272]. The
analysis also revealed that these favourable effects were not confounded by differences in
blood pressure or metabolic control [272]. Accordingly, it is likely that IDDM patients
benefit from a restriction in their daily protein intake. For this reason, the American
Diabetes Association has proposed to reduce dietary protein intake to 0.8 g/kg per day. It
should be noted that such a protein restriction is difficult to maintain. In fact, a protein
intake of 0.8 g/kg per day was on average achieved in Dutch IDDM patients following
intensive dietary counselling [234]. Thus, the effectiveness of a low protein diet may be
limited by suboptimal compliance. Clearly, there is currently no place to recommend -
protein rich diets to IDDM patients.
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Purpose of the thesis 
This thesis aims to answer to following questions: 
1. Does an increase in plasma NE levels contribute to the exercise-induced rise in 
albuminuria and are there differences between normo- and microalbuminuric
IDDM patients and healthy subjects? 
2. Are ambient plasma NE levels related to renal haemodynamic parameters in normo-
and microalbuminuric IDDM patients and in healthy subjects? Introduction 35
3. Do exogenous NE infusions, given at doses that induce predetermined rises in blood
pressure, cause a microproteinuric response in normo- and microalbuminuric IDDM
patients and healthy subjects? What are the determinants of such a putative
microproteinuric response? Are differences in renal haemodynamic NE responsive-
ness responsible for possible differences in NE-stimulated microproteinuria among
these subjects?
4. Does ACE-inhibition treatment attenuate the NE-induced blood pressure rise and
renal vasoconstriction in microalbuminuric IDDM patients.
5. Does low dose dopamine oppose NE-induced renal vasoconstriction in healthy
subjects? 
6. Are abnormal GH-IGF-I levels, as encountered in (un)treated acromegalic patients
and GH deficient patients, associated with differences in urinary protein excretion as
compared to healthy subjects? 
7. Is renal functional reserve as assessed by amino acid infusion inversely related to
baseline renal haemodynamic parameters among GH deficient patients, healthy
subjects, patients with (un)treated acromegaly, and normo- and hyperfiltering IDDM
patients? Are basal renal haemodynamic parameters positively related to the plasma
IGF-I levels in these subjects?
7. Do IDDM patients with an elevated GFR have an exaggerated GH-response after
exercise and a higher plasma glucagon level and as compared with IDDM patients
with a normal GFR? Is exercise-stimulated GH secretion and the glucagon level
related to GFR, ERPF and kidney size in IDDM patients?
8. Is an increased urinary IgG excretion a genuine feature of normoalbuminuric IDDM
patients or are laboratory artefacts responsible for this thus far unexplained 
observation? 
9. Are there differences in urinary cortisol and cortisone metabolites in normo- and
microalbuminuric IDDM patients compared to healthy subjects? Does this indicate a
shift in the so-called cortisol-cortisone shuttle towards cortisol that could be involved
in sodium retention and volume expansion in IDDM? Does ACE inhibition treatment
influence the cortisone-cortisol shuttle in microalbuminuric IDDM  patients? Department of Endocrinology, University Hospital Groningen, The Netherlands
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CHAPTER 2
ABNORMAL PLASMA NOREPINEPHRINE RESPONSE AND
EXERCISE-INDUCED ALBUMINURIA IN IDDM PATIENTS
K. Hoogenberg  and R.P.F. Dullaart
1 1
Submaximal exercise provokes an abnormal elevation in albuminuria in patients with IDDM.
Plasma catecholamines might be involved in this phenomenon by a renal vasoconstrictive effect.
Twelve healthy subjects (Controls: albuminuria<10µg/min), 13 normoalbuminuric IDDM patients
(DNormo:albuminuria<10µg/min) and 13 microalbuminuric IDDM patients (DMicro: albuminuria
10-200µg/min) performed a fixed bicycle workload (600 kpm for 20 min + urine collection 40 min
postexercise). None of the patients suffered from autonomic neuropathy or hypertension. Fractional
albumin clearance (FalbCl) rose in DNormo (p=0.02) and DMicro (p=0.01) but not in the Controls
(p=0.40). Basal plasma epinephrine and norepinephrine (NE) were not different in the three groups.
The increments in NE were more pronounced in DNormo and DMicro than in Controls
(Controls<Dnormo, p<0.05; Controls< DMicro, p<0.01). The changes in FalbCl were
significantly correlated with the changes in NE (all subjects r=0.65, p<0.001). The increments in
epinephrine were not different in the IDDM groups compared to the controls, and were not related
to the changes in FalbCl. Multiple regression analysis showed that changes in plasma NE (p<0.002)
and in mean arterial pressure(MAP, p<0.005) independently contributed to the changes in FalbCl
(multiple R=0.73).It is concluded that the exercise induced plasma NE response is increased in
normo- and microalbuminuric IDDM patients. NE appears to contribute in the exercise-induced
changes in renal protein handling, possibly by its effect on renal haemodynamics. 
Introduction
Submaximal exercise has been reported to result in a marked elevation of
albuminuria in patients with insulin-dependent diabetes mellitus (IDDM) with either
normal or slightly elevated urinary albumin excretion at rest [1-7]. This albuminuric
response is thought to be related to an increased glomerular passage of macromolecules,
and possibly indicates an early impairment in the glomerular filtration barrier in IDDM
[8]. Changes in tubular protein reabsorption are not considered to be of great importance
during moderately strenuous exercise since the excretion of $2-microglobulin, a marker
of tubular protein handling, does not increase under these circumstances [2,3].
The mechanisms by which exercise leads to a pronounced increase in albuminuria
in IDDM patients are still poorly understood. During exercise the effective renal plasma
flow (ERPF) decreases more than the glomerular filtration rate (GFR). Consequently,
the filtration fraction i.e. the GFR divided by the ERPF increases [4,6,9]. A rise in theChapter 2 38
intraglomerular pressure, which is assumed to be reflected by this increase in filtration
fraction [9], might be an important factor that contributes to the enhanced excretion of
urinary albumin. An abnormal rise in systolic blood pressure has also been implicated
in the exercise induced rise in albuminuria in IDDM particularly in conjunction with
microalbuminuria [5], although this has not always been reported [2,6]. Studies in the
rat have shown that norepinephrine (NE) increases renal vascular resistance predomi-
nantly via efferent glomerular vasoconstriction [10]. Both epinephrine and NE increase
renal vascular resistance in humans [11-13]. It has therefore been proposed that the renal
haemodynamic changes during exercise are related to increased circulatory levels of
plasma catecholamines [9,14]. By a renal haemodynamic mechanism, plasma catechol-
amines thus could possibly affect renal protein handling during exercise in IDDM
patients. 
The purpose of the present study was to determine whether an altered plasma
catecholamine response could play a role in the exaggerated rise in albuminuria in
IDDM with normo- and microalbuminuria during moderately strenuous exercise.
Subjects and methods 
Subjects
All subjects consented to the procedure after explanation of the purpose of the
study, which was approved by the local medical ethics committee. Three groups of
subjects were investigated (Table 1): 12 healthy control subjects (urinary albumin
excretion rate (Ualb.V<10 µg/min, Controls); 13 IDDM patients with normo-
albuminuria (Ualb.V<10 µg/min, DNormo), 13 IDDM patients with microalbuminuria
(Ualb.V ranging from 10 to 200 µg/min, DMicro).  
Ualb.V was determined in three consecutive overnight urine collections obtained
within three months prior to the study. Three urine samples were used to classify the
IDDM patients because of the high variability of Ualb.V [15]. A level of Ualb.V above
10 µg/min was considered to be abnormal (above the 97.5 percentile for 50 healthy
controls subjects). Urinary tract infection was excluded by bacterial culture. All IDDM
patients suffered from ketosis prone diabetes mellitus and were considered to be insu-
lin-dependent on clinical grounds. All subjects had a serum creatinine level below 120
µmol/l and were normotensive (systolic blood pressure #140 mmHg and diastolic blood
pressure #90 mmHg). No medication other than insulin or oral contraceptives were
allowed. The IDDM patients did not have autonomic neuropathy as determined by
Valsalva manoeuvre, beat to beat variation during deep breathing and blood pressure
response to standing [16]. A questionnaire showed no differences in physical activity
among the three groups. As is shown in Table 1 the three groups were closely com-
parable in age. There were no significant differences in sex distribution.  The two
IDDM groups were comparable with respect to duration of disease, metabolic control
and retinopathy. All subjects were studied in the fasting state while the morning insulin
dose was withheld. Blood pressure was measured using a sphygmomanometer
(Baumano- meter, W.A. Braun Inc, N.Y., USA).  Korotkoff phase 5 was taken as the
diastolic blood pressure. Blood pressure and pulse rate were measured at 5 min intervalsPlasma norepinephrine and albuminuria during exercise 39
Table 1. Clinical characteristics of the study groups.
Controls DNormo DMicro
(n=12) (n=13) (n=13)
Age (years) 25±3 26±6 27±5
Duration of disease (years)  -- 10±4 12±5
Sex (males/females) 6/6 5/8 10/3
Ualb.V (µg/min) 3.1 (1.6-7.8) 5.1(2.6-9.8) 21.3(10.2-166.7)
a c
Serum creatinine (µmol/l) 79±8 76±12 89±17
d
Overnight creatinine clearance 109±27 110±29 102±23
d
(ml/min per 1.73m )
2
Body mass index (kg/m ) 21.6±1.7 22.9±2.1 23.4±2.3
2
HbA  (%) 5.3±10.4 7.7±1.6 7.6±1.2 1
e
Fasting blood glucose (mmol/l) 4.6±0.4 11.9±4.7 12.1±5.2
e
Retinopathy (O/B/P)  -- 11/1/1 6/4/3
b
Systolic blood pressure change to  1 (-11 to 12)  3 (-12 to 15) 1 (-13 to 12)
standing (mmHg)
Beat to beat variation (beats/min) 35±7 39±13 32±12
Valsalva ratio  1.76±0.28 1.72±0.28 1.78±0.32
Controls: control subjects; DNormo: IDDM patients with Ualb.V<10 µg/min; DMicro: IDDM
patients with Ualb.V>10 µg/min and <200 µg/min.   Ualb.V: urinary albumin excretion rate;
a
 Retinopathy: O: absent; B:background; P:proliferative. Values are given in mean±SD, except
b
Ualb.V and systolic blood pressure change to standing which are given in median(range);   denotes
c
p<0.001 from Controls, DNormo;   denotes p<0.05 from DNormo;   denotes p<0.01 from DNormo,
d e
DMicro.
during
the exercise and the recordings were averaged for analysis. Mean arterial pressure
(MAP) was calculated as b diastolic + a systolic blood pressure.
 
Experimental design
The exercise protocol of Mogensen [1,2] was used, except that the subjects
exercised only at 600 kpm for 20 min. The subjects drank 250 ml water per 20 min
throughout the test from 0800 hours until 1200 hours to promote diuresis. Before the
exercise the subjects were sitting for three hours. Urine was collected at 20 min intervals
from 1000 hours until 1200 hours, including two postexercise collections. The exercise
was performed on a bicycle ergometer from 1100 hours until 1120 hours. Blood samples
were taken at regular intervals from a cannula inserted into an antecubital vein which
was kept patent with a saline drip. During the study, the fractional clearance of albumin
(FalbCl), calculated as the albumin clearance divided by the creatinine clearance, was
used instead of the Ualb.V. This allowed us to take account of differences in GFR
between the individuals and possible changes in GFR during the test, to correct forChapter 2 40
changes in serum albumin concentration due to exercise induced haemoconcentration
[17], and for possible errors in urine collection due to incomplete bladder emptying
[15]. It was assumed that urinary albumin excretion had returned to baseline levels after
two hours water loading [18] and so the 20 min urine collection directly before the
exercise test was used as the reference period. FalbCl during the 20 min of exercise until
40 min thereafter was averaged for each subject to evaluate the effect of exercise.
Laboratory methods 
Urine samples were stored at -20 C for a maximum of 2 weeks until analysis.
o
Samples from each subject were determined in one run. Urinary albumin was measured
using a commercially available double-antibody radioimmunoassay (Diagnostic Products
Corporation, Apeldoorn, The Nether-lands, cat no KHAD2). The lower detection limit
was 0.07 mg/l. Serum albumin was measured on a SMAC autoanalyzer (Technicon
Instruments Inc. Tarrytown, NY, USA). Urinary and serum creatinine were measured
on SMA(C) auto-analyzers. Blood glucose was measured on a Yellow Springs glucose
analyser (Model 23A, Yellow Springs Inc., Yellow Springs, Ohio, USA). HbA1c was
determined by colorimetry [19]. Plasma epinephrine and NE concentrations were mea-
sured using high-performance liquid chromotograhpy as previously described [20]. 
Statistical analysis
Results are expressed as mean±SD for parametrically distributed data and as
median (interquartile ranges) for non-parametrically distributed data. Comparisons of
variables between groups were carried out using analysis of variance for parametrically
and non- parametrically distributed data as appropriate. Changes of variables within
groups were assessed by paired Student's t-tests or Wilcoxon tests. Adjustment for
multiple comparisons was carried out using Duncan's method [21]. Differences in
prevalence of clinical variables were analyzed by chi-square statistic. Correlations were
sought using Spearman's rank correlation. Multiple regression analysis was used to
disclose the independent contribution of parameters. P-values less than 0.05 were con-
sidered to be significant.   
Results 
Blood glucose
Blood glucose concentrations, measured directly before and after the exercise,
were 4.5±0.4 and 4.4±0.6; 11.2±3.1 and 11.7±2.8; 11.1±3.6 and 10.7±4.2 mmol/l
in Controls, DNormo and DMicro, respectively.
Blood pressure and pulse rate
Systolic and diastolic blood pressure were similar in the three groups at rest 
(Table 2). During exercise systolic blood pressure was higher in DMicro than in
DNormo whereas diastolic blood pressure was lower in DNormo than in the other two
groups. The increments in systolic blood pressure and MAP were larger in DMicro than
in the other groups. The changes in Controls and in DNormo were similar. The pulsePlasma norepinephrine and albuminuria during exercise 41
rate was significantly higher in the two IDDM groups compared with the controls but
the increment in response to exercise were comparable in all groups (Table 2). Chapter 2 42
Table 3. Effect of exercise on fractional albumin clearance.
 Fractional albumin clearance (×10 ) exercise+postexercise
-6
preexercise exercise+postexercise % of prexercise
Controls (n=12) 0.69 (0.54-1.44) 0.82 (0.51-2.19) 111 (70-296)
DNormo (n=13) 0.75 (0.33-1.53) 2.04 (0.79-6.69) 272 (87-1599)
a,e e
DMicro (n=13) 2.99 (1.77-11.97) 10.93 (3.38-26.25) 215 (104-524)
c,d f,g b,d,f
Controls, DNormo, DMicro: see text and Table I. Data are given in median (interquartile ranges).
 denotes DNormo>Controls, p<0.05;   denotes DMicro>DNormo, p<0.05;   denotes
a b c
DMicro>DNormo, p<0.001;   denotes DMicro>Controls, p<0.001;   denotes p=0.02 from pre-
d e
exercise;   p=0.01 from preexercise;    % change in Dmicro>Controls, p<0.05.
f g
Table 2. Blood pressure and pulse rate response to exercise.
preexercise    during exercise increase
Bloodpressure (mmHg) systolic/diastolic   systolic/diastolic systolic MAP
Controls (n=12) 122±11 / 79±8  154±16 / 73±7 32±8  6±2
a a
DNormo (n=13) 118±10 / 73±6  150±17 / 66±9 32±15  6±5
c a a
DMicro (n=13) 120±10 / 76±9  166±14 / 74±8 46±15 15±9
b a,d a,d
Pulse rate (beats/min)
Controls (n=12)  67±11   128±24 61±19
e e a
DNormo (n=13)  79±9   150±21 71±22
a
DMicro (n-13)  80±10   145±13 69±12
a
Controls, DNormo, DMicro: see text and Table I. MAP: mean arterial pressure. Data are given in
mean±SD.  denotes p<0.001 from preexercise;   denotes DMicro>DNormo, p<0.05;
a b
 denotes DNormo<Controls, DMicro, p<0.05;   denotes Dmicro>Controls, DNormo, p<0.01; 
c d e
denotes Controls<DNormo, DMicro, p<0.01
Fractional albumin excretion
In the preexercise period no difference in FalbCl could be demonstrated between
DNormo and Controls, but FalbCl was significantly higher in DNormo than in Controls
during the exercise+postexercise period (Table 3). In DMicro, FalbCl was significantly
higher compared with DNormo and Controls during both periods (Table 3). During the
exercise + postexercise period, FalbCl increased in DNormo (p=0.02) and in DMicro
(p=0.01) but not in Controls (p=0.40). The relative change in FalbCl, expressed as a
percentage of the preexercise values, was greater in DMicro than in Controls (p<0.05).
Plasma norepinephrine and epinephrine concentrations
At baseline there were no differences in plasma epinephrine and NE concentrations
among the three groups (Table 4). In all groups, plasma epinephrine and NE concentra-
tions increased significantly in response to exercise. The exercise-induced increments inPlasma norepinephrine and albuminuria during exercise 43
Table 4. Plasma norepinephrine and epinephrine concentrations.
preexercise exercise  postexercise
1000 hours  1100 hours 1120 hours  1200 hours
Norepinephrine (nmol/l)
Controls (n=12) 2.3 (2.0-3.7) 2.5 (2.0-4.3) 3.5 (2.7-5.1)   1.9 (1.2-2.5)
a
DNormo (n=13) 2.4 (1.4-3.1) 2.9 (1.9-3.3) 5.2 (3.7-6.7)   2.3 (1.7-2.9)
b,c
DMicro (n=13) 2.1 (1.6-2.3) 2.2 (1.5-3.1) 5.8 (4.4-6.6)   2.1 (1.6-2.4)
b,d
Epinephrine (nmol/l)
Controls (n=12) 0.14 (0.08-0.21) 0.11 (0.09-0.18) 0.40 (0.20-0.50)   0.16 (0.13-0.23)
b
DNormo (n=13) 0.13 (0.10-0.21) 0.12 (0.10-0.16) 0.30 (0.18-0.43)   0.15 (0.06-0.25)
b
DMicro(n=13) 0.10 (0.08-0.26) 0.14 (0.07-0.29) 0.88 (0.43-0.97)   0.18 (0.07-0.29)
b,e
Controls, DNormo, DMicro: see text and Table I. Data are given in median (interquartile ranges).
 denotes p<0.05 and   denotes p<0.01 from preexercise;   denotes DNormo>Controls, p<0.05; 
a b c d
denotes DMicro>Controls, p<0.02;   denotes DMicro>Controls and DNormo, p<0.05.
e
plasma NE concentration were greater in both IDDM groups (DNormo: 2.5(1.0- 4.6)
nmol/l; DMicro: 3.2(2.1-3.8) nmol/l) than in Controls (1.0(0.0-2.0) nmol/l) (Dnormo>
Controls, p<0.05; DMicro>Controls, p<0.01) (Figure 1A). The exercise induced
increments in plasma epinephrine were not different in Controls (0.24(0.11-0.35)
nmol/l) compared with DNormo (0.18(0.08-0.29) nmol/l) and DMicro (0.52(0.22-0.70)
nmol/l), but the increments in DMicro were greater than in DNormo (p<0.05) (Figure
1B).
Relationships between plasma catecholamines, haemodynamics and glycaemia 
The relative changes in FalbCl were positively related to the increase in plasma
NE in all groups (All subjects r=0.65, p<0.001; Controls r=0.62, p<0.05; DNormo
r=0.63, p<0.05; DMicro r=0.56, p<0.05) (Figure 2). The exercise induced changes
in FalbCl were also correlated with the increase in MAP in DNormo (r=0.64, p<0.01)
and in DMicro (r=0.60, p<0.02) but not in Controls (r=0.25, p=0.22). Multiple
regression analysis demonstrated that both changes in plasma NE (p<0.002) and in
MAP (p<0.005) independently contributed to the exercise induced alterations in FalbCl
(multiple r=0.73, n=38). Multiple regression analysis in two IDDM groups showed
similar independent effects of plasma NE (p<0.02) and MAP (p<0.005) on the
changes in FalbCl (multiple r=0.75, n=26). When multiple regression analysis was
carried out using the increments in systolic blood pressure instead of MAP the contribu-
tion of blood pressure rise was not significant (p=0.20).1.2
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Figure 1. Changes in plasma norepinephrine and epinephrine concentrations in response to exercise.
Controls F, DNormo F, DMicro M: see text and Table 1. Bars are median values. Upper panel:
Increments in plasma epinephrine concentration. * denotes p<0.01 from preexercise; ** denotes in-
crement in DMicro>DNormo,  p<0.05. Lower panel: Increments in plasma norepinephrine con-
centration. * denotes p<<0.05 from preexercise; ** denotes increment in DNormo and
Dmicro>Controls, p<<0.05. Plasma norepinephrine and albuminuria during exercise 45
Baseline plasma NE concentrations and pulse rate were not correlated. During
exercise a positive relationship was observed between plasma NE and pulse rate in Con-
trols (r=0.77, p<0.01) as well in the combined IDDM groups (r=0.53, p<0.01). No
significant correlations were found between plasma epinephrine concentrations and
either FalbCl, pulse rate or blood pressure during exercise in any of the groups. In the
IDDM groups the changes in plasma epinephrine and NE concentrations were not related
to actual glycaemia and HbA1.
Discussion
Exercise has been proposed to provoke abnormalities in renal protein handling in
IDDM [1,2]. It is unclear whether plasma catecholamines are involved in this abnormal
rise in albuminuria. The subjects participating in the present study did not have systemic
hypertension or signs of autonomic neuropathy. Patients with an abnormal urinary
albumin excretion rate above 10 µg/min were designated microalbuminuric but it should
be noted that levels higher than 20 µg/min are considered to represent a risk marker for
diabetic nephropathy [22]. 
Exercise induced an abnormal rise in albuminuria in both IDDM groups in accor-
dance with many previous studies employing a comparable fixed workload [1-5]. The
mechanisms which are responsible for this abnormal rise in albuminuria are still not
precisely understood. Systemic blood pressure rise, alterations in renal haemodynamics
and in glomerular perm selectivity or a combination of these factors are likely to be
involved [1-9]. As earlier studies have shown [2,6] no difference in blood pressure
response was observed between the normoalbuminuric IDDM and non-diabetic subjects,
making it unlikely that an abnormal increase in blood pressure per se was responsible for
the marked albuminuric response in this group of patients. In the microalbuminuric
IDDM subjects, the increase in blood pressure was larger than in the other groups, in
accordance with other data [5], suggesting that alterations in systemic haemodynamics
could have contributed to the abnormal rise in albuminuria in these patients. This study
showed a significant relationship between the increase in plasma NE and the albuminuric
response during exercise. In addition, the rise in plasma NE was significantly greater in
normo- and microalbuminuric IDDM patients than in the normal subjects, although there
was a considerable overlap in individual responses. Multiple regression analysis substan-
tiated that both the exercise induced rise in plasma NE and in MAP had an independent
effect on the albuminuric response. It is noteworthy that, although used by some investi-
gators [7], diastolic blood pressure recordings are probably underestimated when
measured by the auscultatory method during exercise [23]. Several studies have shown
a relationship between (change in) systolic blood pressure and albuminuria during
exercise [3,5], but this has not consistently been reported [4,6]. In this investigation,
excluding patients with hypertension, the contributory effect of systemic blood pressure
was not significant when using systolic blood pressure instead of MAP in the multiple
regression analysis. 
It has been documented that the filtration fraction rises more and is higher during
exercise in IDDM subjects, especially in patients with microalbuminuria [4,6]. It is
therefore probable that there is a link between the increased glomerular passage of10
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Figure 2. Changes in plasma norepinephrine concentration and relative changes in fractional
albumin clearance in response to exercise. Controls ", DNormo ", Dmicro •: see text and Table
1. Relative changes in fractional albumin clearance are expressed as % of pre-exercise values. All
subjects (n=38):r=0.65, p<0.001; Controls (n=12) F:r=0.62, p<0.05 DNormo (n=13)
F:r=0.63, p<0.05; DMicro (n=13) !:r=0.56, p<0.05
albumin and the rise in filtration fraction during exercise in IDDM patients. Experimen-
tal studies in the rat have shown that infusion of NE results in an increase in filtration
fraction in parallel with directly measured increments in intraglomerular pressure [10],
whereas the degree of albuminuria in response to NE is closely related to changes in
filtration fraction [24]. Taken together, the previously reported renal haemodynamic
changes [4,6] and the presently shown significant relationship between changes in
albuminuria and changes in plasma NE concentrations during exercise would support the
hypothesis that NE is involved in the increase in albuminuria during exercise [9,14].
This present observations also suggest that an altered catecholamine response could
possibly contribute to an abnormal rise in albuminuria in IDDM.
Several factors might be involved in the abnormal rise in plasma NE during
exercise in IDDM. A fixed workload was employed in the expectation that this wouldPlasma norepinephrine and albuminuria during exercise 47
discriminate IDDM and non-diabetic subjects with respect to their albuminuric response
[1-5]. It has been suggested that the maximal working capacity is reduced in
microalbuminuric but not significantly so in normoalbuminuric IDDM patients [6].
Aerobic working capacity was found to be decreased in patients with autonomic neurop-
athy [17,25] and microalbuminuria whereas normoalbuminuric patients showed a normal
maximal oxygen uptake [26]. It seems therefore probable that the fixed workload was
more stressful for the microalbuminuric patients but it is unlikely that the relative
workload was larger for the normoalbuminuric IDDM patients. In addition, it has been
shown that an exaggerated catecholamine response can be related to suboptimal meta-
bolic control [27,28], but no relationship between plasma catecholamines and HbA1c or
actual glycaemia could be demonstrated in this study. The expected increase in pulse rate
[2,7] raises the possibility of an abnormal regulation of the autonomic nervous system
in IDDM [29]. Moreover, an enhanced vasopressor responsiveness to infusion of NE
has been demonstrated in IDDM patients either without overt microvascular compli-
cations [30] or with microalbuminuria [31]. Whether glomerular vascular structures
exhibit such an increased sensitivity to circulatory catecholamines remains to be eluci-
dated.
In conclusion, the present observations suggest that renal protein handling during
exercise is related to both circulating plasma NE and blood pressure in IDDM. The
exaggerated albuminuric response, even in the absence of an increased urinary albumin
excretion at rest, was associated with abnormalities in systemic catecholamine
regulation. Direct experiments are needed to demonstrate a causal relationship between
these phenomena. In addition, the rise in plasma NE was significantly greater in normo-
and microalbuminuric diabetic patients than in the normal subjects, although there was a
considerable overlap in individual responses.
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CHAPTER 3
INFLUENCE OF AMBIENT PLASMA NOREPINEPHRINE ON
RENAL HAEMODYNAMICS IN IDDM PATIENTS AND
HEALTHY SUBJECTS
K. Hoogenberg , A.R.J. Girbes , C.A. Stegeman , W.J. Sluiter , 
1 4 2 1
W.D. Reitsma  and R.P.F. Dullaart  
3 1
Imbalances in renal vasodilatory and vasoconstrictive mechanisms are responsible for the renal
haemodynamic changes observed in IDDM patients. Animal experiments have shown that
norepinephrine (NE) infusion increases the intraglomerular pressure by predominantly efferent
arteriolar vasoconstriction. The relationships between ambient plasma NE levels and renal
haemodynamics were studied in 18 healthy control subjects (group C), in 17 normoalbuminuric
(albumin excretion rate (Ualb.V) <20 µg/min; group D1) and in 17 microalbuminuric (Ualb.V  20-200
µg/min; group D2) IDDM patients without overt autonomic neuropathy. Supine glomerular filtration
rate (GFR (ml/min per 1.73m )) and effective renal plasma flow (ERPF (ml/min per 1.73m )) were
2 2
determined over a 2 h period using constant infusions of  I-iothalamate and  I-hippuran, respec-
125 131
tively. The subjects were studied in the fasting state. The IDDM patients were investigated during near
normoglycaemia. Data are given as means±SD. In group D1, GFR and ERPF (126±15 and 538±89,
respectively) were elevated as compared to group C (108±15 and 478±73; p<0.01 and p<0.05, respec-
tively). In group D2, GFR (124±25, p<0.05) but not ERPF (515±104) was higher than in group C. GFR
and ERPF were negatively correlated with venous plasma NE in C (r=-0.61, p<0.005 and r=-0.64,
p<0.001, respectively), in group D1 (r=-0.54, p<0.03 and r=-0.63, p<0.005, respectively) and in group
D2 (r=-0.53, p<0.03 and r=-0.60, p<0.01, respectively). Multiple regression analysis disclosed that
diabetes per se, independent from plasma NE, had a positive contribution to GFR. In contrast, ERPF
was only related to plasma NE levels. In conclusion, GFR and ERPF are inversely related to venous
plasma NE levels both in healthy and in IDDM subjects, supporting the hypothesis that plasma NE is
a vasoconstrictive substance. The independent positive effect of diabetes as a categorial variable on
GFR, suggests that concomitant vasodilating mechanisms play a role in the renal haemodynamic
alterations in IDDM patients.
Introduction 
In patients with insulin-dependent diabetes mellitus (IDDM) the presence of micro-
albuminuria does not only predict the future development of diabetic nephropathy [1], but
is also associated with generalized vascular damage [2]. Microalbuminuria is thought to
result from an increased glomerular leakage of macromolecules. Both changes in the
glomerular permselectivity properties as well as in systemic and intrarenal haemo-dynami-Chapter 3 50
cs factors have been demonstrated to underlie elevations in urinary albumin excretion [3].
Before and during the microalbuminuric phase renal haemodynamic changes, commonly
reflected by an increase in glomerular filtration rate (GFR), are frequently observed in
IDDM patients [4-7]. In animal models of diabetes mellitus an increase in GFR is
associated with the development of glomerulosclerosis and the progressive loss of kidney
function [8]. Some clinical observations also support the notion that an elevated GFR per
se might contribute to the subsequent development of diabetic nephropathy [5,9]. 
The elevated GFR associated with IDDM has been attributed to an increase in
effective renal plasma flow (ERPF) [5-7], an increase in the glomerular filtration surface
area [10] and possibly an increase in the intraglomerular pressure [5]. Many vasodilatory
and vasoconstrictive substances are able to modulate renal haemodynamics by influencing
the glomerular afferent and efferent arteriolar tone [6,7,11]. Glomerular arterioles contain
"-adrenoreceptors which mediate vasoconstriction induced by norepinephrine (NE)
released at the terminal nerve ending of the sympathetic nervous system (SNS).
Intravenous infusion to reach high physiological NE levels lowers ERPF, whereas the fall
in GFR is less marked [11-14]. Consequently, the filtration fraction (FF) (i.e. the quotient
of GFR and ERPF) rises, reflecting a change in pressure profile along the arterioles.
Recent data suggest that IDDM with microalbuminuria are hypersensitive to NE-induced
vasoconstriction of dorsal hand veins which also carry "-adrenoreceptors [15]. Thus
alterations in SNS activity might be implicated in the pathogenesis of diabetes-associated
renal haemodynamic abnormalities. However, the relation between plasma NE and renal
haemodynamic parameters is uncertain. In a small group of adolescent IDDM patients a
strong negative relationship between the plasma NE level and GFR was observed [16],
whereas others did not find such a relationship [17,18].  
Therefore, the present cross sectional study was conducted to establish the relation-
ships between circulatory NE levels and renal haemodynamic changes in normo- and
microalbuminuric IDDM patients as compared with matched healthy subjects. 
Subjects and methods 
Subjects
All participants consented to the procedure after explanation of the purpose of the
study, which was approved by the local medical ethics committee. Eligible subjects had
an age between 21 and 50 years, a serum creatinine #120 µmol/l, a urinary protein
excretion # 500 mg/day, and a body mass index <27 kg/m . Subjects with hypertension
2
(systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg), using
antihypertensive or anti-inflammatory drugs were excluded from participation. The IDDM
were considered to be insulin-dependent since their glucagon stimulated C-peptide levels
were <0.2 nmol/l. They had a disease duration of at least 5 years. Autonomic function was
assessed with beat-to-beat variation (abnormal if variation less than 10 beats per minute),
valsalva manoeuvre (abnormal if lower than 1.11) and systolic blood pressure response to
standing (abnormal if exceeding 30 mmHg) [19]. None of theAmbient plasma noradrenaline and renal haemodynamics 51
Table 1. Clinical characteristics of the study groups.
Group C Group  D1 Group D2
 (n=18)  (n=17)  (n=17)
Age (years) 30.8 ± 7.7 32.0 ± 8.3 35.8 ± 8.0
Duration of disease (years)  - 14.8 ± 6.0 18.8 ± 5.3
Sex (males/females) 13 / 5 15 / 2 14 / 3
Ualb.V (µg/min) n.d.  9.1(6.4-11.5) 34.4(22.9-105.3)
a c
Mean arterial blood pressure (mmHg) 92 ± 9 95 ± 7 100 ± 8
d
Body mass index (kg/m ) 22.6 ± 2.3 22.5 ± 2.0 23.7 ± 2.0
2
HbA1c (%) n.d. 8.6 ± 1.4 8.3 ± 1.0
Urinary sodium excretion (mmol/day) 182 ± 76 156 ± 63  203 ± 82
Urinary urea excretion (mmol/day) 425 ± 108  435 ± 127 384 ± 113
Insulin dose (U/kg per day)  - 0.74 ± 0.23 0.79 ± 0.22
 
Retinopathy (O/B/P) - 11/4/2 8/5/4
b
Valsalva ratio n.d. 1.57 ± 0.26 1.62 ± 0.38
Beat-to-beat variation during
deep breathing n.d. 29 ± 13 28 ± 10
Change in systolic blood pressure
in response to standing (mmHg) n.d. -5 (-10 to 5) -4 (-8 tot 2)
a
Group C: control subjects; group D1: IDDM patients with UalbV <20 µg/min; group D2: IDDM
patients with UalbV > 20 µg/min and <200 µg/min. n.d. denotes not determined;   Ualb.V: urinary
  a
albumin excretion rate;   Retinopathy: O: absent; B: background; P: proliferative. Values are given
b
in mean ± SD, except for Ualb.V and blood pressure response to standing which are given in median
(interquartile range).   denotes p<0.001 from group D1;   denotes p<0.01 from groups C and D1
c d
subjects suffered from overt autonomic neuropathy defined as at least 1 abnormal test.
Because of the high variability of urinary albumin excretion [20], three timed overnight
urine collections were obtained to measure urinary albumin excretion rate (Ualb.V).
Microalbuminuria was defined as Ualb.V ranging 20 to 200 µg/min in at least two urine
samples [1].
Three groups of subjects were included in the study: 18 healthy controls (group C);
17 IDDM patients with normoalbuminuria (group D1), 17 IDDM patients with micro-
albuminuria (group D2). Table 1 shows the clinical characteristics of the study groups and
data of the autonomic function tests. The groups were closely comparable with respect to
age and there was no difference in sex distribution. Mean urinary sodium and urea
excretion was similar in the groups and none of the subjects used a protein (<0.8 g/day per
kg bodyweight) or a sodium restricted (<50 mmol/day) diet. The two IDDM groups did
not differ in diabetes duration and metabolic control. The proportion of patients with
retinopathy was similar in each IDDM group. 
Procedure of the renal haemodynamic measurements Chapter 3 52
All participants were studied after an overnight fast and remained fasting during the
procedure. Starting at 0800 h, the subjects were studied in the supine position and 
were only allowed to stand on voiding. Diuresis was promoted by a waterload of 300 ml/h,
and no other liquids than water were permitted to drink. The IDDM patients received their
last regular insulin dose 8 to 12 h before the start of the study. 
The IDDM patients were studied during near normoglycaemia to minimize the
possible effects of actual glycaemia on GFR and ERPF [21]. Thus, a 5% glucose solution
was initially infused at a rate 1 ml(0.28 mmol)/h per kg bodyweight together with regular
acting insulin (Velosulin H.M., Novo-Nordisk, Bagsvaerd, Denmark). The amount of
insulin infused was 1% of the total daily requirements per hour. Blood glucose was
measured at 30 min intervals. If blood glucose exceeded 8.3 mmol/l extra insulin was
given intravenously until one hour before the start of the renal haemodynam/ic
measurements. Further insulin boluses were not given since insulin can acutely stimulate
catecholamine release [22]. After a stabilisation period of at least 2 h the renal clearance
studies were carried out. 
GFR and ERPF were measured simultaneously during a 2 h clearance period, using
primed infusions of   I-iothalamate and  I-hippuran, respectively [23].  I-iothalamate
125 131 125
and  I-hippuran were infused at a constant rate of 4.8µCi/h (178 kBq/h) and 12 µCi/h
131
(444 kBq/h), respectively. The clearances were calculated using the formulas U.V/P and
I.V/P, respectively. U.V represents the urinary excretion rate of the tracer, I.V represents
the infusion rate of the tracer, P represents the mean tracer value of 2 plasma samples
taken at the beginning and at the end of the clearance period. Errors in the estimation of
the GFR due to incomplete bladder emptying and dead space were corrected by
multiplying the clearance of  I-iothalamate with the formula: clearance of  I-hippuran
125 131
(I.V/P) / clearance of  I-hippuran (U.V/P). The coefficients of variation for GFR and
131
ERPF are 2.2% and 5.0%, respectively [23]. The GFR and ERPF were corrected to 1.73m
2
of body-surface area. The FF was calculated as the ratio of the GFR and the ERPF. 
Blood pressure was recorded every hour, using a sphygmomanometer. Korotkoff
phase I and V were taken as the systolic and the diastolic blood pressure, respectively. At
the beginning and the end of the clearance period venous blood was drawn from a catheter
inserted into an antecubital vein (kept patent with 0.9% NaCl 20 ml/h). 
Laboratory methods
Blood glucose was measured using a Yellow Springs glucose Analyser (Model 23A,
Yellow Springs Inc,. Yellow Springs, Ohio, USA). HbA1c was determined by colorimetry
(24) (reference values: 4.5 to 5.8%). Serum creatinine, albumin, and urinary sodium and
urea were measured on SMA(C) autoanalysers (Technicon Instru-ments Inc. Tarrytown,
N.Y., USA). Urinary albumin was measured by radioimmuno-assay (Diagnostic Products
Corporation, Apeldoorn, The Netherlands; coefficient of variation 8%). Plasma insulin
and plasma C-peptide concentrations were measured by radioimmuno-assay. Plasma
epinephrine and NE concentrations were determined by high-performance liquid
chromatography (coefficient of variation 4%) [25].
Statistical analysis
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(interquartile ranges) for non-parametrically distributed data. Comparisons of variables
between groups were carried out using analysis of variance for para-metrically and
non-parametrically distributed data as appropriate. Changes of variables within groups
were assessed by paired Student's t-tests or Wilcoxon tests. Adjustment for multiple
comparisons was carried out using Duncan's method [26]. Differences in prevalence of
clinical variables were analysed by chi-square statistic. Correlations were studied using
Spearman's rank analysis. Multiple stepwise regression analysis was used to disclose the
independent contribution of the hormonal and metabolic parameters to GFR and ERPF.
Two-sided p-values less than 0.05 were considered to be significant.
Results 
Blood glucose, plasma insulin and renal haemodynamic parameters
During the 2-h clearance period, insulin and blood glucose concentrations were not
different between the two IDDM groups and did not change significantly (Table 2). 
GFR was significantly higher in both IDDM groups as compared to group C (p<0.01
and p<0.05 for groups D1 and D2, respectively, Table 2), whereas ERPF was only higher
in group D1 than in group C (p<0.05, Table 2). FF was significantly elevated in group D2
as compared to group C (p<0.05) (Table 2). In the combined IDDM groups, ERPF as well
as FF were higher than in group C (p<0.05, for both, Table 2).
Plasma norepinephrine and epinephrine. 
Plasma NE levels were higher in group C than in groups D1 and D2 at the beginning
(p<0.05 for both, Table 3) but not significantly so at the end of the 2 h clearance period
(Table 3). The differences in averaged plasma NE levels did not reach significance
(p=0.08 for group C compared with groups D1 and D2, Table 3). Plasma epinephrine
concentrations were not significantly different between the groups. No significant changes
were observed in plasma NE and epinephrine during the 2 h study period.
Correlation analysis
The averaged values of plasma NE and epinephrine were used for the correlation
analysis. GFR and ERPF were negatively correlated with plasma NE levels in group C
(r=-0.61, p<0.005 and r=-0.64, p<0.001, respectively), in group D1 (r=-0.54, p<0.03 and
r=-0.63, p<0.005, respectively) and in group D2 (r=-0.53, p<0.03 and r=-0.60, p<0.01,
respectively, Figure 1A,B). In the combined IDDM groups, a positive correlation was
found between FF and plasma NE (r=0.34, p<0.05, Figure 1C) which was not present in
group C (r=0.11, NS, not shown). GFR was significantly related to HbA1c
(r=0.34,p<0.05) in the combined IDDM groups, whereas no significant relation existed
between HbA1c, ERPF (r=0.24, p=0.17) and FF (r=0.02, NS). Plasma epinephrine was
not correlated with renal haemodynamics.Chapter 3 54
Table 2. Renal haemodynamics and corresponding plasma glucose and insulin levels. 
Group C  Group D1 Group D2 IDDM all 
 (n=18)  (n=17)  (n=17)  (n=34)
Glomerular filtration rate 108 ± 15 126 ± 15 124 ± 25 125 ± 20
a b b
(ml/min per 1.73m )
2
Effective renal plasma flow 478 ± 73 538 ± 89 515 ± 104 527 ± 96
b b
(ml/min per 1.73m )
2
Filtration fraction 0.22 ± 0.02 0.23 ± 0.03 0.24 ± 0.03 0.24 ± 0.03
b b
Fractional sodium excretion 0.95 ± 0.53 0.78 ± 0.31 0.93 ± 0.42 0.88 ± 0.33
Plasma glucose (mmol/l)
08.00 h 4.6 ± 0.4 12.2 ± 5.5 11.6 ± 4.4 11.9 ± 4.9
a a a
begin        n.d.     6.6 ± 1.1    6.9 ± 1.4  6.7 ± 1.1
end        n.d.     6.5 ± 1.1     6.5 ± 1.2   6.5 ± 1.1
Free plasma insulin (mU/l)
    begin        n.d. 28 (23 - 49) 26 (18 - 35) 28 (19 - 35)
end    n.d. 32 (19 - 43) 23 (13 - 34) 26 (17 - 40)
Group C: control subjects; group D1: IDDM with Ualb.V <20µg/min; group D2: IDDM patients with
UalbV >20 µg/min and <200 µg/min, IDDM all: combined IDDM groups; n.d. not determined;
Values are given in mean±SD, except for free insulin which is given in median (interquartile range).
 denotes p<0.01 and   denotes p<0.05 from group C
a b
Table 3. Plasma norepinephrine and epinephrine concentrations during the renal haemodynamic
measurements.
 Group C Group D1 Group D2 IDDM combined 
  (n=18)  (n=17)  (n=17)  (n=34)
Plasma norepinephrine (nmol/l)
Begin 1.56 ± 0.45 1.32 ± 0.56 1.28 ± 0.40 1.29 ± 0.48
a
End 1.52 ± 0.53 1.30 ± 0.50 1.33 ± 0.49 1.31 ± 0.49
Mean 1.54 ± 0.50 1.31 ± 0.45 1.30 ± 0.44 1.31 ± 0.44
Plasma epinephrine (nmol/l)
Begin 0.15 ± 0.10 0.20 ± 0.14 0.19 ± 0.10 0.19 ± 0.12
End 0.13 ± 0.10 0.18 ± 0.13 0.20 ± 0.10 0.19 ± 0.11
Mean 0.14 ± 0.11 0.18 ± 0.12 0.22 ± 0.10 0.19 ± 0.11
Group C: control subjects; group D1: IDDM patients with Ualb.V <20 µg/min; group D2: IDDM
patients with Ualb.V >20 µg/min and <200 µg/min. Values are given in mean ± SD.   denotes p<0.05
a
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Multiple regression analysis was carried out to evaluate whether renal
haemodynamics were independently related to the plasma NE level and to establish if
plasma NE contributed to the differences in GFR and ERPF between the IDDM and the
non-diabetic subjects. In the analyses plasma NE as well age, diabetes duration, HbA1c,
sodium and urea excretion, and blood pressure were the independent variables. In the
combined groups (n=52), ERPF was only related to plasma NE (r=-0.61, P<0.001). The
model was not improved by including the presence of IDDM as a categorial variable
(p=0.30, multiple r=0.59). Thus IDDM per se did not influence ERPF, independently from
the level of NE. GFR was related to ERPF both in the combined groups (r=0.79, p<0.001)
as well as in IDDM groups (r=0.86, p<0.001). However in the combined groups, IDDM,
included in the model as a categorial variable, had an independent effect on GFR (r=0.22,
p<0.01; multiple r=0.88), indicating that diabetes associated vasodilation influenced GFR.
The other covariates did not contribute to either ERPF or GFR in a model including
plasma NE and IDDM. 
Discussion 
The elevations in GFR and ERPF associated with IDDM are considered to reflect an
imbalance between glomerular vasodilatory and vasoconstrictive mechanisms [5-7,11,17].
This study demonstrates that GFR and ERPF are inversely related to plasma NE levels in
normo- and microalbuminuric IDDM patients as well as in healthy subjects. Our results
extend recent observations in a small group of adolescent IDDM patients showing a
negative correlation between plasma NE and GFR [16] and the possibility arises that
plasma NE is a determinant of renal haemodynamics.
No differences were observed in the inverse correlations between plasma NE and
ERPF in the IDDM patients as compared to the control subjects. This raises the possibility
that the presently observed slightly lower plasma NE levels in the IDDM subjects could
contribute to the elevations in ERPF. Clearly, our study design does not permit a
conclusion with respect to potential differences in renal NE sensitivity in association with
IDDM or microalbuminuria [15]. 
Both animal and human studies indicate that renal blood flow is an important
determinant of GFR [5-7,27]. Our data support this view since GFR was strongly related
to ERPF. However, the elevated GFR cannot be fully accounted for by an increase in
ERPF, since the filtration fraction was higher in the IDDM patients, particularly in those
with microalbuminuria. GFR is also determined by the intraglomerular pressure, the
oncotic pressure and the ultrafiltration coefficient and any of these factors or a combina-
tion of them might explain the IDDM related increase in filtration fraction [5]. Indeed, the
intraglomerular pressure is elevated in experimental diabetes [8] and capillary hyperten-
sion has been documented in IDDM patients [28]. In addition, the glomerular filtration
surface area is increased in IDDM [10] which will influence the ultrafiltration coefficient.
The present study did not differentiate between these mechanisms but multiple regression
analysis disclosed an independent effect of the diabetic state per se on GFR, thus
suggesting that concomitant vasodilating mechanisms are present in IDDM patients. 
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Figure 1. Relationships between renal haemodynamics and plasma norepinephrine levels (NE). F Control
subjects, F IDDM patients with Ualb.V<20 µg/min,! IDDM patients with Ualb.V>20 µg/min and
<200µg/min. A: plasma NE and GFR in F r=-0.61, p<0.005; in F r=-0.54, P<0.03; in ! r=-0.53, p<0.03;
B: plasma NE and ERPF in F r=-0.64, p<0.001; in F r=  -0.63, p<0.005; and in
! r=-0.60, p<0.01; C: plasma NE and FF in the combined IDDM groups r=0.34, p<0.05.Ambient plasma noradrenaline and renal haemodynamics 57
NE constricts renal vasculature via stimulation of "1-adrenoreceptors, which are
located along afferent and efferent renal arterioles [11,14,29]. As compared with other
isolated renal vessels, efferent glomerular arterioles from the rabbit have the highest
sensitivity to the vasoconstrictive action of NE [30] and micropuncture studies in the rat
have shown that NE lowers glomerular blood flow and increases the transglomerular
pressure [13]. In humans NE infusion results in a decrease in ERPF and a rise in filtration
fraction [12]. Moreover, an increase in plasma NE appears to contribute to exercise-
induced changes in microalbuminuria possibly by a renal haemodynamic mechanism [31].
The pathophysiological mechanisms responsible for the relation between the basal
plasma NE level and renal haemodynamics are unknown. NE, present in venous forearm
blood, is derived both from local skeletal muscular nerve activity and from the arterial
circulation [32]. The forearm venous plasma NE concentration is the net result of these
sources minus local neuronal uptake. Thus, the peripheral venous forearm NE concentra-
tion is influenced by other factors than SNS activity alone. NE acts both locally as a
neurotransmitter and distantly as a hormonal factor [33]. It cannot be discriminated
whether the relationship between plasma NE and renal haemodynamics indicates a distant
effect or reflects a generalized or local neurotransmitter spillover of the SNS. To study the
role of SNS activity in diabetes related renal haemodynamic abnormalities it would be
necessary to obtain arterial and venous renal blood samples simultaneously with GFR and
ERPF determinations. 
In conclusion, GFR and ERPF are inversely correlated with the venous plasma NE
level in healthy subjects as well as in IDDM patients with normo- and microalbuminuria,
supporting the hypothesis that circulatory NE can be a renal vasoconstrictive factor. The
positive contribution of IDDM per se to GFR, independently from the negative effects of
plasma NE, suggests that concomitant vasodilating mechanisms play a role in the renal
haemodynamic alterations in IDDM patients.
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CHAPTER 4
EXOGENOUS NOREPINEPHRINE INDUCES AN ENHANCED
MICROPROTEINURIC RESPONSE IN
MICROALBUMINURIC IDDM PATIENTS 
K. Hoogenberg , W.J. Sluiter , G. Navis , T.W. van Haeften , A.J. Smit , W.D.
1 1 2 1 3
Reitsma  and R.P.F. Dullaart  
4 1
Exogenous norepinephrine (NE) increases intraglomerular pressure in animal experiments, but
it is unknown whether NE induces a microproteinuric response in man. Moreover, it has not been
studied whether possible microproteinuric and renal haemodynamic changes induced by NE are
altered in IDDM complicated by microalbuminuria. Therefore, the microproteinuric and renal
haemodynamics responses to exogenous NE infusions were measured in 8 matched normoalbuminuric
IDDM patients (group D1), microalbuminuric IDDM patients (group D2) and control subjects (group
C). As anticipated, mean arterial pressure (MAP)-NE dose response curves were significantly shifted
leftwards in groups D1 and D2 compared to group C (p<0.05), indicating a higher systemic NE
responsiveness in IDDM. On separate days, NE or placebo was infused at individually determined NE
threshold (˛MAP = 0mmHg, T), 20% pressor (˛MAP = 4mmHg, 20%P) and pressor doses (˛MAP =
20mmHg, P) with measurement of urinary albumin and IgG excretion (Ualb.V and UIgG.V), and of
glomerular filtration rate (GFR, by  I-iothalamate) and effective renal plasma flow (ERPF, by  I-
125 131
hippurate). At NE pressor dose Ualb.V and UIgG.V rose in all groups (p<0.05 to 0.01), whereas
urinary $2-microglobulin was unchanged. The increases in Ualb.V and UIgG.V were more
pronounced in the microalbuminuric group than in the other groups (p<0.05). An NE dose-dependent
fall in ERPF and rise in filtration fraction (FF) was found in all groups (p<0.05 to 0.001 for all),
whereas GFR did not change significantly. The renal haemodynamic dose-response relationship was
similar in the groups. In conclusion, exogenous NE acutely promotes glomerular protein leakage, and
it is plausible that intraglomerular NE effects contribute to this phenomenon. The microproteinuric
response is enhanced in microalbuminuric IDDM despite unaltered renal haemodynamic
responsiveness, which may reflect a specific NE response or a general effect of vasopressor stimuli to
promote glomerular protein leakage in patients with a preexistent defect in glomerular perm
selectivity.
Introduction
Microalbuminuria predicts the future development of nephropathy in insulin-
dependent diabetes mellitus (IDDM) [1-3]. Both structural changes in the glomerular
basement membrane and changes in systemic and renal haemodynamics are thought to be
involved in the development and progression of microalbuminuria in IDDM [2-5].
Diabetes-associated glomerular hyperfiltration and elevations in intraglomerular pressureChapter 4 62
may contribute to the progression to overt diabetic nephropathy [6-10]. Several
neurohormonal systems, such as the renin-angiotensin system (RAS) and the sympathetic
nervous system (SNS) are involved in the regulation of glomerular pressure [11].
Norepinephrine (NE) increases intraglomerular pressure in the rat [12]. In accordance with
a renal vasoconstrictive effect of NE, the effective renal plasma flow (ERPF) is correlated
negatively with the ambient plasma NE level in man [13], and in non-diabetic subjects
exogenous NE lowers ERPF without much change in glomerular filtration rate (GFR) [14-
16]. 
Exogenous NE may increase proteinuria in non-diabetic subjects with overt
proteinuria [15], but it is unknown whether exogenous NE affects microproteinuria in
IDDM. In an uncontrolled study in healthy subjects, NE did not evoke an albuminuric
response [17]. Exercise, a manoeuver that increases NE levels, is well known to increase
microproteinuria in normo-and microalbuminuric IDDM patients and healthy subjects.
Increases in urinary albumin excretion during exercise are related to changes in plasma NE
and systemic blood pressure [18]. Systemic and intraglomerular effects of NE may,
therefore, be involved in the increased microproteinuria following strenuous activities
[18,19]. It has, moreover, been proposed that an exaggerated renal haemodynamic NE
responsiveness could play a role in the pathogenesis of diabetic renal disease [20].
This randomized, placebo controlled study was performed to test whether NE evokes
an increase in microproteinuria and if so whether such an increase is more pronounced in
normo- and microalbuminuric IDDM patients. Therefore, we compared the micro-
proteinuric and renal and systemic haemodynamic responses during stepwise exogenous
NE infusions in IDDM patients with and without microalbuminuria and healthy subjects.
Since an enhanced systemic blood pressure response to NE was anticipated in IDDM [21-
23], the subjects were studied at individually determined NE threshold, 20% pressor and
pressor doses.
Methods 
Subjects
All subjects consented to participate in the study, which was approved by the local
medical ethics committee. Eligible subjects had an age between 30 and 55 years, a serum
creatinine <120µmol/l, a urinary protein excretion <500 mg/day, a body mass index <28
kg/m , no overt hypertension (systolic blood pressure <160 mmHg and diastolic blood
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pressure <95 mmHg), no signs of clinical autonomic neuropathy assessed by beat-to-beat
variation during deep breathing (abnormal if difference <10 beats per min), Valsalva
manoeuver (abnormal if ratio <1.1) and systolic blood pressure response to standing
(abnormal if decline >20 mmHg) [24]. Diabetic patients were insulin-dependent,
glucagon-stimulated plasma C-peptide level was <0.2 nmol/l in all of them. They had a
disease duration of at least 15 year. Patients with untreated proliferative retinopathy,
symptomatic coronary heart disease, or peripheral vascular disease were excluded.
Microalbuminuria was defined as a persistently elevated urinary albumin excretion rate
(Ualb.V) between 20 and 200µg/min in at least 2 of the 3 overnight urine collections
obtained over 1 year [1,25]. Urinary tract infection was excluded in all subjects by
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Table 1. Prestudy clinical characteristics of control and IDDM subjects.
Non-diabetic  Normoalbuminuric  Microalbuminuric
 Subjects    IDDM patients  IDDM patients
   Group C Group D1 Group D2
Number    8 8 8
Age (years)  44.4 ± 3.2 45.5 ± 3.6 46.7 ± 3.5
Duration of disease (years)   -  21.6 ± 2.1 27.6 ± 2.2
Sex (males/females)    7 / 1      7 / 1      7 / 1
Cigarette smokers (n)      3     3     3
Urinary albumin excretion(µg/min)  4.0 (2.6-6.2)    4.5 (2.5-8.4)       65.9 (40.1-108.1)  
a
Serum creatinine (µmol/l)     84 ± 4    83 ± 4    88 ± 7
Creatinine clearance (ml/min)  108 ± 5 114 ± 7 116 ± 12
Mean arterial pressure (mmHg)  94.8 ± 2.5 92.4 ± 3.6 101.9 ± 1.5
b
Body mass index (kg/m )  23.2 ± 1.0 24.5 ± 1.1 25.6 ± 0.9 
2
Glycated haemoglobin (%)  5.7 ± 0.2 8.3 ± 0.3 8.2 ± 0.3
c
Sodium excretion (mmol/day)  109 ± 13 103 ± 9 109 ± 7
Protein intake (g/kg per day)  1.11 ± 0.07 0.94 ± 0.07 1.03 ± 0.05
Insulin dose (U/kg per day)    -  0.74 ± 0.10 0.79 ± 0.09
Retinopathy (absent/
background/proliferative)    -       5 / 2 / 1      0 / 5 / 3
d
Valsalva ratio  1.63 ± 0.08 1.59 ± 0.07 1.52 ± 0.07
Beat-to-beat variation     25 ± 3    24 ± 4    16 ± 3 
during deep breathing 
Change in systolic blood pressure  -9.4 ± 2.6 -6.9 ± 3.5 -7.3 ± 2.8
in response to standing (mmHg) 
Values are given in mean±SEM, except UalbV which is given in geometric mean and 95%
confidence interval.  p<0.001 and   p<0.05 from group C and D1;  p<0.001 from group D1 and
a b c    
D2; and  p<0.05 from group D1 by ￿  analysis.
d  2
  Eight healthy control subjects (group C), 8 normoalbuminuric (group D1) and 8
microalbuminuric IDDM patients (group D2) were included (Table 1). They were
individually matched for gender, age (within 5 yr), body mass index (within 2.5 kg/m )
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and smoking habits. Metabolic control and daily insulin requirement was similar in the
normo- and microalbuminuric diabetic groups. Retinopathy was more severe in the
microalbuminuric group. Creatinine clearance was similar in the groups. Mean arterial
pressure (MAP) was higher in patients with microalbuminuria (Table 1). Seven
microalbuminuric diabetic patients used an angiotensin converting enzyme (ACE)
inhibitor that was stopped 6 weeks before the study. No other medication was used.
To avoid bias due to differences in sodium and protein intake on NE sensitivity and
renal haemodynamics [26,27], all participants adhered to diet containing 100 mmol
sodium and 1 g protein/kg body wt per day 1 week before the studies. Protein intake was
calculated from urinary urea excretion assuming nitrogen balance as described [28].Chapter 4 64
Dietary compliance was acceptable in the participants and similar in the groups (Table 1).
The 3 women were studied in the luteal phase of the menstrual cycle.
Study design
The experiments were carried out during 3 consecutive days (see below) in a room
with a controlled temperature of 22 C. The subjects were studied after an overnight fast
o
and remained so during the experiments. Smoking was prohibited and no other liquid than
water was allowed to drink. After completion of each study day meals were provided at
1700 h and 2000 h. The diabetic patients received an intravenous insulin infusion
(Velosulin H.M., Novo-Nordisk, Bagsvaerd, Denmark) at a rate of 30 mU/kg per h,
starting at 0600 h. Blood glucose was measured every 5 to 10 min and clamped at 5
mmol/l by varying the infusion rate of a 20% glucose solution using the euglycaemic
clamp technique [29]. Potassium chloride (10 mmol per 100 g of glucose) was added to
the glucose bottles. The euglycaemic insulin clamp was used to minimize effects of
differences in actual glycaemia on renal haemodynamics [30] and to avoid that changes in
insulin levels during the experiments would potentially influence NE sensitivity [31]. The
diabetic subjects had been admitted to the hospital the evening prior to the study. Blood
glucose was kept between 7 and 11 mmol/l in the evenings and nights before and between
study days. The controls received a 5% glucose infusion (without insulin) to keep blood
glucose unchanged from fasting levels, to prevent a decline in plasma insulin during
prolonged fasting and to prevent increases in endogenous catecholamine release as a
consequence of glucose counter regulation. The minimal glucose infusion rate was 30
ml/h, because a 5% glucose solution was used as vehicle for renal tracers as well as for NE
and placebo.
 NE dose-response curves (day 1)
On day 1, individual dose-response curves to exogenous NE started at 1230 h as
described [32]. After a 30 min baseline period, an NE infusion (norepinephrine tartrate,
Centrafarm BV, Leiden, The Netherlands, dissolved in 5% glucose) was given in the right
antecubital vein. The NE infusion rate was increased at predetermined 25 min steps of 10,
20, 40, 80, 100, 150, 200, 250, 300, 400 and 600 ng/kg per min. The maximal infusion
rate was reached if MAP was increased by 20 to 25 mmHg. Blood pressure was measured
every 2 min at the left upper arm with a semi-automated sphygmomanometer (Dinamap®
1846, Critikon, Tampa, FL, USA). Pulse rate was recorded continuously on an ECG
oscilloscope (Hewlett Packard, Boblingen, Germany). MAP was calculated as a systolic
blood pressure+b diastolic blood pressure (mmHg). 
The pressor dose was defined as the NE infusion rate required to induce a rise in
MAP of 20 mmHg above baseline and was calculated from a semi-logarithmic plot of the
NE dose vs the individual changes in MAP. The individual regression lines were con-
structed from the linear part of the dose-response curve [32]. For each participant the NE
threshold dose (0 mmHg change in MAP), 20% pressor dose (increase in MAP of 4
mmHg) and pressor dose (increase in MAP of 20 mmHg) were calculated from the
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Renal haemodynamic studies and proteinuria assessment (day 2 and 3)
On day 2 and 3, NE or placebo were infused in randomized order in a single-blinded
fashion at threshold, 20% pressor and pressor doses. The subjects remained supine and
were only allowed to stand on voiding. At 0700 h, each subject drank 600 ml water to
promote diuresis. Thereafter, urinary volume loss was supplemented by oral water after
subtraction of the amount of intravenous solutions. Note that urinary albumin excretion
temporarily rises after a water load and that its level has returned to baseline after a 2 h
period [33]. Between 0900 h and 1630 h, renal haemodynamics were measured during 10
consecutive clearance periods each lasting 45 min. Two baseline clearance periods were
followed by 6 periods of NE (2 periods each at threshold, at 20% pressor and at pressor
doses) or placebo. Finally, 2 determinations were obtained after cessation of NE or
placebo infusion (recovery period).
GFR and ERPF were measured simultaneously as the urinary clearances of
I-iothalamate and  I-hippurate, respectively, and corrected for incomplete urine
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collections as described previously [34]. The coefficients of variation for GFR and ERPF
are 2.2% and 5.0%, respectively [34]. The GFR and ERPF were corrected to 1.73 m  of
2
body-surface area. Filtration fraction (FF) was calculated as the quotient of GFR and
ERPF. 
Laboratory measurements
Venous blood samples were taken at the end of each clearance period with the
subjects in supine position. Blood was drawn from a needle inserted into the left antecubit-
al vein that was kept patent with a saline drip (0.9% NaCl, 30 ml per h). Blood samples
were immediately centrifuged at 4EC and the samples were stored at -20EC before assay.
Breakdown and in vitro generation of angiotensin II (AII) was prevented by the addition
of o-phenantroline, enalapril and neomycin. Aliquots of urine for measurement of urinary
proteins were stored at -20EC and analysed within 2 weeks. For proper determination of
IgG, urine was 1:1 diluted with buffered glucose (0.1 M NaCl, 40 mM phosphate, sodium
azide (0.2%), 5% bovine serum albumin and 100 mM glucose adjusted to pH 7.4) [35]. 
Plasma insulin was determined by RIA. Plasma NE was analysed by HPLC [13,18].
Plasma total renin and plasma active renin were determined with commercially available
double-antibody RIA’s (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
The antibody to renin has a cross-reactivity with prorenin of 0.2%. Prorenin was
calculated as the difference between total renin and active renin levels. Serum ACE
activity was measured with an HPLC technique. AII was determined by RIA [36] by
courtesy of P.M.H. Schiffers (Dept. of Pharmacology, State University Maastricht, The
Netherlands). Cross-reactivity of the AII antibody with angiotensin I is <0.1%. Serum
aldosterone was determined by RIA. Serum albumin and IgG were measured using
ELISA. Blood glucose was measured using a Yellow Springs glucose Analyser (Model
23A, Yellow Springs Inc,. Yellow Springs, Ohio, USA). 
Urinary albumin was measured with ELISA using rabbit anti-human albumin
antibody (DAKO). The detection limit is 1 µg/l. Urinary IgG was measured using an
in-house developed ELISA using polyclonal goat-antihuman-IgG (gammachain) (Tago,
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Tilburg, The Netherlands) as conjugate [35]. The detection limit is 1.5 µg/l. Urinary $2-
microglobulin was measured by nephelometry. 
Sodium, potassium, urea and creatinine in serum and urine were measured on
SMA(C) autoanalysers (Technicon Instruments Inc. Tarrytown, N.Y., USA). Glycated
haemoglobin was measured by HPLC (Bio-Rad, Veenendaal, The Netherlands).
Statistical analysis
Results are expressed as mean±SEM for normally distributed data and as geometric
mean (95% confidence interval, CI) for not-normally distributed data unless stated
otherwise. The 2 clearance periods obtained at baseline, threshold, 20% pressor, pressor
and recovery were averaged for analysis. The NE effects were analysed after subtraction
of the data obtained during the placebo day. Within-group and between-group differences
were analysed with one-way ANOVA and repeated measurements ANOVA, for
parametrically or non-parametrically distributed data where appropriate. Adjustment for
multiple comparisons was carried out using Duncan's method. Bivariate correlations were
sought using Spearman's rank correlation. If correlations were significant, logistic
regression lines were constructed using standard curve fitting models where appropriate.
Multiple regression analysis evaluated independent contributions of parameters on the
time-controlled observations during the 3 NE infusion periods. In case of not-normally
distributed data, logarithmically transformed values were used. P-values less than 0.05
were considered to be significant.   
Results
Blood glucose and insulin concentrations during NE and placebo administration
In the diabetic groups, blood glucose remained unchanged and was similar during
NE and placebo infusions (Table 2). In group C, blood glucose rose modestly with
increasing NE dose to levels that were slightly higher than in group D1 and D2 (Table 2).
A reduction of glucose infusion rate was, however, not possible (see study design). In all
groups, plasma insulin was stable during NE and placebo administration. As expected,
plasma insulin levels were consistently higher in group D1 and D2 compared to group C
(p<0.001, Table 2). 
NE dose response curves, blood pressure and venous plasma NE during renal
 haemodynamic studies
The dose-response curves of the calculated threshold, 20% pressor and pressor doses
were significantly shifted leftwards in group D1 and D2 compared to group C (p<0.05 for
both, Figure 1A). As a consequence of the lower NE doses required, lower plasma NE
levels were attained in group D1 and D2 compared to group C during the NE infusion day
(p<0.05, Table 3). There was a close relationship between the NE infusion rate and
increments in plasma NE levels in all groups (C: r =0.93, p<0.001 (n=24); D1: r =0.91, s s
p<0.001 (n=24); and D2: r =0.88, p<0.001 (n=24), Figure 1B). As this relationship was s
similar in the 3 groups, the averaged venous plasma NE-pressor curves were also
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Table 2. Blood glucose and plasma insulin during norepinephrine (NE) and placebo infusions.
 Non-diabetic   Normoalbuminuric   Microalbuminuric
Subjects (n=8)   IDDM patients (n=8) IDDM patients (n=8)
Group C Group D1 Group D2
Period  NE  Placebo    NE  Placebo   NE  Placebo 
Blood Glucose (mmol/l)
Baseline  5.1±0.1 5.1±0.1 4.9±0.1 5.3±0.1 5.2±0.2 5.1±0.1
Threshold 5.8±0.2 5.0±0.1 5.0±0.1 4.9±0.1 5.2±0.2 5.0±0.1
b,d
20%Pressor 6.1±0.2 5.0±0.1 5.1±0.1 5.1±0.1 5.3±0.1 5.0±0.1
c,e
Pressor  6.8±0.4 4.9±0.1 5.1±0.1 5.1±0.1 5.3±0.1 5.0±0.1
c,e
Recovery 6.1±0.3 4.9±0.1 5.1±0.1 5.0±0.1 5.2±0.1 5.1±0.1 
b,e
Plasma Insulin (mU/l)  
a
Baseline  10 ± 2  11 ± 2    30 ± 3  31 ± 3  31 ± 4  31 ± 3
Threshold  11 ±2  12 ± 2    30 ± 3  28 ± 4  30 ± 4  30 ± 3
20% Pressor  12 ± 2  13 ± 2    31 ± 3  31 ± 3  30 ± 4  30 ± 3
Pressor      13 ± 1  12 ± 2    32 ± 4  29 ± 3  32 ± 4  31 ± 4
Recovery  19 ± 4  12 ± 2    30 ± 3  31 ± 3  30 ± 3  29 ± 3
b
Values are given in mean±SEM.   p<0.001 for all values in group C from group D1 and D2; 
a b
p<0.05,   p<0.001 from baseline after correction for placebo day;   p<0.05,   p<0.01 from group D1
c d e
and D2
NE infused at the calculated threshold, 20% pressor and pressor doses resulted in similar
changes in MAP in the 3 groups with adequate achievement of target blood pressures
(Figure 1C, Table 3), while MAP was unaltered with placebo. Baseline pulse rate was
similar among the groups (group C: 63±4, group D1: 62±4, group D2: 67±4 (beats/min)).
In group C, pulse rate declined with each infusion step (threshold dose: -5±2, p<0.05; 20%
pressor dose: -7±2, p<0.01; pressor dose: -11 ±2 (beats/min), p<0.001). In group D1 and
D2 this fall was only present at NE pressor dose ( -7±2 and -6±2 (beats/min), p<0.01,
respectively). The overall pulse rate response was less pronounced in group D1 and D2
compared to group C (p<0.05).
Plasma renin and angiotensin II
During the placebo day, plasma renin and prorenin levels were higher in group D2
than in group C and D1 (renin, see Table 3; averaged prorenin 173 (125 to 241), 281 (196
to 403) and 512 (297 to 884) mU/L (geometric mean and 95%CI) in group D1, D2 and C,
respectively). During NE pressor dose, renin increased in all groups (p<0.05) and
remained so after cessation of NE infusion (p<0.05 for all, Table 3). Chapter 4 68
Table 3. Blood pressure, venous plasma norepinephrine (NE),plasma active renin and
angiotensin II concentrations during NE and placebo infusions.
 Non-diabetic   Normoalbuminuric   Microalbuminuric
Subjects (n=8)   IDDM patients (n=8) IDDM patients (n=8)
Group C Group D1 Group D2
Period  NE  Placebo    NE  Placebo   NE  Placebo 
Mean Arterial Pressure (mmHg)
Baseline 92.7±2.0 90.2±2.7 91.4±3.0 90.3±2.6 97.4±1.3  96.5±2.3
“ at Threshold    2.0±0.5  -0.2±0.7  2.3±0.6  -1.0±0.4   2.5±0.6    0.1±0.9
c
“ at 20%Pressor 4.7±1.1    -1.7±0.8  5.7±0.7  -1.8±0.9   6.0±1.0  -1.3±0.8
d e d
“ at Pressor  20.6±1.6     -0.6±1.0 18.5±1.3  -2.0±0.7  20.8±1.4  -2.1±0.8
e e e
“ at Recovery   -7.0±3.0   0.5±1.6   -3.3±1.8  -3.6±1.3  -2.8±2.1   -0.8±0.7
Venous Plasma NE (nmol/l)  
a
Baseline   2.6(2.0-3.4)   2.6(1.7-3.8)  2.3(1.7-3.2)  2.3(1.6-3.2)  3.0(2.2-4.0)  2.7(2.2-3.4)
Threshold  7.0(4.0-12.4)  2.6(1.9-3.8)  4.8(3.4-6.9)   2.4(1.7-3.3)  5.3(4.2-6.5)   2.9(2.3-3.6)
e e e
20%Pressor  10.4(6.1-17.5)  2.6(2.0-3.5)  5.9(3.7-9.4)  2.5(1.8-3.6)  6.7(5.3-8.4)   2.7(2.0-3.5)
e e e
Pressor         29.2(20.8-41)  2.5(1.9-3.3) 16.0(8-32.2)   2.6(2.0-3.5) 17.3(11-27.1)  2.6(2.2-3.1)
e e e
Recovery  3.6(2.7-4.9)   2.9(2.1-4.1)   3.1(2.1-4.6)  2.5(2.0-3.1)  3.6(2.6-5.1)   3.2(2.4-4.2)
Plasma Active Renin (mU/l)
b
Baseline 40 (27-60)  41 (30-55) 37 (20-69) 37 (16-61) 57 (36-98) 74 (48-113)
Threshold 42 (30-59)  40 (32-49) 36 (19-67) 29 (15-59) 53 (33-84)  59 (34-103)
20%Pressor 46 (33-65)  39 (29-53) 40 (22-75) 28 (14-55) 61 (34-109)  59 (34-101)
Pressor 57 (38-85)   40 (30-53) 52 (30-90) 31 (16-59) 87 (48-159)  66 (41-107)
c c d
Recovery  55 (33-99) 37 (27-51) 55 (28-108)  31 (14-65) 84 (50-139)  71 (47-107)
d d c
Plasma Angiotensin II (pmol/l)
Baseline 16.2±2.3 15.2±2.1 13.9±2.4 13.6±2.1 16.3±2.0 18.1±2.2
Threshold 16.3±1.6 14.8±2.4 13.6±2.1 14.1±2.3 16.1±2.0  16.9±2.4
20% Pressor 18.1±1.6 14.8±2.7 15.3±2.4 13.3±1.9 18.1±2.6  17.6±2.7
Pressor  24.6±3.5 15.8±2.5 18.3±3.1 14.6±2.6 25.1±4.6 17.9±2.8
c c d
Recovery 22.6±5.2 14.3±1.8 20.1±4.6 14.4±2.3 20.9±3.3 16.5±1.8
c c
Values are given in mean±SEM, except plasma NE and plasma active renin which are given in
geometric mean and 95% confidence interval.   Overall values in group C>groups D1 and D2
a
(p<0.05);   overall values in group D2>groups C and D1 (p<0.05);   p<0.05,   p<0.01 and   p<0.001
b c d e
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Figure 1. Relationships between norepinephrine (NE) infusion, plasma NE increment and changes in
mean arterial pressure (MAP). A. Systemic pressor responses to exogenous NE infusions at threshold
(T), 20% pressor (20% P) and pressor (P) dose. B. NE infusion dose and changes in plasma NE at NE
threshold, 20% pressor and pressor dose. Spearman's rank correlation coefficients: control subjects
r =0.93, p<0.001; normoalbuminuric IDDM patients r =0.91, p<0.001 and microalbuminuric IDDM s s
patients r =0.88, p<0.001. The logistic regression lines are constructed by curve fitting. There were no s
differences in the relationships. C. Actual changes in MAP vs
changes in plasma NE at T, 20% P and P dose during NE infusions. Data in geometric means ±
antilog SEM. ! control subjects  (group C), Q normoalbuminuric (group D1) and ˛microalbuminuric
(group D2) IDDM  patients; * denotes p<0.05 from normo- and microalbuminuric IDDM.Chapter 4 70
During placebo infusion, serum ACE activity and plasma angiotensin II were not different
among the groups (Table 3). During NE pressor infusion, plasma AII levels increased
similarly in all groups (p<0.05 for all).
Urinary excretion of albumin, IgG and $2-microglobulin.
Urinary albumin and IgG excretion rates (Ualb.V and UIgG.V) were higher in group
D2 than in groups C and D1 at all observation periods (p<0.01, Table 4). During the
placebo day UIgG.V fell in all groups (p<0.05 to 0.01). Ualb.V also fell significantly
during placebo in group D2 (p<0.05 to 0.01) with a tendency to fall in the other groups as
well (Table 4). Interestingly, during NE pressor infusion, Ualb.V and UIgG.V rose
significantly in all groups (p<0.05 for all, Table 4) and some of these parameters were still
elevated at recovery in group C and D1. The increments in Ualb.V and UigG.V (corrected
for placebo) were more pronounced in group D2 (31.3 (11.8-83.1) and 4.0 (2.0-8.1)
µg/min, respectively) than in group C (4.2 (1.3-13.7) and 0.6 (0.2-2.8) µg/min,
respectively) and D1 (3.8 (1.4-10.1) and 0.6 (0.2-2.0) µg/min, respectively) (p<0.05, Table
4 and Figure 2). Fractional albumin and IgG excretion also increased during NE pressor
infusion in all groups (p<0.05 to 0.01, Table 4). $2-Microglobulin excretion was not
different in the groups during placebo and remained stable during NE infusion (Table 4,
Figure 2). 
Multiple stepwise regression analysis was carried out to evaluate which parameters
contributed independently to the changes in microproteinuria and renal haemodynamics
in response to exogenous NE. Baseline Ualb.V, change in MAP and change in plasma NE
independently contributed to 37% (p<0.001), 8% (p<0.01) and to 6% (p<0.05) of the
variance in change in Ualb.V (multiple r=0.56, 72 data sets). The variance in change in
UIgG.V resulted for 27% from baseline UIgG.V (p<0.001), for 7% from the change in
MAP (p<0.02) and for 5% from the change in plasma NE (p<0.05, multiple r=0.48, 72
data sets). No independent effects of plasma insulin, blood glucose and  angiotensin II on
microproteinuria were demonstrated (p>0.20, for all).
When the relative increments in Ualb.V and UIgG.V at NE pressor infusion were
compared, no differences in the responses were observed between the 3 groups (% incre-
ment in Ualb.V and UIgG.V at NE pressor dose in group C: 233(122-344)% and 233(104-
361)% (geometric mean and 95% confidence interval), in group D1 202(127-278)% and
154(115-193)%, in group D2 166(133-202)% and 166(117-214)%, respectively). Further-
more, multiple regression analysis showed that the relative changes in Ualb.V and UIgG.V
were not independently related to baseline microproteinuria (p>0.20 for both). Thus, the
extent of baseline glomerular protein leakage was the main determinant of the absolute
microproteinuric response to NE.
 Renal haemodynamic studies
During the placebo day, GFR and ERPF were not significantly different between the
3 groups, whereas FF was slightly but significantly higher in group D2 compared to the
other groups (p<0.05). Glomerular hyperfiltration, defined as GFR>130 ml/min per 1.73
m  [9], was present in 2 patients of group D1 and 3 patients of group D2. GFR remained
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Table 4. Urinary excretions of albumin, IgG and $2-microglobulin during norepinephrine
 (NE) and placebo infusions.
 Non-diabetic  Normoalbuminuric   Microalbuminuric
Subjects (n=8)     IDDM patients (n=8) IDDM patients (n=8)
Group C Group D1 Group D2
Period    NE  Placebo    NE  Placebo   NE  Placebo 
Urinary albumin excretion rate (µg/min)
a
B  4.6(3.5-6.2)  5.6(3.5-7.6) 4.2(2.9- 6.0)   5.6(3.4-9.3) 47.9(23.2-98.8)  52.2(22.3-122.2)
T  4.7(2.9-7.8)    4.6(3.2-6.6) 4.3(2.9- 6.6)   5.1(3.1-8.3) 47.6(23.9-94.7)  38.9(16.2-93.4)
S  5.5(3.5-8.8)     4.3(2.9-6.3) 5.6(3.7- 8.6)   5.2(3.2-8.7) 50.3(24.9-101.5)  36.8(14.8-91.8)
b
P  9.7(4.6-20.2)   4.5(3.1-6.7) 7.3(4.8-11.2)  4.6(2.8-7.4)  58.5(33.6-101.7)  33.8(14.9-72.2)
e e d,f c
R  8.2(4.0-16.7)  4.6(3.1-6.9) 7.4(5.1-11.0)  4.1(2.6-6.4) 43.7(24.4-78.1)  31.3(15.2-64.6)
d e b c
Fractional albumin clearance(10 )
-6 a
B 1.1(0.8-1.4)  1.1(0.8-1.5) 1.0(0.8-1.4) 1.2(0.8-1.8) 11.7(4.9-28.1) 12.8(4.8-34.2)  
T 1.0(0.7-1.5)  1.1(0.8-1.4) 1.0(0.8-1.4) 1.2(0.9-1.8) 11.5(4.8-27.9) 9.6(3.2-28.8)
S 1.3(0.9-1.8)  1.0(0.7-1.3) 1.3(0.9-1.8)  1.2(0.8-1.9) 12.4(5.3-29.1) 8.6(2.9-25.4)
P 2.2(1.1-4.3)   1.0(0.8-1.4) 1.7(1.2-2.6) 1.1(0.7-1.7)   15.3(7.4-31.7) 7.9(3.0-21.0)
e d d,f b
R 1.9(1.0-3.4)  1.0(0.7-1.5) 1.9(1.3-2.6)   1.0(0.6-1.4)  11.7(5.6-24.3) 7.7(3.0-19.9)
e c
Urinary IgG excretion rate(µg/min)
a
B 1.1(0.9-1.3)   1.1(0.9-1.4) 1.2(0.8-1.6)   1.4(1.1-1.9)    4.4(3.0-6.6)  4.9(2.4-9.9) 
T 1.1(0.8-1.5)   1.0(0.7-1.3) 1.2(0.8-1.7)   1.1(0.7-1.8)    4.7(3.2-6.7) 4.1(2.4-6.9)
S 1.1(0.8-1.6)   1.0(0.7-1.2) 1.3(0.9-1.1)   1.2(0.9-1.7)    5.1(3.3-7.7) 3.6(2.3-5.8)
b b
P 1.9(0.9-4.0)   0.9(0.7-1.2) 1.4(0.8-2.5)   1.1(0.9-1.4)    5.7(4.4-7.3)   3.2(2.0-5.1)
e b d c d,f c
R 1.4(0.8-2.8)   0.9(0.7-1.2)   1.3(0.8-2.1)   1.0(0.7-1.5)    3.8(2.2-6.5) 3.2(2.3-4.6)
b d c c
Fractional IgG clearance(10 )
-6 a
B 1.3(1.1-1.7)  1.3(1.1-1.5) 1.2(1.0-1.4)   1.3(1.1-1.4)  4.9(2.7-9.2) 5.2(2.2-12.5)
T 1.3(0.9-1.7)  1.2(0.9-1.5)  1.2(1.0-1.4)   1.1(0.9-1.3)  5.1(2.8-9.3) 4.3(1.9-9.5)
S 1.4(1.0-2.0)  1.1(0.9-1.4)   1.2(0.9-1.6)   1.1(0.9-1.3)  5.5(3.1-9.5) 3.6(1.7-7.5)
P 2.4(1.2-5.6)   1.1(0.9-1.3)   1.5(1.0-2.2)   1.0(0.9-1.2)   6.7(4.2-10.8) 3.2(1.5-6.9)
d d b d,f c
R 1.8(0.9-3.6)  1.0(0.8-1.3)   1.3(0.8-1.9)   0.9(0.7-1.3)   4.4(2.2-9.0) 3.3(1.6-6.7)
b b b
$2-Microglobulin excretion(µg/min) 
B 68(53-87)  72(43-122)     62(43-89)      59(43-82)       94(53-167)     88(48-163)
T 53(31-91)   65(45-93)      52(36-75)      52(38-72)       89(54-145)     84(53-133)
S 34(20-56)    63(36-112)     43(30-62)      50(37-68)       76(45-128)     73(48-110)
P 37(24-58)    61(37-101)     39(26-57)      46(33-66)       63(33-119)     66(39-113)
R 38(22-65)    57(37-88)      30(22-42)      44(29-66)       38(18-80)      69(47-100)
Values are given as geometric mean and 95% confidence interval. B: baseline; T: threshold; S: 20%
pressor; P: pressor; R: recovery.    All values in group D2>group C and D1 (p<0.01);   p<0.05,   p<0.01
a b c
from baseline(decline at placebo day);   p<0.05,   p<0.01 from baseline(increase during NE corrected
d e
for placebo day);   p<0.05 from groups C and D1 (absolute increase).
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Figure 2. Relationship between plasma norepinephrine (NE) and A. urinary albumin (Ualb.V), 
B. IGG (UIgI.V) and C. $2-microglobulin excretion. Data in geometric mean ±antilog SEM, values
corrected for placebo day. ! control subjects (group C), Q normoalbuminuric (group D1) and ˛
microalbuminuric (group D2) IDDM patients; * denotes p<0.05 and ** p<0.01 from baseline; 
*** p<0.05 increase in group D2 > group C and D1. Norepinephrine, microproteinuria and renal haemodynamics 73
Table 5. Renal haemodynamics during norepinephrine (NE) and placebo infusions.
 Non-diabetic   Normoalbuminuric   Microalbuminuric
Subjects (n=8)   IDDM patients (n=8) IDDM patients (n=8)
Group C Group D1 Group D2
Period  NE  Placebo    NE  Placebo   NE  Placebo 
Glomerular Filtration Rate (ml/min per 1.73m2)
Baseline 103±5  103±4  105±5  107±6  104±8 108±8 
Threshold 106±6  105±5  109±5  109±8 108±9  109±9 
20%Pressor 104±5  103±4  109±6  111±8 108±9 111±8 
Pressor  103±4 103±4  108±5 108±7 106±19  109±8 
Recovery     92±5 102±3     94±5 107±8   95±8 108±8
c d d
Effective Renal Plasma Flow (ml/min per 1.73m2)
a
Baseline 458±24  461±17  451±22  464±23  442±40   435±38
Threshold 399±17 454±16 411±21 467±24  408±39 435±38 
c d e
20%Pressor 368±14   452±16  385±26 460±26  385±35 438±35 
e e e
Pressor  303±15 446±13  323±20   453±23  308±22 432±36 
e e e
Recovery  441±39 434±8 396±17 457±24 386±32 428±38
e d
Filtration Fraction (%)
a,b
Baseline 21.8±0.7 22.0±0.9  23.4±0.7  23.0±0.8  23.5±0.8   24.6±0.8
Threshold 26.8±1.1   23.1±1.0  26.7±1.1   23.0±0.9  26.9±1.0   25.4±1.0 
c d c
20%Pressor 28.2±1.0 22.9±0.8  28.7±1.2   23.7±0.7  28.4±1.0   25.6±0.8
d e d
Pressor  34.4±1.7   23.2±0.9  33.8±1.3   23.6±0.7  34.2±1.0   25.3±0.8
e e e
Recovery  21.3±1.0 23.5±0.7  23.8±0.5 23.8±0.5  24.6±1.0 25.4±0.8
Values are given in mean±SEM.   Overall responses at threshold, 20% pressor and pressor period
a
in group C >groups D1 and D2 (p<0.05);   p<0.05 from group C and D1 at placebo day;
b
 p<0.05,   p<0.01 and   p<0.001 from baseline, after correction for placebo day.
c d e
ERPF progressively decreased in all groups with increasing NE infusion rates
(p<0.05 to 0.001). As a result, FF rose significantly with all NE infusion steps (Table 5).
The overall changes in ERPF and FF during NE infusions were more pronounced in group
C compared to the diabetic groups (p<0.05 and p<0.01, respectively). In each group, the
changes in ERPF and FF were strongly correlated with the changes in plasma NE levels
(group C: r =-0.82 and r =0.85, n=24, p<0.001; group D1: r =-0.87 and r =0.85, n=24, s s s s
p<0.001; group D2: r =-0.76 and r =0.83, n=24, p<0.001, respectively, but no differences s s
in the relationships between the 3 groups were observed (Figure 3A-B). A similar
relationship was observed with NE infusion dose (data not shown). Thus, for a given
increase in plasma NE level the changes in ERPF and FF were similar in group D1 and D2
compared to group C and the differences in NE dose fully accounted for the between
group differences in ERPF and FF responses. These relationships were not confounded by
variation in plasma insulin and blood glucose (data not shown).0.1 1 10 100
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Figure 3.A. Relationships between changes in plasma norepinephrine (NE) and change in effective
renal plasma flow (ERPF), and B. and filtration fraction (FF) following exogenous NE infusions. The
logistic regression lines are constructed by curve fitting (3 data sets per subject). No difference
in ERPF and FF responses between the groups were demonstrated. ! control subjects (group C), 
R normoalbuminuric (group D1) and ˛ microalbuminuric (group D2) IDDM patients. Norepinephrine, microproteinuria and renal haemodynamics 75
Discussion 
The present study is the first to document that exogenous NE increases
microproteinuria in conjunction with a systemic blood pressure rise and renal
vasoconstriction in normo-and microalbuminuric IDDM patients and healthy subjects. The
lack of effect on urinary $2-microglobulin indicates that NE did not affect tubular protein
handling. The rises in absolute and fractional urinary albumin and IgG excretion,
therefore, support the notion that NE increases glomerular protein leakage. Furthermore,
in absolute terms the microalbuminuric response was more pronounced in micro-
albuminuric IDDM patients than in normoalbuminuric IDDM patients and healthy
controls. By contrast, the renal haemodynamic responses to NE were similar in the 3
groups, as indicated by similar relationships between plasma NE increments and renal
haemodynamic responses. 
As systemic blood pressure is an important determinant of microproteinuria in
IDDM [4,5,18,37], this study was designed to evaluate the microproteinuric and renal
haemodynamic effects of NE given in doses that induced predetermined blood pressure
increments. We were thus able to avoid confounding effects of differences in blood
pressure responses to NE. The enhanced blood pressure responsiveness in the diabetic
groups is in keeping with earlier reports  [21-23] and underscores the relevance of this
approach. The less pronounced decline in heart rate in the IDDM patients, which may
reflect impaired baroreflex function, could have contributed to this enhanced systemic NE
responsiveness [38].
The prevailing plasma insulin and blood glucose levels can affect systemic vascular
NE responsiveness, as well as ERPF and GFR [30,31,39-41]. Exogenous insulin acutely
elevates renal plasma flow at levels of 90 mU/L, but not significantly so at levels of 30 to
40 mU/l [40,41], and rises in blood glucose from normal to moderately elevated levels
modestly increases GFR [30]. In our study, plasma insulin was kept constant during NE
infusion in all groups. Its level was higher in the IDDM patients (approximately 30 mU/l)
than in the control subjects (approximately 10 mU/l). This difference was intentionally
allowed since plasma insulin levels of 30 mU/L are normally encountered in IDDM, but
non-physiologically high in fasting healthy subjects [13]. The normoglycaemic
circumstances allowed evaluation of the NE effects unaffected by the prevailing blood
glucose. The slight increase in blood glucose during NE infusion in the control subjects is
very unlikely to be of relevance in the interpretation of the NE effects, as supported by the
lack of effect of this parameter in statistical analyses. 
The similar regression lines between NE doses and venous plasma NE increments
in all groups, is in keeping with an unaltered plasma NE clearance in diabetic patients
[42]. Although venous antecubital NE measurement has the disadvantage of being
confounded by forearm NE spillover and extraction [43], it is thus improbable that the
interpretation of our results was biassed by using venous plasma NE levels. Yet, our study
does not allow conclusions to potential differences in intrarenal NE handling between
(microalbuminuric) IDDM patients and control subjects.
Based on observations in hand vein studies, which like renal arterioles also contain
"-adrenoceptors, it has been suggested that an exaggerated renal vascular responsiveness
to NE might be involved in elevations in albumin excretion rate in IDDM [20]. In thisChapter 4 76
study, we found no evidence for an altered renal vascular NE responsiveness in normo-
and microalbuminuric IDDM as indicated by similar the relationships between increments
in plasma NE and renal haemodynamic changes in the 3 groups. In comparison, the
diabetic state has been variably associated with either an increase, no change or a decrease
in vascular reactivity to vasoconstrictive agents [44]. These discrepancies may be
attributed to differences in the species investigated, in the blood glucose and insulin levels
during the experiments, or the vascular bed under study. 
Posture and diurnal rhythm affect glomerular protein leakage. Our study clearly
demonstrates that urinary protein excretion falls under conditions of supine rest. Interest-
ingly, for albumin this fall was particularly apparent in the microalbuminuric patients.
This indicates that it is mandatory to include time-control data to properly evaluate the
effects of acute interventions on microalbuminuria. The previous reported lack of effect
of NE to increase microalbuminuria in healthy subjects may thus have been due to the
uncontrolled data use in that study [17]. Two recent studies report that exogenous angio-
tensin II does not influence microalbuminuria in non-diabetic [45] and diabetic subjects
[46], in spite of a clear-cut effect on renal haemodynamics. This could indicate that low
doses of exogenous angiotensin II, unlike our findings with NE, are indeed unable to
induce a rise in albuminuria in man. On the other hand, the absence of time-control data
in those studies also hampers a direct comparison with our data. 
The microproteinuria promoting effect of NE may have arisen from its systemic
blood pressure elevating effects as well as from an intrarenal effect, like a rise in glomer-
ular pressure. Animal experiments have shown that NE, irrespective of systemic blood
pressure, induces a rise in glomerular pressure [12], thereby promoting glomerular protein
leakage. Although glomerular pressure can not be measured directly in man, our findings
of a well-preserved GFR despite a pronounced decrease in ERPF during NE are strongly
suggestive for a rise in filtration pressure. To identify the determinants of this
microproteinuric response, we performed multiple regression analysis. This analysis
revealed blood pressure to be an independent determinant of the microproteinuric
response, suggesting that the rise in blood pressure is causally involved in the rise in
microproteinuria. Microalbuminuria was also independently related to the plasma NE
level, indeed suggesting a blood pressure independent effect of NE as well. 
The exaggerated rise in microproteinuria in microalbuminuric IDDM could not be
explained by an altered blood pressure response or renal haemodynamic responsiveness to
NE nor by a difference in NE-induced angiotensin II release. Instead, the baseline level of
microproteinuria appeared to be the main determinant of the microproteinuric response to
NE across the groups. In accordance, no between group differences in relative increments
in urinary albumin and IgG excretion were seen. This underscores that the preexistent
defect in glomerular perm selectivity is crucial in the absolute microproteinuric effect of
NE. Our data do not allow a conclusion whether such an effect is specific for NE, or
alternatively, whether any proteinuria-promoting manoeuver is inclined to induce a larger
response when a defect in glomerular capillary permselectivity is already present. The
enhanced microproteinuric response was found both for the negatively charged albumin
and for the much larger and predominantly neutrally charged IgG, raising the possibility
that a loss of anionic charge of the glomerular basement membrane is not the only
abnormality at this early stage of diabetic nephropathy [47]. Norepinephrine, microproteinuria and renal haemodynamics 77
What is the clinical relevance of our findings? The present results are consistent with
the concept that NE contributes to a rise in microproteinuria as for instance observed
during strenuous exercise [18,19]. The larger absolute response in micro-albuminuric
IDDM may implicate that this phenomenon contributes to persistent microproteinuric
glomerular protein leakage. As glomerular protein leakage is presumed to be involved in
the progression of diabetic nephropathy [48,49], such small but repetitive increases in
glomerular protein leakage could be involved in progressive renal damage in the long run.
In conclusion, exogenous NE causes a microproteinuric response in association with
a rise in blood pressure, renal vasoconstriction and possibly intraglomerular hypertension.
In microalbuminuric IDDM, this microproteinuric response is enhanced, which may
reflect either a specific response to NE or a general effect of vasopressor stimuli to
promote glomerular protein leakage in patients with a preexistent defect in glomerular
permselectivity.
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CHAPTER 5
NOREPINEPHRINE-INDUCED BLOOD PRESSURE RISE
AND RENAL VASOCONSTRICTION IS NOT ATTENUATED
BY ENALAPRIL IN MICROALBUMINURIC IDDM 
K. Hoogenberg , G. Navis and R.P.F. Dullaart
1 2  1
In non-diabetic subjects an attenuated systemic norepinephrine (NE) responsiveness may
contribute to the mechanisms of action of angiotensin-converting enzyme (ACE) inhibitor treatment.
We determined whether ACE-inhibitor treatment influences systemic and renal haemodynamic
responsiveness to exogenous NE, as well as urinary albumin excretion during NE, in micro-albuminur-
ic IDDM patients, representing a patient category that benefits by strict blood pressure control. In 7
microalbuminuric IDDM patients, systemic and renal responsiveness to NE, infused at individually
determined threshold (˛mean arterial pressure (MAP)=0mmHg), 20% pressor (˛MAP =4mmHg) and
pressor (˛MAP=20mmHg) doses, were compared before and after 8 weeks treatment with enalapril,
10 mg daily. Blood glucose was clamped at 5 mmol/l and insulin was infused at 30 mU/kg per h.
Enalapril decreased MAP (p<0.05) and microalbuminuria (p<0.05), whereas effective renal plasma
flow (ERPF) increased (p<0.01) and glomerular filtration rate (GFR) remained unaltered. Filtration
fraction tended to decline (p=0.09). The ACE inhibitor-induced fall in MAP disappeared at NE pressor
dose, and the overall mean increase in MAP in response to NE was even higher with than without
enalapril (p<0.05). After enalapril, ERPF remained higher at all NE doses (p<0.05), but the magnitude
of the NE-induced fall in ERPF was not altered by ACE inhibition treatment. Overnight urinary
albumin excretion fell by ACE-inhibition (p<0.05), but this effect was not seen during NE infusion.
The angiotensin II/active renin ratio and serum aldosterone levels remained lower with enalapril at all
NE doses (p<0.05). In conclusion, enalapril does not attenuate systemic and renal vascular
responsiveness to exogenous NE in microalbuminuric IDDM despite adequate inhibition of the renin-
angiotensin-aldosterone system. These findings suggest that the effect of NE on vasoconstriction is not
effectively counteracted by ACE inhibition treatment alone.
Introduction 
Blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin-con-
verting enzyme (ACE) inhibitors lowers blood pressure, (micro)albuminuria and slows
progression of diabetic and non-diabetic renal insufficiency, although such treatment is
unable to completely prevent this serious complication [1-3]. The mechanism of action of
these agents is still incompletely understood. Both angiotensin II-dependent and
independent mechanisms are thought to be involved. The sympathetic nervous system
(SNS) and RAAS are closely related [4] and ACE inhibition may influence systemic
norepinephrine (NE) reactivity. Experimental studies indeed have shown that systemicChapter 5 82
vascular NE responsiveness is attenuated by ACE inhibitors [5,6]. A decrease in systemic
NE responsiveness after ACE inhibition treatment has been demonstrated in hypertensive
subjects [7-9]. Moreover, in healthy subjects the renal vasoconstrictive response has been
found to be reduced after ACE inhibition [10]. This would suggests that attenuation of
renal NE responsiveness may be involved in the renoprotective effect of ACE inhibitors
in non-diabetic subjects.
In insulin-dependent and non-insulin-dependent diabetes mellitus (IDDM and
NIDDM), the systemic vasopressor response to exogenous NE has been repeatedly found
to be enhanced [11-13]. The effect of ACE inhibition on systemic and renal NE respon-
siveness is less well characterised in diabetes mellitus. In patients with NIDDM and in a
heterogeneous group of NIDDM and IDDM patients, treatment with enalapril or captopril
did not normalise the exaggerated systemic NE responsiveness [14,15], but this has not
been studied in IDDM complicated by microalbuminuria. It is of particular relevance to
evaluate the NE responsiveness after ACE-inhibition treatment in microalbuminuric
IDDM patients, because control of factors that contribute to a blood pressure rise in such
patients appears to be indicated to prevent progression to overt nephropathy. The purpose
of our study was, therefore, to evaluate the effect of enalapril treatment on systemic and
renal haemodynamic responsiveness to exogenous NE in IDDM patients with
microalbuminuria.
Subjects and methods 
Subjects 
The study was approved by the local medical ethics committee and all participants
gave written informed consent. The patients were considered insulin-dependent, and
glucagon stimulated C-peptide levels were less than 0.2 nmol/l. Seven patients (6 men, 1
women) participated. They had a mean age of 48±9 (mean±SD) years and a diabetes
duration of 29±5 years. None had severe obesity (body mass index ranging from 23.5 to
27.9 kg/m ). All of the patients had persistent microalbuminuria (defined as an urinary
2
albumin excretion rate (Ualb.V) between 20 to 200 µg/min in at least two out of three
overnight urine collections for a 1-year period). All patients were treated with enalapril for
elevated blood pressure related to the presence of incipient nephropathy (systolic/ diastolic
blood pressure >140/90 mmHg), but none had essential hypertension before development
of microalbuminuria. ACE inhibition treatment was stopped for 6 weeks before the start
of the study. Without enalapril, 6 patients had a systolic blood pressure > 140 mmHg and
1 patient had a diastolic blood pressure >90 mmHg. None of the patients had untreated
proliferative retinopathy, symptomatic coronary heart disease, peripheral vascular disease,
or clinical autonomic neuropathy as evaluated by standard tests (beat-to-beat variation
during deep breathing, Valsalva manoeuvre and systolic blood pressure response to
standing). All participants were instructed by dietician to adhere to a diet containing 100
mmol sodium and 1 gram protein/kilogram body weight per day throughout the studies.
Three timed overnight urine collections were obtained directly prior to the studies. Enalapril and norepinephrine reactivity in IDDM  83
Table 1.Baseline characteristics before and after 8 weeks treatment with enalapril.
before ACEi  with ACEi
HbA1c (%) 8.4 ±0.2 8.5 ± 0.2
Body weight (kg) 83.2 ± 2.7 83.3 ±2.7
Urinary urea excretion (mmol/day) 279 ±26 282 ± 16
Sodium excretion (mmol/day) 110 ±8 123 ± 10
Mean of 3-timed overnight urinary  71.4 (33.5 - 152.2) 50.9 (36.8 - 97.2)
a
albumin excretion rates (µg/min)
Data in mean±SEM, except for urinary albumin excretion rate which is geometric mean (95%
confidence interval). ACEi: angiotensin converting enzyme inhibition.   denotes p<0.05 
a
Study design
NE-infusions were performed on three separate study days. On the first day,
systemic MAP-NE dose response curves were made. The individual NE threshold (˛mean
arterial pressure (MAP)=0mmHg), 20% pressor (˛MAP=4mmHg) and pressor doses
(˛MAP=20mmHg) were calculated from MAP-NE dose response curves. On a separate
day, the stepwise NE infusions were given with renal function measurements during 10
consecutive 45 min clearance periods. Two baseline periods were followed by 6 periods
of NE (2 periods for threshold, 20% pressor and pressor doses, respectively), after which
2 determinations were obtained after cessation of the infusion (recovery period). Blood
pressure was recorded every 5 min (Dinamap). These systemic and renal haemodynamic
studies were repeated after 8 weeks of treatment with the ACE inhibitor enalapril (10
mg/day), given at 0800 h. The same NE doses were administered during this second
evaluation. The patients also participated in another study that aimed to compare the renal
haemodynamic and microproteinuric NE responses in micro- and normoalbuminuric
IDDM patients and control subjects, and the pre-enalapril data were also used for that
study [13]. One initially studied patient declined to participate in the second evaluation. 
The experiments were carried out in a temperature-controlled room kept at 22 C.
o
The subjects were studied after an overnight fast and remained so during the experiments.
Smoking was prohibited and no liquid other than water was allowed to drink. The subjects
remained in supine position and were only allowed to stand on voiding. Two hours before
the start of the renal haemodynamic measurements, each subject drank 600 ml water to
promote diuresis. Thereafter, urinary volume losses were suppleted by water drinking. An
euglycaemic insulin clamp was used to minimise effects of differences in actual glycaemia
on renal haemodynamics [16] and to avoid that changes in insulin levels during the experi-
ments would potentially influence NE sensitivity. Insulin was infused (Velosulin H.M.,
Novo-Nordisk, Bagsvaerd, Denmark) at a rate of 30 mU/kg per h. Blood glucose was kept
at 5 mmol/l by varying the infusion rate of a 20% glucose solution. Potassium chloride (10
mmol per 100 g of glucose) was added to the glucose vials.
GFR and ERPF were measured simultaneously using primed infusions of  I-
125
iothalamate and  I-hippurate, respectively [16]. The clearances were calculated using the
131
formula U.V/P and I.V/P, respectively. U.V represents the urinary excretion rate of theChapter 5 84
tracer, I.V represents the infusion rate of the tracer, and P represents the tracer value of
plasma samples taken at the end of each clearance period. Errors in the estimation of GFR
due to incomplete bladder emptying and dead space were corrected by multiplying the
clearance of  I-iothalamate with the formula: clearance of  I-hippurate (I.V/P) /
125 131
clearance of  I-hippurate (U.V/P). The coefficients of variation for GFR and ERPF are
131
2.2% and 5.0%, respectively [16]. The GFR and ERPF were corrected to 1.73m  of body-
2
surface area. Filtration fraction (FF) was calculated as the quotient of  I-iothalamate and
125
I-hippurate clearances. 
131
Analytical methods
Blood samples were taken from an intravenous catheter at the end of each clearance
period with the subjects in supine position. Blood was immediately centrifuged at 4 C and
o
samples were stored at -20 C before assay. Aliquots of urine for measurement of urinary
o
proteins were stored at -20 C and analysed within 2 weeks. Plasma insulin was determined
o
by RIA. Plasma NE was analysed by HPLC [17]. Active plasma renin was determined
with a commercially available double-antibody RIA (Nichols Institute Diagnostics, San
Juan Capistrano, CA, USA) with a cross-reactivity with prorenin of 0.2%. Serum ACE
activity was measured with an HPLC technique. Angiotensin II was determined by RIA
(Dept. of Pharmacology, State University Maastricht, The Netherlands). Cross-reactivity
of the angiotensin II antibody with angiotensin I is <0.1%. Serum aldosterone was
determined by RIA. Blood glucose was measured using a Yellow Springs glucose
Analyser (Model 23A, Yellow Springs Inc, Yellow Springs, Ohio, USA). Urinary albumin
was measured with ELISA using rabbit anti-human albumin antibody (DAKO). The
detection limit is 1 µg/l. Sodium, potassium, creatinine and serum albumin in serum and
urine were measured on SMA(C) autoanalysers (Technicon Instruments Inc. Tarrytown,
N.Y., USA). 
Statistical analysis
Results are expressed as mean±SEM for parametrically distributed data and as
geometric mean (95% confidence intervals) for non-parametrically distributed data unless
stated otherwise. The 2 clearance periods obtained at baseline, threshold, 20% pressor,
pressor and recovery were averaged for analysis. Where appropriate, repeated measure-
ments ANOVA for parametrically or non-parametrically distributed data was used to
analyse the effects of the NE-infusions before and after ACE inhibition. Paired t-tests or
Wilcoxon tests were then used to establish differences between corresponding observation
periods. Differences in NE effects on MAP and ERPF before and after ACE inhibition
were evaluated by comparing the overall mean changes of each individual. p-Values less
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Results 
Metabolic control, body weight, urinary urea and sodium excretion were similar
before and after treatment with enalapril (Table 1). Enalapril lowered baseline MAP by
5%, but did not change pulse rate (Table 2). GFR was unaltered, whereas ERPF increased
by 9% (Table 2). FF tended to fall (p=0.09). Overnight microalbuminuria fell by 28%
(Table 1). Enalapril increased plasma active renin and decreased serum ACE activity and
serum aldosterone levels (Table 3). Baseline plasma AII did not significantly change, but
the AII/active renin ratio profoundly decreased, indicating adequate RAAS inhibition. 
Plasma NE concentrations during NE infusions were similar before and after ACE
inhibition (Table 2). Before enalapril, NE increased MAP at 20%pressor and pressor doses
to target levels (Table 2). With enalapril, NE infusion also increased MAP. At NE pressor
dose there was no difference in MAP compared to before enalapril. The overall mean
increment in MAP was greater during than before enalapril (p<0.05, Figure 1A). At
recovery, MAP was again lower with than without enalapril. ACE inhibition treatment did
not influence the fall in pulse rate at NE-pressor dose and its rise at recovery (Table 2). 
GFR remained essentially unaltered during NE infusions before and after enalapril,
but declined at recovery (Table 2). ERPF progressively decreased at 20% pressor and at
pressor dose both before and during enalapril, and corresponding rises in FF were seen.
During all observation periods, ERPF remained significantly higher with than before
enalapril, and the magnitude of the NE-induced decrease in ERPF was not influenced by
enalapril treatment (Figure1B). The overall urinary albumin excretion rate during NE
infusion was 51.5 (24.3-109.1) µg/min before and 57.6 (26.3-126.3) µg/min after enalapril
(p>0.20).
Before enalapril, plasma active renin, angiotensin II and serum aldosterone levels in-
creased at NE pressor dose, whereas the angiotensin II/active renin ratio remained una-
ltered (Table 3). With enalapril, plasma active renin and serum aldosterone levels rose at
NE-pressor dose, but plasma angiotensin II did not significantly increase. At NE- pressor
dose a slight fall was seen in the angiotensin II/active renin ratio. The overall mean levels
of plasma active renin, serum ACE activity, angiotensin II, the angiotensin II/active renin
ratio and serum aldosterone were lower after enalapril. 
Mean blood glucose and plasma insulin concentrations were 5.2±0.1 and 5.1±0.1
mmol/l and 230±22 and 251±19 pmol/l, before and after enalapril,  respectively (NS). 
Discussion 
As expected, enalapril lowered blood pressure and overnight urinary albumin
excretion, and induced renal vasodilatation in microalbuminuric IDDM patients. The
systemic haemodynamic and the renal responsiveness to exogenous NE, as well as urinary
albumin excretion during NE, were however not altered by ACE inhibition treatment.Chapter 5 86
Table 3. Parameters of the renin-angiotensin II-aldosterone system during stepwise
norepinephrine infusions without and with enalapril
Plasma active Angiotensin- Angiotensin II Angiotensin II/ Serum
Renin (mU/l)  convering-  (pmol/l) plasma active    aldosterone
a a
enzyme (U/l)   renin ratio     (nmol/l)
a a
without enalapril
Baseline    61 (33-111)  29 ± 3   15 ± 2 0.26 ± 0.05  360 ± 40
Threshold  55 (32-94) 28 ± 3   14 ± 1 0.28 ± 0.05  330 ± 40
20% Pressor  64 (49-187) 28 ± 4   16 ± 1 0.28 ± 0.06  420 ± 40
Pressor  95 (49-187) 28 ± 4   25 ± 5 0.25 ± 0.05  710 ± 130
e e e
Recovery  91 (51-160) 25 ± 3   21 ± 4 0.24 ± 0.03  460 ± 50
d
with enalapril
Baseline 121 (41-359)  6 ± 2   14 ± 4 0.10 ± 0.02    90 ± 20
b b b
Threshold 127 (49-335)  6 ± 2   11 ± 2 0.09 ± 0.02  100 ± 30
b c b
20% Pressor 137 (54-485)  7 ± 2   12 ± 2 0.09 ± 0.02  110 ± 20
b b b
Pressor 201 (85-485)  8 ± 2   18 ± 4 0.08 ± 0.01  220 ± 30
e b b,d b,e
Recovery 198 (98-402)  9 ± 2   15 ± 2 0.07 ± 0.01  170 ± 40
c,d b c,e b
Data in mean±SEM and geometric mean (95% confidence intervals).   p<0.01 overall mean values
a
without vs with enalapril,   p<0.05 and   p<0.01 from corresponding infusion period before
b c
enalapril,   p<0.05 and   p<0.01 from baseline values
d e
Table 2. Systemic and renal hemodynamic parameters during stepwise norepinephrine
infusions without and with enalapril.
Plasma    Mean arterial Pulse   Glomerular   Effective renal Filtration
  norepinephrine pressure  rate   filtration rate  plasma flow    fraction
(nmol/l)    (mmHg) (beats/min) (ml/min/1.73m ) (ml/min/1.73m )  (%) 
2 2
without enalapril
Baseline    2.9 (2.1-4.2)    98± 2   70 ± 5 107 ± 9    460 ± 40 23 ± 1
Threshold  5.1 (4.0-6.6)  100 ±1 66 ± 4 111 ±10    427 ± 40 26 ± 1
20% Pressor  6.6 (5.1-8.6)  102 ± 2 66 ± 4 110 ± 9    400 ± 34 28 ± 1
c d d
Pressor 17.7(10.3-30.2)  118 ±1 63 ± 4   109 ± 9   318 ± 22 34 ± 2
d d d d
Recovery  3.6 (2.4-5.4)    95 ± 3 76 ± 5  97 ± 10 398 ± 32 24 ± 1 
d d d
with enalapril
Baseline  2.9 (2.0-4.0)    92 ± 3 67 ± 4 111 ± 11 500 ± 44 22 ± 1 
a b
Threshold  5.7 (4.8-6.9)    96 ± 2 65 ± 4 117 ± 12 463 ± 38 25 ± 1
a a d
20% Pressor  6.3 (4.8-8.2)    98 ± 2 65 ± 4 116 ± 11 431 ± 35 27 ± 1
a,c a,c d
Pressor 18.7 (11.1-31.5) 116 ± 2 62 ± 4 115 ± 10 352 ± 27 33 ± 1
d d a,d d
Recovery  4.2 (2.9-6.0)    87 ± 3 74 ± 4 102 ± 9 460 ± 34 22 ± 1 
b d c b
Data in mean±SEM and geometric mean (95% confidence intervals).   p<0.05 and   p<0.01 from
a b
corresponding infusion period without enalapril,   denotes p<0.05 and   denotes p<0.01 from
c d
baseline 50 1A
0 10 20 30 40 50
40
30
20
10
0
c
h
a
n
g
e
 
i
n
 
M
A
P
 
a
f
t
e
r
 
e
n
a
l
a
p
r
i
l
 
(
m
m
H
g
)
change in MAP before enalapril (mmHg)
0 1B
-300 -250 -200 -150 -100 -50 0
-50
-100
-150
-200
-250
-300
c
h
a
n
g
e
 
i
n
 
E
R
P
F
 
a
f
t
e
r
 
e
n
a
l
a
p
r
i
l
(
m
m
m
)
2
i
n
p
e
r
1
7
3
.
l
/
change in ERPF before enalapril
(m m m ) 2 in per 1 73 . l/
Enalapril and norepinephrine reactivity in IDDM  87
Figure 1(A,B). Plot comparing individual changes in mean arterial pressure (MAP, A) and effective
renal plasma flow (ERPF, B) in response to stepwise norepinephrine infusions before and after ACE
inhibition. The lines indicate identical changes. Overall mean change in MAP was greater with than
without enalapril (n=7, p<0.05 by paired Wilcoxon test). No difference in overall ERPF response was
observed.Chapter 5 88
Apart from general factors like basal vasomotor tone and vascular reactivity, sodium
and volume homeostasis, as well as baroreceptor feedback control are determi
nants of the systemic reactivity to exogenous NE, and may thus contribute to an enhanced
systemic NE responsiveness in diabetes mellitus [8,11,13,18]. Such an exaggerated
responsiveness has been found to be associated with an increased exchangeable sodium
and a higher extracellular volume, and this hyperreactivity decreases after diuretic
treatment  [11]. In addition, microalbuminuric IDDM patients have an attenuated pulse
rate decline during NE infusion [13], which suggests that an altered baroreceptor
feedback control may also contribute to the systemic NE hyperresponsiveness in IDDM
[18]. 
The observation that enalapril treatment failed to diminish systemic vascular NE
reactivity in microalbuminuric IDDM is in keeping with previous findings in diabetic
patients [11,12]. By contrast, in essential hypertension, the systemic responsiveness to NE
appears to be attenuated after ACE inhibition treatment [7-9]. Several factors could be
involved in the lack of attenuation of the systemic NE responsiveness after ACE inhibition
in diabetes mellitus. First, ACE inhibition therapy is unlikely to have influenced sodium
and volume status in the present study since body weight remained unchanged. Indeed,
captopril does not significantly decrease exchangeable sodium in diabetes mellitus [14].
In this respect, it is noteworthy that ACE inhibition treatment induces a negative sodium
balance in essential hypertension [19]. Second, a similar heart rate decline during NE
before and after enalapril was observed, suggesting no important alterations in
baroreceptor sensitivity, in agreement with findings in hypertensive diabetic patients [14].
Third, although enalapril induced adequate RAAS suppression, it cannot be excluded that
a more complete inhibition of angiotensin II formation is required to blunt systemic NE
reactivity. Finally, we consider a type II error very unlikely to explain the lack of attenua-
tion of enalapril on systemic NE reactivity, since the mean increment in MAP in response
to NE was even higher after ACE inhibition. 
This study is the first to document the effect of ACE-inhibition treatment on NE-
induced renal vasoconstriction in microalbuminuric IDDM patients. In IDDM, ACE
inhibitors increase renal plasma flow without having much effect on glomerular filtration
rate. As a consequence, filtration fraction tends to decline [20]. These changes are ascribed
to a predominantly postglomerular dilatation which is in part due to decreased angiotensin
II formation. In our study, the renal vasodilatory effects of enalapril remained present
during NE infusion, a finding thus far only documented in healthy volunteers [10].
Enalapril prevented the rise in angiotensin II levels during NE pressor infusion. It may
thus be inferred that this partial RAAS blockade accounted for the ongoing renal
vasodilatation of the ACE inhibitor during NE infusion as compared to pretreatment.
Although difficult to demonstrate in humans, animal studies have unequivocally docu-
mented bidirectional interactions between the RAAS and the SNS in a way such that each
system is able to potentiate the other [4]. ACE inhibition treatment could, therefore,
induce a decrease in SNS activation. In the isolated kidney, ACE inhibitors indeed have
been demonstrated to diminish renal vascular NE responsiveness [5,6], and neuronally-
induced renal vasoconstriction [21], suggesting interference in the RAAS-SNS interaction.
The present in vivo study does, however, not support the assumption of an intrarenal
sympathicolytic effect of enalapril in microalbuminuric IDDM patients, since theEnalapril and norepinephrine reactivity in IDDM  89
exogenous NE-induced fall in ERPF was not altered by ACE inhibition treatment. 
Our findings may have clinical implications for the future design of renoprotective
strategies in IDDM patients. Currently, ACE inhibition treatment is considered to be the
main tool to retard the decline in renal function loss in IDDM, both by lowering systemic
blood pressure and by decreasing intraglomerular pressure [1-3]. Despite this proven
renoprotective potential, many patients still progress to end stage renal failure. Albeit in
a small number of patients, the present study is consistent with the possibility that
microalbuminuric IDDM patients are not sufficiently protected by ACE inhibition
treatment against rises in systemic blood pressure due to bouts of SNS activation during
daily life activities. Although the effects of exogenous NE cannot be directly extrapolated
to physiological SNS stimulation, it is noteworthy that increases in urinary albumin excre-
tion are well related to rises in blood pressure and plasma NE levels during exercise,
which represents a strong endogenous SNS stimulus [17].
In conclusion, we found that enalapril does not attenuate systemic and renal vascular
responsiveness to exogenous NE in microalbuminuric IDDM patients. These findings
suggest that a potentially adverse effect of NE on systemic and renal vascular tone is not
effectively counteracted by ACE inhibition treatment alone.
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CHAPTER 6
EFFECTS OF LOW DOSE DOPAMINE ON RENAL AND
SYSTEMIC HAEMODYNAMICS DURING INCREMENTAL
NOREPINEPHRINE INFUSION IN HEALTHY VOLUNTEERS
K. Hoogenberg , A.J. Smit  and A.R.J. Girbes
1 2 3
Dopamine is widely used to prevent a fall in renal function and blood flow in septic patients,
especially when other pressor agents like norepinephrine (NE) are used. No human renal
haemodynamic studies exits to support this. Therefore, the effects of low dose dopamine on NE-
induced renal and systemic vasoconstriction in were assessed in 7 normotensive healthy volunteers. On
separate days, either a low dose dopamine (4 µg/kg per min) or a placebo (5% glucose) infusion, in a
single blinded randomized order, was added to incremental NE infusions of 40, 80, and 150 ng/kg per
min given for 60 min each. Blood pressure and heart rate were measured with a semi-automated
device, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined with
constant infusions of  I-iothalamate and  I-hippurate, respectively. NE-alone progressively
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increased mean arterial pressure (MAP) to pressor levels, whereas this effect was attenuated by
addition of dopamine (p<0.05 vs NE-alone). GFR increased during lower nor-epinephrine doses and
did not decline at the highest NE dose. Addition of dopamine further increased GFR. ERPF fell with
each NE-alone infusion step, but this decline was completely prevented by concomitant dopamine
infusion (p<0.01 vs NE-alone). Sodium excretion tended to decrease with NE, but increased 2 to 3 fold
after addition of dopamine (p<0.01 from NE-alone). In conclusion, NE causes a large decrease in
ERPF but not in GFR in healthy man. Concomitant dopamine administration prevents this fall in ERPF,
increases sodium excretion, and also attenuates the NE-induced rise in MAP. These findings warrant
further clinical evaluation of the effect of concomitant low-dose dopamine and NE administration in
critically ill patients. 
Introduction 
Norepinephrine (NE) is increasingly recognized as a valuable agent in the treatment
of septic shock [1-6]. By eliciting a strong vasoconstrictive response, NE has been
reported to restore blood pressure and tissue perfusion more efficaciously than high dose
dopamine [1,4,6]. However, the NE-induced reduction in renal blood flow [7-9] make
many clinicians reluctant to use this agent in hypotensive patients since an already
comprimised renal function may further deteriorate under these circumstances. Intrave-
nous dopamine at dosages from 1 to 4 µg/kg per min augments renal blood flow in healthy
man [10,11] as well as in mechanically ventilated patients [12]. These low infusion rates
of dopamine have been proposed to oppose the renal vasoconstrictive actions of NE -
[13,14]. For this reason low dose dopamine is widely used as a renoprotective agentChapter 6 92
during NE therapy. However, the renal supportive action of dopamine to overcome NE-
induced renal vasoconstriction has not been proven in these situations, and the
haemodynamic effects of combined infusions has received little attention. In the dog,
dopamine has been documented to increase in renal blood flow during NE infusions, but
these observations cannot be easily extrapolated to humans since dogs have a different
renal haemodynamic profile during NE infusion from man [15]. In healthy subjects, very
recent results suggested that dopamine may blunt the renal vasoconstrictive effect of NE
that was given as a single pressor dose [16]. In the present study, we evaluated whether
dopamine could counteract NE's actions on renal haemodynamics by adding low dose
dopamine to stepwise incremental NE doses in normotensive healthy subjects. 
Materials and methods
Written informed consent was obtained after explanation of the purpose of the study
which was approved by the local medical ethics committee. Eligible subjects were males
with an age between 20 to 35 years, a body mass index <27 kg/m , a systolic/diastolic
2
blood pressure <140/85 mmHg, a serum creatinine concentration< 90 µmol/l, no history
of cardiovascular disease and no use of any medications. Seven healthy males with a mean
of age 28 (range 22-35) years, mean body mass index of 23.8 (range 20.9-26.7) kg/m , and
2
mean blood pressure of 123/76 (range 112-132/66-85) mmHg, participated in the studies.
A 24 h urine collection revealed a normal creatinine clearance (mean 127 (range 117-161)
ml/min/1.73 m ) in all of them. Mean sodium excretion amounted to 255 (range 189-321)
2
mmol/day and was considered appropriate in the studies so that all subjects were advised
to adhere to their usual dietary habits. They were only requested to avoid large protein
meals 24 h prior to the studies. 
The experiments were carried out on 2 separate days, with a 1 wk interval, in a
temperature controlled room of 22 C. The subjects were studied after an overnight fast and
o
remained fasting during the experiments. Smoking was prohibited and water was the only
liquid available to drink. Measurements were made with the subjects in the supine posi-
tion, and they were only allowed to stand on voiding. To promote diuresis, each subject
drank 600 ml water at 0730 h after which urinary volume losses were supplemented by
oral water. A cannula was inserted in an antecubital vein for infusions of renal tracers, NE,
dopamine or placebo. Venous blood was collected from the contra lateral arm. After an
equilibration period of 120 min, baseline measurements were made from 1000 h to 1130
hrs. From 1130 hrs to 1430 hrs, NE was infused at 3 incremental doses of 40, 80, 150
ng/kg per min, respectively, with each infusion lasting 60 min. In a single blinded,
randomized order, either dopamine (4 µg/kg/min) or placebo (5% glucose) was added to
NE infusions. After cessation of the infusions at 1430 hrs, measurements were continued
during a 60 min recovery period. 
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were mea-
sured with constant infusions of  I-iothalamate and  I-hippurate, respectively, as
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described previously [17]. After a priming dose, the radiopharmaceuticals were allowed
to equilibrate for 120 min. Thereafter, hourly clearances were calculated using the for-
mulas U.V/P and I.V/P, respectively. U.V represents the urinary excretion rate of the
tracer, I.V represents the infusion rate of the tracer, and P represents the plasma tracerRenal effects of combined norepinephrine and dopamine 93
level. Values were corrected to 1.73m  of body-surface area. Filtration fraction (FF) was
2
calculated as the ratio of the iothalamate and hippurate clearances. Blood pressure was
recorded every 5 minutes with a semiautomated device (Dinamap 1846, Critikon, Tampa,
FL, USA). Mean arterial pressure (MAP) was calculated as a systolic blood pressure + b
diastolic blood pressure (mmHg). Pulse rate was recorded continuously on an
electrocardiography oscilloscope (Hewlett Packard, Boblingen, Germany). Renal vascular
resistance (RVR) in dyn.sec/cm  per 1.73 m  was calculated as MAP×80/ (1/haematocrit)
5 2
× ERPF).
Blood samples were taken in the middle and the end of each clearance period while
the subjects were in supine position. Plasma samples for determination of NE and dopa-
mine were collected in pre-chilled tubes containing 10% EDTA, immediately centrifuged
at 4 C, and stored at -20 C until HPLC analysis [18]. Electrolytes and creatinine in serum
o 0
and urine were measured on SMA(C) autoanalysers (Technicon Instruments Inc.
Tarrytown, N.Y., USA). 
Based on previous studies in healthy volunteers, ERPF was expected to decline 20-
30% with the maximal NE dose [19]. The hypothesis was tested that dopamine counter-
acted this NE-induced decline in ERPF. A sample size of 7 subjects was large enough to
demonstrate a difference between no change vs. 20-30% change in ERPF with a power of
85% and a two-sided p-value<0.05. The coefficients of variation of ERPF and GFR are
<5% [17]. Results are expressed as mean±SEM for parametrically distributed data and
geometric mean (95% confidence interval) for non-parametrically distributed data. Within
day changes were evaluated using ANOVA for repeated measurements for parametrically
and non-parametrically distributed data as appropriate. Between infusion differences were
tested separately for each period with paired Student t-tests for parametrically and
Wilcoxon test for non-parametrically distributed data. p-Values less than 0.05 were
considered significant.   
Results 
On both study days, plasma NE concentrations increased similarly with the
infusions. At recovery from the combined NE/dopamine infusions plasma NE was still
elevated from baseline values. The dopamine infusions led to high circulating levels of
plasma dopamine (Table 1). 
Baseline blood pressure and heart rate were not different on both study days.
Systolic blood pressure increased similarly with both infusion regimens (p<0.05 to 0.01,
Table 2). Diastolic blood pressure was evidently increased during 80 and 150 ng/kg per
min NE-alone infusion (p<0.01), while only a modest rise was present during the
combined NE/dopamine at the 150 ng/kg per min infusion dose (p<0.05). Diastolic blood
pressure was lower with NE/dopamine compared with NE-alone during all infusion
periods (p<0.01, Table 2). Consequently, NE/dopamine augmented pulse pressure (differ-
ence in systolic and diastolic blood pressure) more than NE-alone (p<0.05, Table 2), and
MAP was lower with NE/dopamine than with NE-alone (p<0.05, Figure 1A). Heart rate
declined with all NE-alone infusions (p<0.05 to 0.01), whereas no change in heart rate was
present with the NE/dopamine infusions (Table 2). Chapter 6 94
Table 2. Systolic and diastolic blood pressure, pulse pressure and heart rate. 
Period: Baseline Norepinephrine infusion rate       Recovery
40 ng/kg     80 ng/kg 150 ng/kg per min
Systolic blood pressure (mmHg)
NE-alone 123 ± 3 133 ± 3 145 ± 4 163 ± 6 131 ± 4
a b b
NE+dopamine  121 ± 3 137 ± 2 148 ± 4 163 ± 5 126 ± 4
a b b
Diastolic blood pressure (mmHg)
NE-alone 76 ± 4 80 ±3 84 ± 4 91 ± 5 74 ± 4
d b,d b,d
NE+dopamine  75 ± 3 73 ± 3 74 ± 3 81 ± 3 73 ± 3
b
Pulse pressure (mmHg)
NE-alone 47 ± 3 53 ± 3 60 ± 3 72 ± 2 56 ± 3
a b
NE+dopamine  46 ± 4 64 ± 3 74 ± 5 82 ± 5 54 ± 3
b,e b,e b,e
Heart rate (beats/min)
NE-alone 59 ± 3 54 ± 3 51 ± 3 51 ± 4 71 ± 4
c a,c b,c b
NE+dopamine  58 ± 4 61 ± 3 61 ± 3 62 ± 3 82 ± 2
b
Data in mean±SEM. NE: norepinephrine   denotes p<0.05 and   denotes p<0.01 from baseline
a b
values;   denotes p<0.05 and   denotes p<0.01 vs. NE+dopamine;   denotes p<.05 vs. NE-alone
c d e
Table 1. Plasma norepinephrine and plasma dopamine concentrations. 
Period Baseline Norepinephrine infusion rate    Recovery
 40 ng/kg     80 ng/kg   150 ng/kg per min
Plasma norepinephrine (nmol/l)
NE-alone 1.7(1.1-2.8)   5.1(3.3-7.9) 9.6(6.2-14.9) 13.4(8.6-21.1)     2.3(1.2-4.3)
b b b
NE+dopamine 1.4(0.9-2.1)   5.4(4.5-6.5) 9.7(7.2-13.2) 13.4(11.3-23.9)   4.1(1.9-8.4)
b b b a
Plasma dopamine (nmol/l)
NE-alone  n.d.    n.d.   n.d.   n.d. n.d.
NE+dopamine     n.d.   414(195-1039)  612(350-1073)   620(380-1013) n.d.
b b b   
Data in geometric mean and 95% confidence interval. NE: norepinephrine, n.d. not detectable, 
a
denotes p<0.05 and   denotes p<0.01 from baseline values.
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Table 3. Urine flow and fractional sodium excretion.
Period Baseline Norepinephrine infusion rate    Recovery
 40 ng/kg     80 ng/kg   150 ng/kg per min
Urine flow (ml/min)
NE-alone 6.4 ± 0.8  9.4 ± 1.1 8.1 ± 1.2 6.5 ± 1.1 3.6 ± 0.9
NE+dopamine 6.0 ± 0.7 10.0 ±1.1 8.1 ± 1.1 9.8 ±1.0 3.0 ± 0.8
a a,d
Fractional sodium excretion (%)
NE-alone 0.98±0.35 0.91±0.23 0.69±0.09 0.72±0.21 1.02±0.21
NE+dopamine 0.84±0.17 2.29±0.17 2.44±0.43 1.99±0.34 0.81±0.20
b,c b,c
Data in mean±SEM. NE: norepinephrine,   denotes p<0.05 and   denotes p<0.05 from baseline
a b
values;   denotes p<0.05 and   denotes p<0.01 vs NE-alone
c d
Baseline renal haemodynamic parameters were similar on both study days. With
NE-alone, GFR rose slightly but significantly at the 40 and 80 ng/kg per min infusion dose
(p<0.05), whereas no change from baseline values was present at the 150 ng/kg per min
dose (Figure 1B). The combined NE/dopamine infusions increased GFR progressively
(p<0.01) to values that exceeded the NE-alone infusions (p<0.05, Figure 1B). ERPF de-
clined in a dose dependent fashion with each NE-alone infusion step (p<0.05 to 0.01, Fig-
ure 1C), and was accompanied by increases in FF (p<0.01, Figure 1D). These alterations
were opposed by simultaneous dopamine infusion, which in fact induced a modest rise in
ERPF at the 40 and 80 ng/kg per min NE-dose (p<0.05, Figure 1C). FF remained un-
changed with NE/dopamine infusion, and was significantly lower compared with the NE-
alone infusions (p<0.01, Figure 1D). RVR progressively increased with NE-alone
(p<0.01), but changed only marginally with the combined NE/dopamine infusion. Conse-
quently, RVR reached higher levels with NE-alone compared with NE/dopamine (p<0.05
to .01, Figure 1E).
Urine flow did not change with NE-alone, while a slight increase was seen during
NE/dopamine at 40 and 150 ng/kg/min dose (p<0.05, Table 3). Fractional sodium
excretion was similar at the start of both infusions days. A tendency towards a decease in
fractional sodium excretion was noted with the highest NE dose (p<.10). In contrast,
addition of dopamine stimulated fractional sodium excretion (p<0.01), reaching 2 to 3 fold
higher levels than during NE-alone (p<0.05 to 0.01, Table 3). 
Discussion
In the present study, we demonstrated that a 4 µg/kg/min dopamine infusion blunted
the renal vasoconstrictive and overrided the sodium preserving effects of exogenous NE
infusions in normotensive healthy subjects. The dopamine infusion also diminished the
rise in blood pressure, enlarged pulse pressure and blunted the fall in heart rate 
which suggests that dopamine also influenced systemic haemodynamics during the NE
infusions.12,000 E
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Figure 1.A: Mean arterial pres-
sure; B: glomerular filtration
rate; C: effective renal plasma
flow; D: filtration fraction; E:
renal vascular resistance at
baseline, at the incremental nor-
epinephrine (NE) infusions of
40 (NE:40), 80 (NE:80) and
150 (NE:150) ng/kg per min, -
and at recovery from the infu-
sions. !NE-alone infusion, "
NE in combination with low
dose dopamine (4 µg/kg per
min). * denotes p<0.05 and †
denotes p<0.01 from baseline;
‡ denotes p<0.05 and § denotes
p<0.01 vs NE-alone infusion.Renal effects of combined norepinephrine and dopamine 97
Exogenous NE is well known to decrease ERPF and to increase FF without substan-
tially altering GFR, and its administration is generally associated with increases in tubular
sodium reabsorption [7-9]. In contrast, dopamine enhances ERPF and increases GFR to a
lesser extent leading to a fall in FF. Moreover, dopamine strongly augments sodium excre-
tion [10-12]. These renal effects are observed with dopamine doses from 1 to 4 µg/kg/min.
In this study, a 4 µg/kg/min dopamine dose was given with the objective to produce
maximal antagonistic action on the renal NE responses. Dopamine prevented the decrease
in ERPF, increased GFR and fractional sodium excretion during the NE infusions. When
our study was in progress a report in healthy subjects appeared showing that dopamine at
a somewhat lower infusion rate of 3 µg/kg/min blunted the decline in ERPF and increased
sodium excretion when added to a single NE pressor infusion [16]. Except for this slight
difference in study design, the main outcome is remarkably similar. Since hippurate clear-
ances have been found to reliably measure both NE- and dopamine-induced changes in
renal blood flow [20], our findings as well as those in the aforementioned study [16] are
unlikely to be biased by the methods used. Data from animal studies have shown that both
substances influence renal vascular resistance on the level of the glomerular arterioles via
stimulation of "- and DA-adrenoreceptors, respectively [21,22]. While NE constricts,
dopamine dilates pre- and postglomerular vessels concomitantly. Since these vessels are
the major sites of resistance to blood flow in the kidney, NE is supposed to reduce ERPF
via glomerular arteriolar vasoconstriction, whereas dopamine changes vessel tone and flow
in the opposite direction. 
Apart from direct renal vasodilation, indirect effects by changes in cardiac output
could also be involved. Cardiac output and heart rate increase by $1-adrenergic receptor
stimulation at dopamine doses as low as 3 µg/kg/min [23]. In this study, dopamine attenu-
ated the rise in MAP, enlarged pulse pressure and blunted the decline in heart rate during
the NE infusions, and these effects may have resulted from $1-adrenoreceptor stimulation.
If true, an increase in cardiac output could have stimulated ERPF. We [12] previously
suggested such a mechanism in postoperative mechanically ventilated patients in whom
the ratio increase in ERPF/increase in cardiac output was not altered by 4 to 8 µg/kg/min
dopamine infusions. Apart from direct renal haemodynamic or systemic haemodynamic
effects of dopamine and/or NE on intraglomerular pressure, other changes in e.g. oncotic
pressure, filtration area and the diffusion coefficient [24] and a combination of them,
could have caused alterations in GFR during the infusions. Elevations in intraglomerular
pressure have been demonstrated in rat studies with NE infusions when blood pressure was
allowed to increase [25]. Renal vasodilation by dopamine could have resulted in an
increased transmission of systemic blood pressure to the renal vascular bed and conse-
quently raised intraglomerular pressure to higher levels than NE alone. Redistribution of
renal blood flow and increases in filtration area are other mechanisms by which dopamine
may increase GFR [26]. 
The finding that dopamine increased natriuresis during NE illustrates another
important renal action of this substance. The well documented natriuretic effects [7-9]
have been ascribed to stimulation of specific dopamine-receptors at the proximal tubule
[27] and may occur independent of renal vasodilation [28]. Conversely, NE generally
produces antinatriuresis by promoting tubular sodium reabsorption [7-9], but in this study
the number of subjects may have been too small to demonstrate such an effect on renalChapter 6 98
sodium handling. Dopamine's potential to counteract any possible antinatriuretic effect of
NE, is probably due to inhibition of the high energy-dependent sodium reabsorption
process in the proximal tubule [27]. 
NE has many characteristics to fulfill treatment goals in septic shock. It quickly
restores perfusion pressure and thereby oxygen supply to hypoperfused tissues. It is,
therefore, not suprising that NE is a valued treatment option in this condition [1-6].
However, fear of renal function loss with NE monotherapy is widely distributed, but has
in fact only been demonstrated with suprapharmacological doses in experimental studies
[29]. Nonetheless, low-dose dopamine is often proposed to conserve renal function during
NE therapy [13,14]. The present results, although obtained in healthy volunteers and thus
difficult to extrapolate to septic patients, support these assumptions to variable extent: NE
reduced ERPF, but not GFR, and addition of dopamine was indeed able to restore both
GFR and ERPF above baseline. Although little direct evidence is known about the effects
of NE and dopamine on renal haemodynamics in septic patients, some of the tubular
effects have been studied in these patients. 
A recent clinical study reported a loss of effectiveness of dopamine to stimulate
diuresis and natriuresis in patients with sepsis syndrome whereas no effects could be
elicited in patients with septic shock [30]. These findings contrast with our recent observa-
tions that dopamine (2, 4 or 6 µg/kg/min) on top of a constant background NE infusion,
induced a dose-dependent increase in urine output and fractional sodium excretion in
septic patients [31]. Moreover, dopamine increased diuresis in oliguric resuscitated
surgical intensive care patients [32] and critically ill patients considered at risk for renal
insufficiency [33], but was not effective in patients after major abdominal surgery [34].
That human studies addressing renal haemodynamics and not only diuresis and natriuresis
in such patients are warranted, is supported by a recent study which reported disappointing
effects of the benefit of dopamine on prevention of renal failure [35]. 
In conclusion, in healthy volunteers low-dose dopamine prevented the NE-induced
fall in renal blood flow, and it increased sodium excretion. The so often invoked unfavour-
able renal effects of NE were not manifested by a fall in GFR. Future studies have to
extend these findings in patients with sepsis, and should in particular assess whether or not
low-dose dopamine improves clinical outcome in these patients.
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CHAPTER 7
EFFECT OF GROWTH HORMONE (GH) AND INSULIN-
LIKE GROWTH FACTOR-I ON URINARY ALBUMIN
EXCRETION: STUDIES IN ACROMEGALY AND 
GH DEFICIENCY
K. Hoogenberg , W.J. Sluiter  and R.P.F. Dullaart
1 1 1
Glomerular hyperfiltration is a characteristic feature of acromegaly, but it is uncertain whether
albuminuria is elevated in this disease. To investigate the role of abnormal growth hormone (GH) and
insulin-like growth factor 1 (IGF-1) levels on urinary protein excretion we measured overnight urinary
albumin excretion rate (Ualb.V) and creatinine clearance in 14 acromegalic patients with metabolically
active disease (fasting GH>5 µg/l) and IGF-1>2.2 kU/l), 8 GH deficient patients and 20 control
subjects. Ualb.V was higher in the acromegalic patients (8.4 (4.2-68.2) µg/min; median (range)) than
in the GH deficient patients (2.0 (0.9-5.9) µg/min, p<0.001) and control subjects (3.3 (1.0-7.8) µg/min,
p<0.01). Five acromegalic patients had Ualb.V levels above the normal upper normal limit of 10
µg/min. Only one patient with concomitant untreated hypertension had persistent microalbuminuria.
Creatinine clearance was also higher in the acromegalic patients (p<0.05) and lower in the GH
deficient patients (p<0.05) than in the control subjects. In 11 of these acromegalic cases the lowering
of GH by 63% and of IGF-1 by 48%, following treatment with the somatostatin analogue (n=10) or
spontaneous pituitary infarction (n=1), reduced Ualb.V by 29% to 4.9 (3.1-45.2) µg/min (p<0.01).
Among the acromegalic patients (25 observations) Ualb.V was related to GH (r=0.61, p<0.01), IGF-1
(r=0.57, p<0.01) and creatinine clearance (r=0.54, p<0.01). In conclusion, circulatory GH and IGF-1
levels influence albuminuria. Since persistent microalbuminuria is uncommon in acromegaly, it is
unlikely that GH elevations alone predispose to clinically important glomerular damage.
Introduction 
The appearance of microalbuminuria is an early and characteristic sign of renal
involvement in patients with (insulin-dependent) diabetes mellitus (IDDM) [1]. Renal
haemodynamic factors are thought to play an important role in the development of
glomerular damage in experimental diabetes mellitus, renal ablation and intrinsic renal
disease [2,3]. Although not consistently reported, an increased glomerular filtration rate
(GFR) has also been found to precede the development of microalbuminuria, overt
proteinuria and the subsequent decline in renal function in IDDM patients [4-6]. Glo-
merular hyperfiltration is a feature of only few other human diseases. In acromegaly an
increased renal function is well recognized [7-10]. Despite similarities in renal
haemodynamic changes between acromegaly and IDDM [10,11], renal insufficiencyChapter 7 102
Table 1. Clinical and biochemical characteristics.
Acromegalic patients GH deficient Control
  patients subjects
pretreatment post-treatment change
  (n=14)   (n=11) (n=11)    (n=8)  (n=20)
Age (years)  42(24-67)    42(25-67)       40(26-56) 39(19-63)
Female/male 6/8   6/5   4/4    8/12
MAP (mmHg)  93(72-130)      92(77-20)    -4(-10 to 3)   96(92-107)     99(73-110)
Hypertension(n) 2 2 0 0
CrCl (ml/min 125(85-182)   112(87-138)     -8(-16 to -1)    86(56-100)        100(83-148)
a,c b d a
per 1.73m )
2
GH (µg/l) 16.8(6.5-69.5)   5.2(0.5-13.9)  -12(-26 to -7) <0.5 nd
c b e
IGF-1 (kU/l)  4.8(2.2-13.8)    2.1(0.2-6.7)    -2(-7 to -1)    0.15(0.1-0.2) nd
c b e
Data in median(range); changes within acromegalic group in median(95%confidence interval).
GH:growth hormone; IGF-1:insulin-like growth factor-I; MAP:mean arterial pressure; CrCl:
creatinine clearance, nd: not determined;   p<0.05 from control subjects;   p<0.01 and
a b
 p<0.001 from GH deficient patients;   p<0.05 and   p<0.01 from pretreatment.
c d e
seems uncommon in acromegaly [12], whereas in contrast 30 to 40% of diabetic patients
develop nephropathy [13].
Growth hormone (GH) stimulates renal haemodynamics indirectly through an effect
on insulin-like growth factor 1 (IGF-1) [14,15]. The effects of circulatory GH and IGF-1
on urinary albumin excretion are not well studied. In acromegaly no correlation could be
demonstrated between urinary GH and albumin excretion [9], but recent observations
show that IGF-1 infusion increases albuminuria in healthy subjects [16].
To investigate the role of abnormal GH and IGF-1 levels in urinary protein excretion
we measured albuminuria in patients with active acromegaly, severe GH deficiency and
control subjects. In acromegalic patients the influence of effective GH lowering therapy
on albuminuria was also studied.
Subjects and methods
Subjects
All subjects consented to participate in the study which was approved by the local
medical ethics committee. Fourteen adult patients with active acromegaly, 8 adult patients
with severe GH deficiency and 20 control subjects were included. The diagnosis of active
acromegaly was based on a fasting serum GH concentration >5µg/l that did not decrease
to <2µg/l after 100 g glucose, and a plasma IGF-1 level >2.2 kU/l [17]. Two potentially
eligible acromegalic patients were not studied because of renal tract abnormalities. The
pretreatment acromegalic group was composed of 6 patients who had not undergone any
previous treatment for acromegaly and 8 patients in whom surgery, irradiation,
bromocriptine or a combination of them had failed to normalize GH and IGF-1 levels.
None of the participants used GH lowering medical treatment at the start of the study.Growth hormone, insulin-like growth factor 1 and albuminuria 103
Eleven of these 14 patients could be prospectively studied and were included in the post-
treatment acromegalic group. They were reevaluated 3 to 4 months after effective
reduction of GH and IGF-1 levels. In 10 patients this was accomplished by subcutaneous
injections of the somatostatin analogue, octreotide (Sandostatin®, Sandoz, Basel,
Switzerland), in doses of 300 to 600 µg daily. In one patient pituitary infarction shortly
prior to planned therapy obviated the need for octreotide treatment. Severe GH deficiency
was considered to be present if peak GH after insulin-induced hypoglycaemia was <1.5
µg/l and if IGF-1 was <0.34 kU/l [18]. GH deficiency was due to primary hypopituitarism
in 6 patients and to non-functioning pituitary adenoma in 2 patients. The acromegalic and
GH deficient patients received supplementation doses of thyroxine, cortisone acetate and
sex steroids if necessary.
Clinical and laboratory measurements
In the acromegalic and GH deficient patients fasting venous blood was obtained to
assay GH (2 occasions) and IGF-1. Precisely timed overnight urine samples were collected
under sterile conditions to measure urinary albumin excretion rate (Ualb.V) and creatinine
clearance. Three urine samples were obtained from each acromegalic and GH deficient
patient. The control subjects collected one specimen. Creatinine clearance was used as a
parameter of renal function. Blood pressure was measured using the auscultatory method.
Mean arterial pressure (MAP) was calculated as a systolic pressure+ b diastolic pressure.
In the post-treatment acromegalic group the procedures were repeated at follow-up.
Overnight Ualb.V has been previously established to range from 1.6 to 10.0 µg/min (2.5
to 97.5  percentile) in 50 healthy subjects in our clinic. Micro-albuminuria was defined
th
as Ualb.V>20 µg/min [1]. Hypertension was defined as systolic blood pressure >160
mmHg and/or diastolic blood pressure >95 mmHg.
Serum GH was measured by radioimmunoassay (Farmos Diagnostica, Turku,
Finland). The lower detection limit was 0.5 µg/l. Plasma IGF-1 was assayed with a kit
purchased from Nichols Institute of Diagnostics (San Juan Capistrano, CA, USA).
Reference values for adults range from 0.34 to 2.2 kU/l. Urinary albumin was measured
by radioimmunoassay (Diagnostics Products Corporation, Apeldoorn, The Netherlands).
The intra- and interassay coefficients of variation were 2.3% and 7.7% for urinary albumin
concentrations between 0.07 and 60 mg/l [19]. The lower detection limit was 0.07 mg/l.
Serum and urinary creatinine and serum albumin were measured on a SMAC II
autoanalyzer (Technicon Instruments Inc., Tarrytown, NY, USA).
Statistical analysis.
Data are expressed as median (range). Within group changes in variables are given
as median (95% confidence interval (CI)). Parameters from each individual were averaged
for analysis. Between group differences in parameters were assessed by Kruskal-Wallis
analysis of variance. Adjustment for multiple comparisons was carried out using Duncan's
method. Paired Wilcoxon tests were used to analyse within group changes. Spearman's
rank correlation was performed to calculate correlations. Multiple regression analysis was
applied to evaluate the independent contribution of parameters. A two-sided p-value<0.05
was taken as significant.100
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Table 2. Parameters of urinary albumin excretion.
Acromegalic patients GH deficient Control
patients subjects
pretreatment post-treatment change (%)
(n=14) (n=11) (n=11)   (n=8)   (n=20)
Ualb.V  8.4(4.2-68.2) 4.9(3.1-45.2)   -29(-46 to -14) 2.0(0.9-5.9) 3.3(1.0-7.8)
b,d c f
(µg/min)
Ualb.V 7.1(3.2-57.8) 4.4(2.8-50.3)   -23(-44 to -11) 2.4(0.8-7.1) 3.1(0.9-7.5)
b,d c f
(µg/min/1.73m )
2
FalbCl (10 ) 1.3(0.6-10.8) 0.9(0.5-6.7)     -27(-39 to -3) 0.8(0.2-1.6) 0.7(0.2-1.8)
-6 a,c e
Data in median (range); % change within acromegalic group in median (95% confidence interval).
Ualb.V denotes urinary albumin excretion rate. FalbCl denotes fractional albumin clearance. 
a
p<0.05 and   p<0.01 from control subjects;   p<0.05 and   p<0.001 from GH deficient patients; 
b c d e
p<0.05 and   p<0.01 from pretreatment.
f
Figure 1. Urinary albumin ex-
cretion rate (Ualb.V) in G acro-
megalic patients pretreatment
(n=14), G acromegalic patients
post-treatment (n=11), F control
subjects (n=20) and M growth
hormone (GH) deficient patients
(n=8). The bars represent the
median levels. The shaded area
represents the normal range. †
p<0.01 from control subjects; ￿
p<0.05 and 
‡ p<0.001 from GH deficient
patients; § p<0.01 from pre-
treatment.
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The clinical and biochemical characteristics of the study participants are given in
Table 1. The groups were comparable regarding age and sex distribution. Median blood
pressure levels were comparable, although 2 acromegalic patients had hypertension. Dur-
ing the study hypertension was treated with a calcium-entry blocker in one patient, mild
hypertension being untreated in the other. One acromegalic patient had concomitant diabe-
tes mellitus that was adequately controlled with insulin. Creatinine clearance was higher
in the untreated acromegalic patients and lower in the GH deficient patients as compared
with the control subjects. In the post-treatment acromegalic patients serum GH was
reduced by 63(58-77)% and IGF-1 was reduced by 48(32-69)% (p<0.01 for both). Cir-
culatory GH and IGF-1 levels decreased to <5 µg/l and to <2.2 kU/l in 5 and 6 patients,
respectively. The reduction in GH and IGF-1 levels was accompanied by a fall in creatini-
ne clearance (Table 1). Blood pressure (Table 1) and body weight (change -1.0 (-3.8 to 1.5
) kg) were unaltered at follow-up.
Ualb.V was elevated in the group of untreated acromegalic patients and tended to be
lower in the group of GH deficient subjects as compared with the control subjects (Figure
1, Table 2). Ualb.V was above the upper normal limit of 10µg/min in 5 acromegalic
patients (36%). One acromegalic patient with concomitant untreated hypertension had
persistent microalbuminuria (Ualb.V of 68.2µg/min), whereas Ualb.V was 7.6 and
9.1µg/min in the treated hypertensive and the diabetic patient, respectively. In the
acromegalic patients urinary albumin excretion was still elevated after correction for body-
surface area and when expressed as fractional albumin clearance (Table 2). At follow up
Ualb.V was lower in 10 of 11 patients. Ualb.V was also reduced in the patient with pitu-
itary infarction. In this post-treatment acromegalic group both Ualb.V and fractional al-
bumin clearance were significantly decreased to a median level comparable with that in
the control subjects (Figure 1, Table 2).
Among the acromegalic patients (25 observations) Ualb.V was significantly corre-
lated with serum GH (r=0.61, p<0.01, Figure 2A), plasma IGF-1 (r=0.57, p<0.01, Figure
2B) and creatinine clearance (r=0.54, p<0.01, Figure 3A). Multiple regression analysis
confirmed that Ualb.V was independently related to serum GH (p<0.02), or alternatively
to plasma IGF-1 (p<0.03), and creatinine clearance (p=0.05). Ualb.V was not related to
blood pressure (Figure 3B), age and body-surface area. Fractional albumin clearance was
also independently related to circulatory GH (p=0.01) and IGF-1 (p<0.01). 
Discussion
This study demonstrates that urinary albumin excretion rate is elevated in acromega-
ly and tends to be reduced in GH deficiency. Furthermore, urinary albumin excretion was
consistently reduced after GH and IGF-1 lowering. The positive relations between GH,
IGF-1 and albuminuria supports that these hormonal factors are involved in urinary
protein excretion. However, the elevations in albuminuria that occurred with GH excess
were minor and only 1 of 14 patient had microalbuminuria according to the cut-off level
of 20µg/min, proposed to define incipient nephropathy in IDDM [1].100 B
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Figure 2.Relationships between serum growth hormone (GH), plasma insulin-like growth factor I
(IGF-1) and urinary albumin excretion rate (Ualb.V) in G acromegalic patients pretreatment (n=14),
G acromegalic patients post-treatment (n=11) and M growth hormone (GH) deficient patients (n=8).
The shaded area represents the normal range. A: GH and Ualb.V in acromegalic patients (25 observa-
tions) r=0.61, p<0.01; B: IGF-1 and Ualb.V in acromegalic patients (25 observations) r=0.57, p<0.01.100 B
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Figure 3.Relationships between creatinine clearance, mean arterial blood pressure (MAP) and urinary
albumin excretion rate (Ualb.V) in G acromegalic patients pretreatment (n=14),
G  acromegalic patients post-treatment (n=11) and M growth hormone (GH) deficient patients (n=8).
A: creatinine clearance and Ualb.V in acromegalic patients (25 observations) r=0.54, p<0.01 and in
GH deficient patients r=0.26, NS; B: MAP and Ualb.V in acromegalic patients (25 observations)
r=0.07, NS and in GH deficient patients r=-0.18, NS.Chapter 7 108
Previous studies have also shown that microalbuminuria is infrequent in acromegaly
[9,10]. These observations would agree with the contention that the elevated urinary
albumin excretion in acromegaly represents a functional rather than a structural phenom-
enon.
The mechanisms responsible for the stimulatory effects of GH and/or IGF-1 on
albuminuria are not precisely understood. Haemodynamic factors and permselectivity
properties of the glomerular filtration barrier govern the glomerular passage of albumin
[20]. The presence of IGF-1 receptors on all type of glomerular cells represents a
structural basis for the in vivo effects of IGF-1 on glomerular function [21]. IGF-1
infusion rapidly increases GFR, renal plasma flow and albuminuria in human subjects
[16]. Glomerular vasodilation and a rise in the ultrafiltration coefficient are probably
responsible for these stimulatory effects of IGF-1 on renal haemodynamics [22]. The
impaired renal vasodilatory response to amino acid infusion in already hyperfiltering
patients corroborates the presence of abnormal glomerular vasodilation in acromegaly
[10]. In this study the expected increase in renal function could be demonstrated using
creatinine clearance as a parameter of glomerular filtration. The positive relation between
creatinine clearance and albuminuria supports that renal haemodynamic factors play a
contributory role in urinary albumin excretion. The present observations also show that
fractional albumin excretion was elevated in acromegaly. In accordance, IGF-1 infusion
enhances fractional albumin clearance as well [16]. Thus, the elevated urinary albumin
excretion cannot be fully explained by an increase in renal function per se. Experimental
evidence indicating a direct effect of IGF-1 on glomerular protein handling is not yet
available, but IGF-1 could alter glomerular permselectivity properties by relaxing the
mesangium [21]. It cannot be excluded that the observed reduction in albuminuria that
followed GH and IGF-1 lowering was to some extent directly caused by the somastatin
analogue, octreotide. However, albuminuria was also decreased after spontaneous GH and
IGF-1 normalization and octreotide does not acutely reduce albuminuria in IDDM
patients, despite a rapid decrease in renal function [23]. It is evident that systemic blood
pressure can influence albuminuria. In patients with IDDM a rise in blood pressure and
progression of albuminuria develop concomitantly [24]. Microalbuminuria has also been
observed in essential hypertension, albeit at higher blood pressure levels [25]. In our study
systemic blood pressure did not have an independent effect on albuminuria in acromegaly,
which could have been due to the fact that most studied patients were normotensive. In
this respect it is noteworthy that the only patient with persistent microalbuminuria had
untreated hypertension. Moreover, we cannot exclude that alterations in tubular protein
reabsorption contributed to the increased albuminuria, but the normal $2-microglobulin
excretion suggests that tubular function is not impaired in acromegaly [9].
In a retrospective histopathological survey no severe glomerular lesions were
documented in 20 acromegalic cases studied at autopsy [26], consistent with the presently
observed minor elevations in albuminuria. Besides acromegaly and IDDM long-standing
glomerular hyperfiltration is a feature of subjects with one kidney and patients with type
1 glycogen storage disease [27,28]. Microalbuminuria is rare in subjects with a single
kidney [27], but glomerulosclerosis, overt proteinuria and renal insufficiency are common
complications of type 1 glycogen storage disease [28]. Taken together, these observations
suggest that glomerular hyperfiltration does not result in important glomerular injury inGrowth hormone, insulin-like growth factor 1 and albuminuria 109
humans, unless additional, yet to be defined factors, are present. In contrast, experimental
animal studies have shown that mice transgenic for bovine GH and rats bearing GH-
producing tumours develop considerable glomerular enlargement, glomerulosclerosis and
proteinuria, whereas less severe abnormalities have been observed in experimental models
of IGF-1 hypersecretion [29,30]. In such animals, GH is extremely elevated to levels not
encountered in human subjects with acromegaly. Between species differences in
susceptibility to glomerular lesions may possibly also account for these apparently
contradictory findings.
In conclusion, circulatory GH and IGF-1 levels influence urinary albumin excretion.
In active acromegaly slightly elevated levels of albuminuria are observed that can be
reduced with GH-lowering measures. Since persistent microalbuminuria is uncommon in
acromegaly, it is unlikely that GH elevations alone predispose to clinically important
glomerular damage.
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CHAPTER 8
INSULIN-LIKE GROWTH FACTOR I AND ALTERED
RENAL HAEMODYNAMICS IN GROWTH HORMONE
DEFICIENCY, ACROMEGALY AND DIABETES MELLITUS
K. Hoogenberg , P.M. ter Wee , A.G. Lieverse , 
1 2 1
W.J. Sluiter  and R.P.F. Dullaart  
1 1
Growth hormone (GH) influences renal haemodynamics indirectly by enhancing the synthesis
of insulin-like growth factor I (IGF-I). In patients with acromegaly increases in glomerular filtration
rate (GFR) are well correlated with IGF-I levels. Circulatory GH-levels have also been implicated in
the elevated GFR of IDDM patients, but IGF-I levels are often low in these patients. In the present
study, we found IGF-I levels to be highly correlated with renal haemodynamics parameters in
GH-deficient, acromegalic and healthy subjects, whereas this relationship was not present in normo-
hyperfiltering IDDM groups. In contrast, in all groups amino acid stimulated renal function was
inversely correlated with baseline renal haemodynamics, indicating similar renal haemodynamic
abnormalities in hyperfiltering IDDM and acromegalic patients, despite large differences in plasma
IGF-I levels. It is suggested, therefore, that the lack of a relationship between plasma IGF-I and renal
function in IDDM does not exclude the role of elevated GH levels in diabetic glomerular
hyperfiltration.
Introduction 
Evidence has accumulated that glomerular hyperfiltration plays an important role in
the development of glomerular damage in experimental diabetes mellitus [1] and possibly
in human diabetes as well [2]. An increased glomerular filtration rate (GFR) is also a
characteristic feature of acromegaly [3]. Growth hormone (GH) influences renal
haemodynamics indirectly by enhancing the synthesis of insulin-like growth factor I (IGF-
I), which has a direct stimulatory effect on renal function [4]. Since circulatory levels of
GH are frequently elevated in patients with insulin-dependent diabetes mellitus (IDDM),
especially during poor metabolic control, it is possible that circulatory GH plays a
pathogenetic role in diabetic glomerular hyperfiltration. However, no differences in
diurnal GH-profile could be demonstrated between normo- and hyperfiltering diabetic
patients [5]. In contrast, recent studies show a positive correlation between GH-releasing
hormone-stimulated [6] or exercise-stimulated GH levels [7] and renal haemodynamics in
Type 1 diabetes mellitus, independently of metabolic control. 
In the present study we therefore investigated the relationship between plasma IGF-IChapter 8 112
and GFR as well as effective renal plasma flow (ERPF) among GH-deficient, acromegalic,
normo- and hyperfiltering IDDM patients and healthy control subjects. As the assessment
of renal reserve filtration capacity using amino acids (AA) infusion has been demonstrated
to provide insight into the presence of glomerular vasodilation associated with abnormal
GH secretion [3,8] and diabetes mellitus [9], the AA-induced changes in renal
haemodynamics in these patients were compared.
Subjects and methods 
The study was approved by the local medical ethics committee and all participants
consented to the procedure. Fasting GFR and ERPF were determined simultaneously,
using  I-iothalamate and  I-hippuran, respectively [9]. On the second day, renal reserve
125 131
filtration capacity was measured as the % increment of GFR and ERPF after 17-hours of
amino acids infusion (Vamin-N®, 7% weight/volume, Kabi Vitrum, Limoges, France; in-
fusion rate 83 ml/h). All subjects had an age between 21 and 55 years. Only subjects
without hypertension (systolic blood pressure <160 mmHg and diastolic blood pressure
<95 mmHg) and without blood pressure lowering or non-steroidal anti-inflammatory med-
ication participated. The IDDM patients did not have clinical proteinuria and had a disease
duration of at least 5 years. 
The relationships between plasma IGF-I and baseline GFR and ERPF were deter-
mined in 8 GH-deficient patients [8], 7 patients with active acromegaly who were studied
before and after treatment with the somatostatin analogue octreotide [3], 17 normo- and
9 hyperfiltering Type 1 diabetic patients (GFR >130 ml/min per 1.73m ) and 6 healthy
2
controls. Renal reserve filtration capacity was compared among these GH deficient and
acromegalic patients, another 6 normo- and 6 hyperfiltering diabetic patients and 12
healthy controls [9]. Serum GH and plasma IGF-I concentrations were measured by
radioimmunoassays. Data are given as mean ±SEM. Correlation coefficients were cal-
culated with linear regression analysis. A p-value <0.05 was considered significant.
Results 
Serum GH levels were higher in the normo- and hyperfiltering IDDM patients than
in the control subjects (4.1±1.2 and 5.9±2.9 µg/l vs 0.8±0.2 µg/l, p<0.001 for both). In
contrast, plasma IGF-I was significantly lower in both IDDM groups as compared to
controls (0.37±0.02 and 0.36±0.03 kU/l vs 1.08±0.20 kU/l, p<0.02 for both). In the com-
bined groups of GH-deficient, acromegalic and control subjects, positive correlations were
observed between plasma IGF-I, GFR (r=0.87, p<0.001, Figure 1A) and ERPF (r=0.77,
p<0.001, Figure 1B). In the combined IDDM groups, these renal haemodynamics
parameters were not related to plasma IGF-I (r=0.08 for GFR and r=0.11 for ERPF).
AA infusion significantly increased GFR in GH-deficient patients (p<0.001), healthy
subjects (p<0.01), normofiltering IDDM (p<0.01) and treated acromegalic patients
(p<0.02) but not in patients with active acromegaly and hyperfiltering IDDM patients
(Figure 2A). ERPF was stimulated in GH-deficient patients (p<0.001), healthy subjects
(p<0.05) and treated acromegalic patients (p<0.02), whereas there was no180
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Figure 1.Relationships of plasma IGF-I with GFR (A) and ERPF (B) in healthy sub-
jects ￿, GH-deficient patients F, acromegalic patients before M and after F treat-
ment, normofiltering G and hyperfiltering G diabetic patients.25%
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Figure 2. Relationships of baseline renal haemodynamics with AA-induced increments in
GFR (A) and ERPF (B) in healthy subjects ￿, GH-deficient patients F, acromegalic
patients before M and after F treatment, normofiltering G and hyperfiltering G diabetic
patients.
increase in patients with active acromegaly as well as in normo- and hyperfiltering IDDMIGF and renal reserve filtration capacity 115
patients (Figure 2B). Taken all groups together, significant inverse relationships could be
demonstrated between mean baseline renal haemodynamics and the mean AA-induced re-
sponses (GFR: r=-0.95, p<0.005; ERPF: r=-0.90, p<0.02). 
Discussion 
This study showed that baseline GFR and ERPF are positively related to the plasma
level of IGF-I in GH-deficient, acromegalic and control subjects, but not in diabetic
patients. Both hyperfiltering diabetic and acromegalic patients had an abolished response
to AA infusion. Thus it appears that hyperfiltering IDDM and acromegalic patients share
comparable renal haemodynamic abnormalities, despite large differences in plasma IGF-I
levels.
The stimulatory effects of IGF-I on renal haemodynamics are ascribed to glo-
merular vasodilation and a rise in the ultrafiltration coefficient [4]. The enhanced re-
sponse of GFR and ERPF to AA in GH deficiency, in contrast to acromegaly, supports
the notion that IGF-I is an important determinant of these renal haemodynamic parame-
ters. The renal vasodilatory effects of IGF-I could be mediated by nitric oxide, whereas
prostaglandins may have a permissive role [4]. These factors are also thought to play a
role in the multifactorial process that leads to diabetic glomerular hyperfiltration [10].
Plasma IGF-I was low in the diabetic patients, despite elevated GH levels. This
paradox is in accordance with other observations [11], but does not exclude the potential
contributory role of abnormalities in the GH-IGF-I-system in diabetic glomerular
hyperfiltration. For example, increases in IGF binding protein I facilitate the action of
IGF-I on aortic smooth muscle cells [12]. Thus alterations in IGF-I binding proteins in
diabetes mellitus may influence its biological activity. Furthermore, augmented accumu-
lation of IGF-I [11] and increased expression of kidney IGF-I receptors [13] have been
found in the diabetic kidney, possibly resulting in an enhanced renal haemodynamic
effect of IGF-I in the diabetic state. Therefore, the lack of a relationship between plasma
IGF-I and renal function in IDDM does not contradict that elevated circulatory GH levels
could play a contributory role in diabetic glomerular hyperfiltration. Obviously, further
experiments are needed to clarify the impact of abnormalities in the GH-IGF-I-axis on
diabetes-related changes in renal function.
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CHAPTER 9
CONTRIBUTORY ROLES OF CIRCULATORY GLUCAGON
AND GROWTH HORMONE TO INCREASED RENAL
HAEMODYNAMICS IN IDDM PATIENTS 
K. Hoogenberg , R.P.F. Dullaart , N.J.M. Freling , 
1 1 3
S. Meijer  and W.J. Sluiter
2 1
The stimulatory effects of growth hormone (GH) and glucagon on renal function are well
known, but it is uncertain whether these hormones are involved in the increase in renal function,
characteristic of IDDM patients. Therefore, the circulatory levels of GH and glucagon were measured
in 10 IDDM patients with an elevated glomerular filtration rate (GFR >130 ml/min per 1.73m ) and
2
in 20 age and sex matched normofiltering patients (GFR ranging from 90 to 130 ml/min per 1.73m ).
2
In the patients, fasting glomerular filtration rate and effective renal plasma flow (ERPF) were
determined using  I-iothalamate and  I-hippuran, respectively, during near-normoglycaemia. On
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a separate day, the levels of glucagon and GH were determined in the fasting basal state and after
exercise. Multiple regression analysis disclosed that GFR was positively correlated with HbA1c
(r =0.18, p<0.01), glucagon (r =0.14, p<0.03) as well as exercise-stimulated GH (r =0.10, p<0.05).
2 2 2
ERPF was independently associated with HbA1c (r =0.24, p<0.005) and glucagon (r =0.18,
2 2
p<0.01), whereas renal vascular resistance (RVR) was negatively correlated with stimulated GH
(r =0.18, p<0.02). Kidney volume was positively correlated with HbA  (r =0.26, p<0.001) and
2 2
1
inversely with RVR (r =0.16, p<0.01), but not with glucagon or stimulated GH. The present study
2
suggests that circulatory GH and glucagon play a contributory role in the renal haemodynamic changes
in IDDM.
Introduction
Elevations in glomerular filtration rate (GFR) are well recognized in insulin-
dependent diabetes mellitus (IDDM) and can persist for many years after onset of the
disease [1-4]. In experimental diabetes mellitus glomerular hyperfiltration appears to be
involved in the pathogenesis of glomerulosclerosis and the progressive loss of kidney
function [5]. Some clinical observations also support the suggestion that an elevated GFR
might contribute to the subsequent development of diabetic nephropathy [6], but in other
studies no such role could be assigned to glomerular hyperfiltration [7].
Moderate hyperglycaemia has been found to increase GFR [8,9], whereas improved
metabolic control reduces renal haemodynamics as well as kidney volume [2,10-12].
Plasma levels of growth hormone (GH) and glucagon, which have a renal vasodilatory
effect [13,14], are frequently elevated under circumstances of suboptimal metabolic
control [15-18]. However, no differences in the diurnal profiles of GH and glucagon couldChapter 9 118
Table 1. Clinical characteristics.
Group  H Group N
(n=10) (n=20)
Age (years) 39 ± 14 40 ± 12
Sex (M/F)  9 / 1 18 / 2
Duration of disease (years) 24 ± 13 21 ± 10
BMI (kg/m ) 24.0 ± 2.4 23.8 ± 2.3
2
Retinopathy (O/B/P)   2 / 4 / 4 6 / 8 / 6
a
Ualb.V (µg/min) 25 (13 - 44) 15 (12 - 44)
b
Ualb.V>20 µg/min 6 6
Mean arterial blood pressure (mmHg)  93 ± 9 95 ± 9
HbA  (%) 8.0 ± 1.5 7.2 ± 0.9 1
Blood glucose (mmol/l) 9.3 ± 2.3 7.7 ± 1.7
c
H: IDDM patiens with glomerular filtration rate >130 ml/min per 1.73m ; N: IDDM patients with
2
glomerular filtration rate ranging from 90 to 130 ml/min  per 1.73m . Data are given as mean±SD,
2
except for Ualb.V which is given in median and interquartile ranges.   Retinopathy: O: absent; B:
a
background; P: proliferative;   Ualb.V: urinary albumin excretion rate;   Blood glucose: mean of
b c
three 8-sample-based 24-h blood glucose profiles
be demonstrated between normo- and hyperfiltering IDDM patients [19], although
recently an increased responsiveness to GH-releasing hormone has been observed in
IDDM patients with glomerular hyperfiltration [20]. Thus, the contributory roles of these
hormones in the maintenance of diabetic glomerular hyperfiltration are still controversial.
Therefore, we employed an exercise test to stimulate GH physiologically and related GH
as well as glucagon levels to renal function and kidney size in IDDM patients without
clinical nephropathy.
Patients and methods
Patients
The study was approved by the local medical ethics committee and all patients
consented to the procedure. Inclusion criteria to participate were an onset of disease before
30 years of age, glucagon-stimulated plasma C-peptide concentration <0.2 nmol/l, diabetes
duration for at least 5 years, no arterial hypertension (systolic blood pressure $160 mmHg
and/or diastolic blood pressure $95 mmHg), no orthostatic hypotension, serum creatinine
#120 µmol/l, urinary albumin excretion rate (Ualb.V) #200 µg/min on three consecutive
overnight urine samples, and no use of anti-inflammatory and antihypertensive drugs. 
The study groups were comprised of 10 patients with glomerular hyperfiltration,
defined as a GFR>130 ml/min per 1.73m  [21], and 20 normofiltering patients (GFR
2
between 90 and 130 ml/min per 1.73m ) (Table 1). The subjects from these groups,
2
designated H for the hyperfiltering and N for the normofiltering patients, were individu-
ally matched with respect to sex, age and diabetes duration (within 5 years) to exclude anyGlucagon, growth hormone and kidney function 119
influence due to differences in clinical parameters. The proprotion of patients with
microalbuminuria, as well as retinopathy was not significantly different (Table 1). HbA1c
values and mean blood glucose concentrations (obtained from the three 8-sample-based
24-h blood glucose profiles) tended to be higher in H than in N, but this difference did not
reach statistical significance (p=0.14 and p=0.08, respectively; Table 1). None of the
patients consumed a protein or sodium-restricted diet. Besides insulin, no other medication
was used.
Renal haemodynamics and kidney volume 
The patients were studied after an overnight fast, both when measuring kidney
function and during the exercise procedure to eliminate the confounding effects of recent
nutrient intake. Supine GFR and effective renal plasma flow (ERPF) were determined
simultaneously using  I-iothalamate and  I-hippuran, respectively [22]. To minimize
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the possible effect of actual glycaemia on GFR and ERPF the patients were studied during
near-normoglycaemia (blood glucose between 4.4 and 8.3 mmol/l [9]. Starting at 0800 h,
a 5% glucose solution was infused intravenously at a rate 1 ml (0.28 mmol)/kg per h to
which regular acting insulin (Velosulin H.M., Novo-Nordisk, Bagsvaerd, Denmark) was
added in a dose of 1% of the total daily requirements per hour. After a 4 h period to
normalize and stabilize blood glucose levels no further corrections of blood glucose were
made and GFR and ERPF were measured over a 2 h clearance period from 1200 to 1400
h. The renal vascular resistance (RVR, in dynes.s/cm  per 1.73m ) was calculated by
5 2
dividing the mean arterial blood pressure by the renal blood flow (RBF) multiplied by 80,
where RBF was estimated from the ERPF and the haematocrit (HTC) using the formula:
RBF(l/min per 1.73m ) = ERPF(l/min per 1.73m )/(1-HTC). Kidney volume was
2 2
determined by summation of the volumes of both kidneys, obtained by ultrasonography
[23].
Exercise test
  On a separate day following the renal haemodynamic studies, the patients performed
a bicycle-exercise test with a fixed workload of 600 kpm for 20 min. The morning insulin
dose was withheld. After 2 h rest, blood samples were taken at 1000, 1100, 1120 (i.e.
directly at the end of exercise) and 1200 h from a cannula inserted into an antecubital vein.
Laboratory methods
Blood glucose was measured using a Yellow Springs glucose Analyzer (Model 23A,
Yellow Springs Inc,. Yellow Springs, Ohio, USA). HbA  was determined by col-orimetry 1
[24]. 300
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Figure 1. Metabolic assessments during the
exercise. Hyperfiltering F, normofiltering M
IDDM patients: see text and Table 1. Mea-
surements at 1000, 1100, 1120 and 1200 h: 1
h before, at the start, directly after and 40
min after the exercise. Data are given in
mean ± SEM. Differences in both IDDM -
groups: * denotes p<0.005 for growth hor-
mone from preexercise,  ** denotes p<0.01
for insulin from baseline.
Urinary albumin was measured by
radioimmunoassay (Diagnostic Prod-
ucts Corporation, Apeldoorn, The
Netherlands). Serum growth hormone
(GH) concentrations were measured
by radioimmunoassay (Farmos
Diagnostica, Turku, Finland). Insulin-
like growth factor-I (IGF-I) was mea-
sured by radio-immunoassay (Nichols
Institute of Diagnostics, San Juan
Capistrano, Calif., USA). Plasma
glucagon was measured by radio-
immunoassay, using antibody 30K
(obtained from Professor RH Unger,
Dallas, Tex., USA [25]). Plasma free
insulin and plasma C-peptide con-
centrations were measured by radio-
immunoassays. 
Statistical analysis
Results are expressed as mean±-
SD or mean±SEM (Figures) for
parametrically distributed data and as
median (interquartile ranges) for non-
parametrically distributed data. Data
were compared with unpaired t-tests.
Within group changes of parameters
were evaluated using analysis of vari-
ance. Duncan's method [26] was used
to adjustment for multiple
comparisons. Multiple regression
analysis was used to disclose the independent contribution of the various metabolic
parameters to GFR, ERPF, RVR and kidney volume. P-values less than 0.05 were
considered to be significant.   Glucagon, growth hormone and kidney function 121
Table 2. Renal haemodynamics, corresponding plasma glucose and insulin levels, and kidney volume.
Group H Group N
 (n=10)  (n=20)
Glomerular filtration rate (ml/min per 1.73m ) 160 ± 22 109 ± 12
2 a
Effective renal plasma flow (ml/min1 per 1.73m ) 670 ± 142 470 ± 74
2 a
Filtration fraction 0.24 ± 0.04 0.24 ± 0.03
Renal vascular resistance (dynes.s/cm  per 1.73m ) 6654 ± 1422 9195 ± 1697
5 2 a
Kidney volume (ml/1.73m ) 332 ± 99 291 ± 54
2
Plasma glucose (mmol/l) 6.7 ± 1.4 6.1 ± 1.1
Insulin (mU/l) 24.4 ± 11.5 23.9 ± 11.1
Group H: IDDM patients with glomerular filtration rate >130 ml/min per 1.73m ; group N: IDDM
2
patients with glomerular filtration rate ranging from 90 to 130 ml/min per 1.73m . Data are given
2
as mean±SD.   denotes P<0.001 from group N.
a
Results 
Renal haemodynamic parameters and kidney volume
The renal haemodynamics and kidney volume measurements are given in Table 2.
By selection, GFR was higher in H than in N, whereas ERPF was also clearly elevated in
group H compared with N (p<0.001). The FF was similar in the groups H and N, but RVR
was lower in group H than in group N (p<0.001). The difference in kidney volume was
not significant. The mean blood glucose and insulin concentrations during the renal
haemodynamic assessments were comparable between the groups (Table 2).
Metabolic assessments during exercise 
As expected, the circulatory level of GH increased in response to the exercise
(p<0.005, Figure 1A). Plasma glucagon did not significantly change during the procedure
(Figure 1B). Plasma insulin levels decreased (p<0.01, Figure 1C). Blood glucose ranged
between 4.9 and 15.4 mmol/l and tended to increase at the end of the exercise (Figure 1D).
No significant differences were found between the two groups in the absolute levels of
growth hormone, glucagon, insulin and glucose neither at the separate measurements nor
in the averaged values of the test (p>0.10 for all comparisons). Baseline plasma IGF-I
levels were 0.35 ± 0.08 kU/l and 0.36 ± 0.07 kU/l in the groups H and N, respectively
(NS).   
Correlation analyses
For GH the averaged baseline and exercise-stimulated levels were used separately
in the regression analysis. For glucagon the averaged values of the whole procedure were
taken since glucagon was not stimulated by exercise.
Simple regression analysis showed significant correlations between stimulated GH
as well as glucagon and GFR (Figure 2A and B). The correlation between GFR and
HbA1c did not reach statistical significance (r=0.32, p=0.054). ERPF was correlated with
HbA1c and glucagon (Figure 2C and D), but not with GH (r=0.28, p=0.13). 200
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Figure 2. Relationships between renal haemodynamics and metabolic parameters. Hyperfiltering F,
normofiltering M IDDM patients. A: exercise stimulated-serum growth hormone and GFR, r=0.40, p<0.05;
B: mean plasma glucagon and GFR, r=0.40, p<0.05; C: HbA1c  and ERPF, r=0.42, p<0.02; D: mean
plasma glucagon and ERPF, r=0.36, p<0.05; E: exercise-stimulated serum growth hormone and RVR, r=-
0.43, p<0.01; F: HbA  and kidney volume, r=0.61, p<0.001. 1Glucagon, growth hormone and kidney function 123
Table 3. Determinants of renal haemodynamics and kidney volume as assessed by stepwise multiple
regression analyses.
Variable Partial correlation Contribution Significance
coefficient to variance
Determinants of glomerular filtration rate.
HbA1c      0.42   18% p<0.01
Glucagon      0.38   14% p<0.03
Stimulated GH    0.32   10% p<0.05
Multiple-r       0.67   44% p<0.002
Determinants of effective renal plasma flow.
HbA1c    0.48   24% p<0.005
Glucagon      0.43   18% p<0.01
Multiple-r       0.62   39% p<0.002
Determinants of renal vascular resistance. 
Stimulated GH      0.43   18% p<0.01
Determinants of kidney volume.
HbA        0.51   26% p<0.001 1
Renal vascular resistance     -0.42   18% p<0.01
Multiple-r       0.72   52% p<0.001
RVR was negatively related to GH (Figure 2E). Basal GH levels were not correlated with
renal haemodynamic parameters. Kidney volume was correlated with HbA1c (Figure 2F),
but not with glucagon or GH. 
Multiple regression analysis disclosed that HbA  (r =0.18, p<0.01), glucagon 1
2
(r =0.14, p<0.03) and stimulated GH (r =0.10, p<0.05) independently contributed to the
2 2
GFR (multiple r=0.67, p<0.002, Table 3). Also, HbA  (r =0.24, p<0.005) and glucagon 1
2
(r =0.18, p<0.01) showed independent relations with the ERPF (multiple r=0.62, p<0.002,
2
Table 3). RVR only showed a negative relation with stimulated GH (r =0.18, p<0.01)
2
Table 3). Kidney volume was positively related HbA1c (r =0.26, p<0.001) independent
2
from the inverse relation with RVR (r =0.16, p<0.01)  (multiple r=0.72, p<0.001, Table
2
3). Blood glucose levels, IGF-I concentrations and clinical parameters such as age,
diabetes duration, body mass index, retinopathy and Ualb.V were not related to renal
function or kidney size.
Discussion
In this study an exercise test was performed to stimulate GH levels physiologically
and on both study days the patients were kept fasting to eliminate the effects of recent
nutrient intake on hormone levels and renal function. Under these circumstances renal
haemodynamic parameters were significantly related to circulatory levels of plasma
glucagon, exercise-stimulated GH levels as well as HbA1c, whereas the absolute levels of
these hormonal and metabolic factors were not significantly different between the hyper-
and normofiltering IDDM patients. Possible between group differences in these parametersChapter 9 124
could have been obscured because of the arbitrarily employed definition of glomerular
hyperfiltration. A GFR above the upper normal limit of 130 ml/min per 1.73m  was
2
designated as glomerular hyperfiltration, comparable to a cut-off value of 135 ml/min per
1.73m  used by others [10]. However, such a ‘control population-based’ definition has the
2
limitation that subtle renal haemodynamic alterations in apparently normofiltering patients
cannot be discriminated and is likely to represent a minimal estimation of the
hyperfiltration phenomenon [27]. 
In the multiple regression analysis with the renal haemodynamic parameters as
dependent variables, glucagon contributed to 14% and 18% of the variances in GFR and
ERPF, respectively. The contributory effect of stimulated GH to GFR was 10% and
amounted to 18% of the variance in RVR. In other studies plasma glucagon and GH
concentrations were not different in normo- and hyperfiltering patients and were not
correlated with renal haemodynamic parameters [1,4,19]. These negative results could
possibly be explained by differences in study design, since stimulatory tests were not used
[1,4,19] or single basal hormone levels were obtained [4]. Recently, an augmented GH
response to GH-releasing hormone has been documented in hyperfiltering patients [20]
supporting an association between an abnormal GH release and renal haemodynamic
changes in IDDM. Long-term metabolic control, as determined by HbA1c levels, contrib-
uted to 18, 24 and 26% of the variances in GFR, ERPF and kidney volume, respectively.
In accordance, other cross-sectional and intervention studies showed a relation of
metabolic control with renal function and kidney size [4,10,11]. 
Several lines of evidence support that glucagon and GH are important humoral
determinants of renal function in man. Infusion of glucagon to reach levels as encountered
in poorly controlled IDDM acutely increases both GFR and ERPF in IDDM patients [14].
Conversely, the rapid decrease in renal function during the administration of the
somatostatin analogue octreotide is closely related to reductions in plasma glucagon [28]
and can be completely prevented by concomitant low-dose glucagon administration [29].
Furthermore, renal haemodynamics have been shown to be more responsive to increments
in plasma glucagon in well-controlled IDDM patients than in normal subjects [14]. The
role of circulatory GH in the maintenance of renal function is illustrated by the fact that
acromegalic and GH-deficient patients show differences in GFR and ERPF of about 50%
[30,31]. The abolished renal-stimulatory effects of amino acids in acromegaly as opposed
to the enhanced response in GH-deficiency further supports that GH is involved in renal
vasodilation [30,31]. GH increases GFR and ERPF indirectly by stimulating IGF-I
synthesis [32,33]. In spite of the high concentrations of GH, plasma IGF-I levels are
frequently found to be reduced in IDDM [34,35]. In agreement, plasma IGF-I levels were
low in both groups of IDDM patients. In the interpretation of these data it should be noted
that plasma IGF-binding proteins could have interfered with the presently used
radioimmunoassay [36] and that free IGF-I concentrations were not measured.
Disturbances in IGF-I binding proteins, modulating its biological activity [36,37], or
alterations in renal IGF-I accumulation [35] might possibly explain why, in accordance
with other observations [4,38], the low circulatory IGF-I levels were not significantly
correlated with renal haemodynamics in these IDDM patients. Moreover, an altered or
variable renal haemodynamic responsiveness to circulatory IGF-I in IDDM cannot be
excluded. Indeed, in vitro studies have shown increased expression of IGF-I receptors inGlucagon, growth hormone and kidney function 125
cultured mesangial cells from diabetic mice [39].
In conclusion, the present results suggests that circulatory glucagon as well as GH
play a contributory role in the increase in renal haemodynamics in IDDM patients.
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CHAPTER 10
INCREASED URINARY IGG/ALBUMIN INDEX IN
NORMOALBUMINURIC IDDM PATIENTS: 
A LABORATORY ARTEFACT
K. Hoogenberg , P. Visser , J. Marrink , W.J. Sluiter  and R.P.F. Dullaart
1 2 2 1 1
The previous observation that urinary IgG excretion is increased in normoalbuminuric IDDM
patients is unexplained and could possibly be related to a laboratory phenomenon. When untreated
urine samples were stored at -20 C for 2 to 4 weeks, the IgG/albumin index (IgG clearance divided by
o
albumin clearance) was higher in normoalbuminuric IDDM patients than in control subjects
(0.91(0.68-1.54), n=27 vs 0.72(0.55-0.79), n=15 (median(interquartile range)), p<0.05). In normo- and
microalbuminuric IDDM patients the IgG/albumin index was higher in urine samples with glucose
than without glucose (1.16(0.93-1.68), n=11 vs 0.73(0.50-0.91), n=16; p<0.05, and 0.33(0.23-0.60),
n=17 vs 0.15(0.10-0.26), n=14, p<0.02 for normo- and microalbuminuric patients, respectively). We,
therefore, evaluated the preserving effects of glucose and bovine serum albumin (BSA) on urinary IgG
after 1 hour to 16 weeks of freezing at -20 C in 4 non-diabetic subjects (proteinuria ranging from 0.05
o
to 8.0 g/day). Urine samples were either stored without precautions or treated with addition of
phosphate buffer, BSA (1%) and glucose (100 and 300 mM). The weekly decline from 1 to 16 weeks
of IgG in the urine aliquots diluted 1:1 with buffered glucose 300 mM and glucose 300 mM + BSA 1%
was insignificant, whereas urinary IgG declined with all other storage regimes (p<0.05). These results
suggest that glucose in urinary specimens of IDDM patients prevents at least in part the loss of urinary
IgG and may thus explain the higher urinary IgG/albumin index when unprocessed urine is stored
frozen before assay. Laboratory precautions are necessary when urinary IgG cannot be measured
immediately.
Introduction
The glomerular filtration of macromolecules is dependent on their charge, size and
structure, on the properties of the glomerular filtration barrier which govern charge and
size selectivity, as well as on renal haemodynamic factors [1]. In the microalbuminuric
stage of diabetic renal disease an important role is attributed to a loss of negative charge
of the glomerular basement membrane, which is probably due to a decrease in the
negatively charged proteoglycan, heparansulphate [2-5]. This impaired charge selectivity
leads to enhanced glomerular passage and urinary excretion of negatively charged
molecules like albumin and IgG4 [1,6,7]. In more advanced stages of diabetic nephropathy
a concomitant defect in glomerular size selectivity is thought to result in a grossly
increased urinary excretion of neutrally charged IgG [1]. Therefore, the observation that
the urinary IgG excretion [3,8] or the IgG/albumin clearance ratio [9] is elevated inChapter 10 128
normoalbuminuric diabetic patients compared to healthy subjects is puzzling and awaits
further explanation. This phenomenon could possibly be related to laboratory conditions
of urine storage before IgG assay. In this respect it is important to note that urinary IgG
concentration decreases within several weeks after freezing of samples at -20 C and that
o
addition of bovine serum albumin (BSA) to the urine specimens and buffering urine to
neutral pH diminishes this decline in IgG concentration [10].
In the present study we describe the apparent increasing effect of glucosuria on
urinary IgG measurement when aliquots were stored at -20 C without precautions.
o
Laboratory experiments were carried out to determine the effect of different storage
conditions, including addition of glucose and BSA, on urinary IgG measurement.
Patients and methods
Study A: Urinary IgG (UIgG.V) and albumin (Ualb.V) excretion were determined
in overnight and in day-time urine collections of 15 healthy controls (age 25±5 years,
group C), in 27 normoalbuminuric (age 30±9 years, diabetes duration 15±10 years, group
D1) and 31 microalbuminuric insulin-dependent diabetic patients (IDDM) (age 43±11
years, diabetes duration 22±9 years, group D2). Microalbuminuria was defined as an
Ualb.V>20 µg/min in an exactly timed overnight urine collection. On the following
morning, directly after completion of the overnight collection, a one hour urine collection
was made and venous blood was taken for measurements of blood glucose, serum albumin
and IgG at the beginning of this period. In the overnight samples, the IgG/albumin index
was calculated as the IgG clearance divided by the albumin clearance. 
Study B: The effects of laboratory storage conditions on urinary IgG measurement
was evaluated in 4 non-diabetic subjects with a total urinary protein excretion of 0.05, 0.2,
2.0 and 8.0 g/day.
In all participants of both studies urinary tract infection was excluded by Dipslide
tests. Urine samples for IgG measurement were stored at -20 C without precautions for 2
o
to 4 weeks in study A. Freshly collected samples were processed in study B (see below).
Urinary IgG was measured by an in-house developed enzyme linked immunosorbent
assay (ELISA), essentially according to Fomsgaard et al. [11]. The following materials
were used: coating: polyclonal goat-antihuman-IgG (gammachain) (Tago, Burlingame,
CA, cat no 4100), as conjugate: goat-antihuman-IgG peroxidase (GAHu/IgG (H+L)/PO,
Nordic, Tilburg, The Netherlands), enzyme substrate: o-phenylenediamine di-HCl
(Eastman Kodak, Rochester, NY, USA). The IgG standard (standard human serum ORDT
06/07, Behringwerke AG, Marburg, FRG) was diluted providing a range from 1.5 to 200
µg/l. Incubations were carried out at 37 C. The colour development was stopped by adding
o
100 µl H SO  (0.5 mol/l). The absorbance was measured at 492 nm using a Titertek 2 4
Multiscan (Flow Laboratories, Irvine, UK). Results were computed according to Rodbard
et al. [12]. The intra- and interassay coefficients of variation (CV) were 5% and 15%,
respectively. The lower detection limit was 1.5 µg/l. 
To evaluate the effect of laboratory storage conditions on urine IgG measurement
(study B) the following experiments were carried out: within 4 hours after voiding urine
aliquots were treated (A) undiluted; (B) diluted 1:1 with 40 mM phosphate buffer, 0.1 M
NaCl adjusted to pH 7.4 and sodium azide (NaN  0.2%); (C) diluted 1:1 with buffer and 2Glucose and urinary IgG in IDDM. 129
BSA 1% (10 g/l); (D) diluted 1:1 with buffer and glucose 100 mM; (E) diluted 1:1 with
buffer and glucose 300 mM; (F) diluted 1:1 with buffer, glucose 100 mM and BSA 1%;
(G) diluted 1:1 with buffer, glucose 300 mM and BSA 1%. IgG was measured in these
samples before freezing and after 1 hour, and 1, 2, 4, 8 and 16 weeks of storage at -20 C.
o
All IgG measurements were performed in quadruplicate. 
In both studies urine aliquots for albumin measurement were stored at 4 C and
o
analyzed within 24 hours. Urinary albumin was measured in duplicate using a commer-
cially available double antibody radioimmunoassay (Diagnostic Products Corporation,
Apeldoorn, The Netherlands, cat no KHAD ). The intra- and interassay CV's were 2.3% 2
and 7.7%. respectively. The lower detection limit was 0.07 mg/l. Serum IgG was
measured by nephelometry (Behring Nephelometer Analyzer , Behringwerke AG,
TM 
Marburg, FRG). The intra- and interassay CV's were 2.4 to 3.6% and 2.5% respectively.
Serum albumin was measured on a SMAC-II autoanalyser (Technicon Instruments Inc.,
Tarry Town, NY, USA). The intra- and interassay CV were 1.9% and 2.5%, respectively.
Blood glucose was measured using a Yellow Springs glucose Analyzer (Model 23A,
Yellow Springs Inc,. Yellow Springs, Ohio, USA). Urinary glucose was measured using
a Polarimeter Type 243 (Thorn Automation, Nottingham, UK). 
Statistical analysis
Results are expressed as mean±SD or as median (interquartile range) for
parametrically and non-parametrically analysed data, respectively. In study A, differences
in urinary albumin excretion, urinary IgG excretion and the albumin/IgG index were
evaluated by Kruskal-Wallis oneway analysis of variance with Duncan's method to correct
for multiple comparisons. Correlation coefficients between urinary and blood glucose and
protein excretion were calculated using Spearman's rank analysis. In study B, mean (±SD)
recovery of IgG at each interval was calculated as percentage of the freshly analysed
samples for each of the four urine collections. The overall means and their common SD's
are given in the Table, and the data are compared by Student t-tests. Using linear
regression analysis, the weekly percentage decline (±SD) from 1 to 16 weeks was
calculated for each collection. The overall mean declines (± SD) are given in the Table. A
two-sided p-value less than 0.05 was considered to be significant.
Results 
Urinary albumin and IgG excretion (study A) 
Overnight Ualb.V and urinary IgG excretion (UIgG.V) were significantly higher in
group D2 (54.6(41.6-109.5) and 3.10(2.35-8.81) µg/min, respectively) than in groups D1
and C (7.1(4.6-10.1) and 4.6(3.0-7.2) for Ualb.V; 1.64(1.02-2.37) and 0.46(0.35-0.66)
µg/min for UIgG.V, p<0.01 for all comparisons). Ualb.V was similar in group D1 and
group C, but UIgG.V was higher in group D1 compared to group C (p<0.05). Since no
differences were present in serum albumin and IgG concentrations, the overnight
IgG/albumin index was higher in group D1 (0.91(0.68-1.54)) than in group C (0.72(0.55-
0.79), p<0.05). This index was lower in group D2 (0.27(0.14-0.40), p<0.01) than in group
C. As shown in Figure 1, in both diabetic groups the IgG/albumin index was higher in
urine samples with glucose as compared to those without glucose (1.16(0.93-1.68) (n=11)2.5
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vs 0.73(0.50-0.91) (n=16), p<0.05, for group D1; 0.33(0.23-0.60) (n=17) vs 0.15(0.10-
0.26) (n=14), p<0.02, for group D2). In group D1, the IgG/albumin index in samples
without glucose was not different from group C (Figure 1). In the day-time urine collec-
tions similar differences were present (not shown). In the combined diabetic patients
(n=58), the day-time IgG/albumin index was positively correlated with urinary glucose
concentration (r  = 0.33, p<0.05), urinary glucose excretion (r =0.44, p<0.01) and blood s s
glucose (r  = 0.56, p<0.01).  s
Fig ure
1. The
overnight IgG/albumin index in non-diabetic control subjects (group C,￿), in normoalbuminuric IDDM
patients (group D1) without (Q) and with glucosuria (#), and in microalbuminuric IDDM patients
(group D2) without (˛) and with glucosuria (>). Bars represent median values. * denotes p<0.05 from
group C and group D1 without glucosuria; † denotes p<0.01 from groups C and D1 with and without
glucosuria ‡ denotes p<0.02 from group D2 without glucosuria.
Effects of laboratory storage condition on urinary IgG measurement (study B) 
In the 4 non-diabetic patients the urinary IgG concentration was 0.68, 1.52, 12.1 and
109 mg/l in the immediately processed samples. The IgG concentrations after storage atGlucose and urinary IgG in IDDM. 131
Table 1. Recovery of urinary IgG after different storage conditions during variable intervals at
 -20 C in 4 non-diabetic subjects with proteinuria. 
o
Storage time      weekly
fresh 1h 1wk 2wk 4wk 8wk 16wk    decline %
Dilution (1:1)    %  %  %  %  %  %   %   
A   undiluted urine mean 100 98 83* 86* 81* 66* 39* 3.18*
SD 6.2 7.2 7.9 6.5 8.5 14.6 24.9 0.92
B   buffer alone  mean 100 98 73* 73* 65* 60* 49* 1.65*
SD 8.3 10.7 10.8 7.7 4.6 5.8 8.9 0.25
C  +BSA 1% mean 100 97 83* 85* 80* 73* 65* 1.37*
SD 3.8 7.4 7.4 7.7 10.0 7.1 8.7 0.34
D  +glucose mean 100 95 86* 86* 77* 78* 65* 1.35*
 100 mM SD 3.6 6.6 13.2 8.1 6.6 8.8 14.7 0.37
E  +glucose mean 100 99 95 96 95 97 86* 0.61
  300 mM SD 3.8 6.1 8.2 8.5 12.9 11.5 8.4 0.43
F  +BSA 1%  mean 100 97 94 96 95 91* 86* 0.66*
   +glucose 100mM SD 3.1 6.2 6.9 8.8 13.8 6.7 7.2 0.28
G  +BSA 1%  mean 100 101 95  100 96 95 91* 0.39
 +glucose 300mM SD 4.3 5.1 6.4 12.5 10.7 11.3 7.1 0.29
Data are given as overall mean and common SD in % of measurements in fresh urine and
percentage decline per week (from 1 to 16 weeks) and common SD. * denotes p<0.05 as  compared
to fresh urine or as compared to zero-decline.
-20 C are given as percentage recovery of the initial value (Table 1). No immediate effect
o
of 1 hour of freezing could be demonstrated. In contrast, the IgG content after 1 week of
storage declined significantly in the untreated (p<0.01, A), buffered (p<0.005, B),
buffered and BSA 1% diluted (p<0.01, C), buffered and glucose 100 mM diluted (p<0.05,
D) urine specimens (Table 1). Moreover, this decline was progressive, since the weekly
decline from 1 to 16 weeks of storage was significant in these storage regimes (p<0.01 for
A,B,C and D). In glucose 300 mM diluted (E), glucose 100mM and BSA 1% diluted (F)
and glucose 300 mM and BSA 1% diluted (G) urine specimens a small but significant
decline in IgG was noted after 16 weeks. The weekly decline in IgG was not significant in
the urine specimens diluted with glucose 300 mM (p<0.20, E) or glucose 300 mM and
BSA 1% (p<0.20, G), but significant if diluted with glucose 100 mM and BSA 1%
(p<0.05, F).
Discussion 
In addition to documentation of microalbuminuria, measurement of IgG with
sensitive assays will gain insight in the glomerular permelectivity defects underlying the
development and evolution of diabetic renal disease. In a cross-sectional study we
confirmed recent unexplained findings showing that normoalbuminuric IDDM patientsChapter 10 132
have a higher urinary IgG excretion and a higher IgG/albumin index compared to controls
[3,8,9]. Of importance, urine samples for IgG measurement were stored at -20 C without
o
precautions in the study by Deckert et al [3] and in the present study, whereas in the other
reports [8,9] the urinary storage conditions were not mentioned. The present data showed
that among both normo- and microalbuminuric IDDM patients the IgG/albumin index was
higher in samples with glucose compared to samples without glucose. Moreover, the
IgG/albumin index was positively correlated with glucosuria. This unexpected finding
prompted us to evaluate the effect of laboratory storage conditions on IgG measurement.
In agreement with other data, storage at -20 C without precautions resulted in a
o
pronounced loss of IgG [10], but in contrast with that study, addition of BSA alone did not
prevent the decline in IgG. Only addition of 300 mM glucose (preferably in combination
with BSA 1%) to the specimens prevented a rapid decline in IgG. Moreover, such high
urinary glucose concentrations can be encountered in vivo during periods of severe
hyperglycaemia. It is, therefore, plausible that the apparently increasing effect of glucose
on IgG excretion in IDDM is attributable to a diminished or absent loss of IgG during
storage without precautions. An alternative explanation, such as a general abnormality in
glomerular or tubular IgG handling in diabetes mellitus, is difficult to envisage, since the
glomerular permselectivity is considered to be intact [13] and $ -microglobulin excretion 2
is unchanged [1] in normo-albuminuric IDDM patients. Indeed, we were unable to
reproduce an elevated IgG/albumin index in normoalbuminuric IDDM patients when using
adequate storage procedures [unpublished observations]. Deckert et al. were also unable
to find a difference in the IgG/albumin index in normoalbuminuric IDDM patients
compared to controls if urine samples were stored at -40 C after predilution with 5% BSA
o
in phosphate buffer [14, personal communication B. Feldt-Rasmussen].
A gradual loss in urinary IgG during storage at -20 C was observed, without an
o
immediate effect of freezing and thawing. Denaturation or aggregation of globulins into
multimeres of 2 to 4 molecules at low temperatures, which might interfere with epitope
recognition in the enzyme-linked immunosorbent assay, can possibly explain this loss in
IgG. The employed glucose concentrations of 100 to 300 mM in the specimens were very
high compared with the measured IgG concentrations that ranged from 0.0045 to 0.716
mM. This excess of glucose molecules could prevent IgG denaturaton or aggregation
during prolonged freezing. In contrast to IgG, urinary albumin does not decline after
freezing for 1 week [15], although a period of longer storage is also associated with a loss
of albumin [16]. Of note, addition of glucose does not influence the albumin measurement
in samples assayed within one week after collection [15].
In conclusion, the presence of glucose in urine samples of IDDM patients most
likely prevents, at least in part, the loss of urinary IgG when aliquots are frozen without
precautions. This may explain the apparently higher IgG/albumin index in
normoalbuminuric IDDM patients as compared to healthy subjects. Addition of glucose
300 mM plus BSA 1% (1:1) to the urine samples is an appropriate measure to prevent a
substantial decline in IgG. It is, therefore, necessary to use such precautions when it is not
possible to assay IgG immediately.
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CHAPTER 11
ALTERATIONS IN CORTISOL METABOLISM IN IDDM
PATIENTS: RELATIONSHIP WITH METABOLIC CONTROL
AND ESTIMATED BLOOD VOLUME AND EFFECT OF
ANGIOTENSIN CONVERTING ENZYME-INHIBITION
R.P.F. Dullaart , F.L. Ubels , K. Hoogenberg , A.J. Smit , J.J. Pratt , 
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J.H.J. Muntinga , W.J. Sluiter  and B.G. Wolthers
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11ß-hydroxysteroid dehydrogenase (11ß-HSD) catalyses the interconversion of cortisol and its
inactive metabolite, cortisone, and protects the mineralocorticoid receptor from activation by cortisol.
Sodium and fluid retention is a well documented phenomenon in IDDM patients, but it is unknown
whether alterations in cortisol metabolism contribute to its pathogenesis. Therefore, we evaluated some
aspects of cortisol metabolism by measuring urinary metabolites of cortisol and cortisone in 8
microalbuminuric and 8 normoalbuminuric IDDM patients and 8 matched control subjects. In both
IDDM groups, the overnight excretion of tetrahydrocortisol (THF), allo-tetrahydrocortisol (allo-THF)
and tetrahydrocortisone (THE) was lower than in the control group (p<0.05 to p<0.01). Both the allo-
THF/THF ratio, a parameter of 5"/5ß reduction of cortisol, and the cortisol to cortisone metabolite
ratio (THF+allo-THF/THE), which reflects the overall direction of the cortisol to cortisone
interconversion, were lower in the IDDM groups (p<0.05 to p<0.01). In the combined subjects (n=24),
allo-THF, allo-THF/THF and THF+allo-THF/THE were inversely correlated with HbA1c (r=-0.69,
p<0.001, r=-0.61, p<0.01 and r=-0.58, p<0.01, respectively). Upper arm segmental blood volume,
estimated by an electrical impedance technique, was positively correlated with the cortisol to cortisone
metabolite ratio both in the control subjects (r=0.77, p<0.05) and in the IDDM patients in whom it was
measured (r=0.56, p<0.05, n=13), whereas the regression line was shifted leftwards in IDDM (i.e. a
lower ratio at the same blood volume, p<0.03 by analysis of covariance). In 7 microalbuminuric IDDM
patients, the angiotensin converting enzyme-inhibitor, enalapril (10 mg daily for 6 to 12 weeks)
resulted in a moderate further lowering of the cortisol to cortisone metabolite ratio (p<0.05). The
present data suggest a chronic hyperglycemia-related impairment in the reduction of corticoids to
tetrahydro metabolites and an imbalance in 11ß-HSD. Altered 11ß-HSD activity is unlikely to be
primarily responsible for the sodium and fluid retention in IDDM. Moreover, an additional mechanism
of action of angiotensin-converting enzyme inhibition might be provided by an effect on 11ß-HSD
activity.
Introduction
Corticosteroid hormones play a central role in extracellular sodium and fluid
homeostasis. The mineralocorticoid receptor has an equal affinity for cortisol and
aldosterone in vitro, but the distal renal tubule binds almost exclusively mineralocorti-coi-Chapter 11 136
ds in vivo [1-4]. Recently, it has become clear that the mineralocorticoid receptor is
protected from excess circulating cortisol by the enzyme 11ß-hydroxysteroid
dehydrogenase (11ß-HSD) [3]. This enzyme, of which several isoforms have been
identified, catalyses the interconversion of cortisol and its inactive metabolite, cortisone
[4]. These observations have provided a link between cortisol metabolism and the regula-
tion of volume and sodium homeostasis, and there is increasing evidence to underscore the
clinical importance of 11ß-HSD. The type 1 syndrome of apparent mineralocorticoid
excess (AME), characterized by sodium retention and hypokalaemic hypertension despite
suppressed plasma aldosterone, has been shown to be caused by impaired 11ß-HSD
activity [5,6]. Similarly, glycyrrhethinic acid, the main metabolite of glycyrrhizic acid
present in licorice, inhibits 11ß-HSD, thus allowing more cortisol to gain access to the
mineralocorticoid receptor [7]. In these situations defective dehydrogenase activity of 11ß-
HSD is reflected by an abnormal proportion of urinary cortisol to cortisone metabolites [5-
8].  
In diabetes mellitus an increase in exchangeable sodium accompanied by extracellul-
ar volume expansion has been well documented and might contribute to the blood pressure
rise associated with microalbuminuria [9-15]. The mechanisms responsible for this
abnormal sodium retention are still incompletely understood, although enhanced renal
tubular sodium reabsorption most probably plays an important role [15-16]. Plasma
aldosterone levels are usually found to be within normal limits in insulin-dependent
diabetic (IDDM) patients [14,15]. Mild hypercortisolism, possibly associated with the
presence of complications, has been found in diabetic patients [17-19], but it is unclear in
how far the diabetic state leads to alterations in cortisol metabolism and whether possible
changes in the cortisol to cortisone conversion influence volume homeostasis. 
Against this background we measured urinary cortisol and cortisone metabolites in
normo- and microalbuminuric IDDM patients and in control subjects. Parameters of
cortisol metabolism were related to metabolic control and upper arm segmental blood
volume, estimated by an electrical impedance technique. Since recent experimental data
indicate that 11ß-HSD can be stimulated by angiotensin converting enzyme (ACE)-
inhibition [20], the effect of this treatment was studied in microalbuminuric patients.
Subjects and methods
Subjects
The protocol was approved by the local medical ethics committee and written
informed consent was obtained from all participants. The subjects also participated in
another study (investigating the effects of catecholamines on renal function) which will be
reported elsewhere. That study was started after completion of the data collection and does
not interfere with the present results. The IDDM patients had ketosis-prone diabetes
mellitus and glucagon-stimulated C-peptide levels were <0.2 nmol/l in all of them. None
of the participants had autonomic neuropathy. Microalbuminuria was defined as urinary
albumin excretion rate (Ualb.V) between 20 and 200 µg/min in at least 2 of 3 overnight
urine collections obtained over a one year period [21]. Ualb.V was assessed in the absence
of urinary tract infection as indicated by a sterile urine culture. Three groups of subjects
were studied: 8 IDDM patients with normoalbuminuria, 8 IDDM patients withCortisol metabolism in IDDM 137
microalbuminuria and 8 healthy control subjects, individually matched for sex and age.
Except for IDDM the participants did not have other diseases. In particular, all subjects
were clinically and biochemically euthyroid, as indicated by a normal TSH level (0.3 to
5.0 mU/l). None of the participants had severe obesity, defined as body mass index (BMI)
>30 kg/m . The mean±SD BMI was 23.2±2.9, 24.5±3.0 and 25.6±2.6 kg/m  for the
2 2
control subjects, the normo- and the microalbuminuric IDDM patients, respectively
(p>0.10). There were 7 men and one woman in each group. Mean age was 44±9, 46±10
and 47±10 yr in these three groups, respectively (p>0.40). The mean diabetes duration was
22±6 and 28±6 yr in the normo- and the microalbuminuric IDDM patients (p<0.08). In the
normoalbuminuric group 5 patients had no retinopathy, 2 had background retinopathy and
one had proliferative retinopathy, whereas in the microalbuminuric group 5 patients had
background and 3 patients had proliferative retinopathy (p<0.05). None of the control and
normoalbuminuric IDDM subjects had arterial hypertension, defined as systolic blood
pressure $160 mm Hg and/or diastolic blood pressure $95 mm Hg. An ACE-inhibitor was
used by 7 microalbuminuric IDDM patients. This treatment was withheld for a 6 week
period before the study. 
Clinical procedures
The participants were instructed by a dietician to adhere to a diet containing 100
mmol sodium/day starting 1 week before the study to avoid possible confounding effects
of differences in sodium intake on gluco- and mineralocorticoid status. At the end of this
period urinary sodium excretion was 109±36, 103±26 and 109±19 mmol/24 h in the
control subjects and the normo- and microalbuminuric IDDM patients (p>0.40), indicating
acceptable diet compliance. An exactly timed overnight urine collection was then obtained
for measurement of steroid metabolites, free cortisol, aldosterone, Ualb.V and creatinine
clearance. None of the IDDM patients had symptomatic nocturnal hypoglycaemia and
blood glucose at 0300 h varied between 4- 9 mmol/l. On the following morning, fasting
venous blood was drawn at 0900 h, while the subjects were in the supine position. Supine
blood pressure was measured at 5 min intervals during one hour using an automated
device (Dinamap ) and the results were averaged for analysis. Initial blood volume,
R
estimated by a previously described electrical impedance technique [22] was used as an
index of upper arm segmental blood volume. In brief, a blood pressure cuff is placed over
a 2 cm wide segment of the left upper arm. With a computer-assisted model the segment's
initial blood volume (expressed in ml/cm) is calculated from the increase in impedance
during rapid inflation of the cuff at a period of constant suprasystolic cuff pressure. In
healthy subjects the coefficient of variation of the initial blood volume measurement
determination is 6% (derived from Ref. 23). This technique can also be used to calculate
other vascular parameters, like arterial blood volume and static arterial compliance. The
validity of the mathematical model and its derived parameters has been demonstrated by
a close correlation of the diameter of the brachial artery as estimated by this technique
with its diameter as assessed by high-resolution echography (r=0.93 in 11 healthy subjects,
Van Leeuwen JTM, unpublished results). The impedance technique was available to all
control subjects, to 7 normoalbuminuric and to 6 microalbuminuric IDDM patients.
The 7 microalbuminuric IDDM patients in whom ACE-inhibition treatment was
stopped before the study consented to be reevaluated 6-12 weeks after resumption of ACEChapter 11 138
inhibition therapy (enalapril, 10 mg/day). Venous blood samples were then taken 30-60
min after enalapril administration. On this second evaluation the electrical impedance
technique was not available. 
Laboratory measurements
Blood samples for measurement of cortisol, aldosterone, ACTH and renin were
collected in EDTA-anticoagulated tubes and placed on ice immediately. The plasma
specimens and aliquots of overnight urine collections were stored at -20 C until assay.
Plasma cortisol and aldosterone were measured by RIA's as described [24,25]. Plasma 
ACTH was assayed with a commercially available IRMA (Nichols Institute of Diagnos-
tics, Wijchen, The Netherlands). PRA was measured by RIA (Du Pont, Billerica, MA,
USA). Urinary steroid metabolites were determined by gas chromatography [26]. ß-
glycyrrhetinic acid in the urine specimens was analysed by gaschromatography/mass
spectrometry (GC/MS) using "-glycyrrhetinic acid as internal standard. The detection
limit of the assay is approximately 5µg/l. Urinary free cortisol and free aldosterone were
measured after extraction and chromatography by RIA's. Aldosterone-18-glucuronide was
assayed by RIA after hydrolysis at pH 2.0 followed by chromatography. Serum and
urinary electrolytes and creatinine were measured on SMAC and SMA-II autoanalyzers,
respectively (Technicon Instruments, Tarrytown NY, USA). HbA1c was measured by
high-performance liquid chromato-graphy (HPLC, Bio-Rad, Veenendaal, The Nether-
lands; normal values 4.6 to 6.1%). Blood glucose was determined on a YSA glucose
analyser (model 23A, Yellow Springs, Yellow Springs OH, USA). Urinary albumin was
measured by RIA (Diagnostic Products Corporation, Apeldoorn, The Netherlands).
Evaluation of cortisol metabolism
5ß tetrahydrocortisol (THF), 5" tetrahydrocortisol (allo-THF) and 5ß tetrahydro-
cortisone (THE) are major metabolites of cortisol and cortisone which are excreted in the
urine [27]. These metabolites are primarily produced in the liver by the irreversible ring
A reduction of glucocorticoids to dihydro metabolites and the subsequent keto reduction
to tetrahydro compounds. The first step is catalysed by 5" and 5ß reductases. The urinary
allo-THF/THF and androsterone (A, 5"-androstan-3"-ol-17-on)/etiocholanolone (E, 5ß-
androstan-3"-ol-17-on) ratios reflect the proportion of 5"/5ß reduced C-21 and C-19
steroids, respectively [27,28]. According to Ulick et al [5,8], the urinary cortisol to
cortisone metabolite ratio (THF+allo-THF/THE) is an index of 11ß-HSD activity and this
ratio reflects the set-point of the overall direction of the cortisol to cortisone
interconversion. Since 11ß-HSD activity may be influenced by food intake [20], we used
overnight instead of 24-h urine collections. It has also been suggested that one calculates
the urinary THF+allo-THF/free cortisol ratio as a measure of the efficiency of the ring A
reduction of cortisol [8]. As urine was collected overnight, we did not use this parameter
but instead calculated the excretion of cortisol metabolites and free cortisol separately.
Statistical analysis
Parameters are expressed as mean±SD, or as median and range. Differences in
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microalbuminuric IDDM group were evaluated by Kruskal-Wallis analysis of variance
using Duncan's method to correct for multiple comparisons. Bivariate correlations were
assessed by linear regression analysis. Analysis of covariance was used to evaluate
independent relationships between variables. In the microalbuminuric IDDM group the
effect of ACE-inhibition therapy on the various parameters was expressed as mean or
median change with 95% Confidence Interval and was analysed by the paired Wilcoxon
rank test. A two-sided p-value < 0.05 was taken as significant.
Results
Table 1 shows some clinical and laboratory data of the study groups. Systolic blood
pressure was higher in the untreated microalbuminuric IDDM patients compared to the
normoalbuminuric IDDM and the control subjects. No differences in diastolic blood
pressure were observed. Overnight Ualb.V was >20 µg/min in each micro-albuminuric
patient and <20 µg/min in all other subjects. Overnight creatinine clearance and  serum
potassium concentration were not different among the groups. Initial blood volume was
higher in the normoalbuminuric IDDM than in the control group, but the difference
between the microalbuminuric IDDM and the control subjects was not significant. Mean
fasting blood glucose and HbA1c levels were similarly elevated in the IDDM groups.
As shown in Table 2 the urinary excretion of the major metabolites of cortisol, THF
and allo-THF, as well as of cortisone, THE, were lower in both IDDM groups than in the
control group. When expressed per mmol of creatinine, the urinary excretion of these
glucocorticoid metabolites was similarly decreased in the IDDM groups (not shown). Of
importance, the excretion of these metabolites was not equally decreased. Consequently,
the THF+allo-THF/THE ratio, i.e. the cortisol to cortisone metabolite ratio, was lower in
both IDDM groups compared to controls. The allo-THF/THF ratio, which reflects 5"/5ß
reduction of cortisol, was also lower in the IDDM groups. This change in 5"/5ß reduction
was not restricted to cortisol, since the A/E ratio, representing 5"/5ß reduction of C-19
steroids, was again lower, especially in the microalbuminuric IDDM group. ß-
glycyrrhetinic acid was detected in the urine samples of 2 control subjects and 1
normoalbuminuric IDDM patient. Exclusion of the steroid data of these subjects from the
analysis did not change the statistical results.
The overnight urinary excretion of cortisol and aldosterone, as well as the fasting
plasma levels of these corticosteroids and of ACTH and PRA are given in Table 3.
Urinary free cortisol, but not plasma cortisol, was lower in the normoalbuminuric IDDM
group than in the other groups. In the microalbuminuric IDDM group the plasma level of
cortisol was higher, but urinary free cortisol was not different compared to the control
group. No differences in plasma ACTH were observed. Urinary free  aldosterone,
aldosterone-glucuronide and plasma aldosterone were not different in the  diabetic groups
compared to the control group, whereas urinary free aldosterone was higher in theChapter 11 140
Table 1. Clinical and laboratory data of study subjects
 Control IDDM patients Change with
 Subjects Normal Ualb.V  Micro Ualb.V  ACE inhibition
 (n=8) (n=8) (n=8)    (n=7)
Systolic BP (mmHg)   127±9 127±12 144±11 -12(-22 to -2)
a,b d
Diastolic BP (mmHg)    79±7  75±8    80±7  -8(-11 to -4)
d
Ualb.V (µg/min)   4(1-11)  5(2-14) 56(32-174)  -8(-55 to 25)
a,b
Creatinine clearance  1.68±0.50 1.84±0.28 1.75±0.50 0.02(-0.44 to 0.46)
(ml/sec per 1.73m )
2
Initial blood volume  3.53±1.14 4.81±1.07 4.25±1.48 ND
c
(ml/cm)    (n=8)   (n=7)   (n=6)
Blood glucose (mmol/l)  5.0±0.5 9.7±4.1 8.9±2.5 1.1(-4.3 to 6.5)
a a
HbA1c (%)  5.7±0.5 8.3±1.0 8.2±0.9 0.2(-0.5 to 0.9)
a a
Serum potassium (mmol/l) 4.2±0.2 4.4±0.4 4.2±0.3 0.1(-0.3 to 0.5)
Data are the mean±SDS or the median range (in parenthesis) changes in the mean or median (95%
confidence interval). BP: blood pressure; Ualb.V: albumin excretion rate; ND: not determined 
a
p<0.01 vs. control subjects;   p<0.01 vs. normoalbuminuric IDDM patients (by selection);   p<0.05
b c
vs. control subjects;   p<0.02 vs without ACE inhibition 
d
microalbuminuric than in the normoalbuminuric IDDM group. PRA was not different
among the groups. 
Significant relationships were present between the HbA1c level and the urinary
excretion of steroid metabolites (Figure 1). In the combined groups (n=24), urinary allo-
THF (Figure 1A, r=-0.69, p<0.001), THF+allo-THF/THE (Figure 1B, r=-0.58, p<0.01),
allo-THF/THF (Figure 1C, r=-0.61, P<0.01), A/E (Figure 1D, r=-0.59, p<0.01), THF (r=-
0.40, p=0.05, not shown) and THF+allo-THF+THE (r=-0.48, p<0.05, not shown) were
inversely correlated with HbA1c. When analysing the data from the IDDM groups (n=16)
separately, the relationships between HbA1c, THF + allo-THF/THE (r=-0.52, p<0.05) and
A/E (r=-0.54, p<0.05) remained significant. No significant correlations were found
between fasting blood glucose and urinary steroid parameters. Figure 2 shows the positive
relationship between the urinary cortisol to cortisone metabolite ratio and initial blood
volume in the control subjects (n=8, r=0.77, P<0.05) and in the IDDM patients (n=13,
r=0.56, p<0.05). Remarkably, the bivariate relationship between the cortisol to cortisone
metabolite ratio and initial blood volume was different between IDDM patients and
control subjects, as depicted by the leftward shift of the regression line in the IDDM
patients (i.e. a lower ratio at the same blood volume). Analysis of covariance disclosed
that initial blood volume was independently related to the cortisol to cortisone metabolite
ratio (p<0.01) and to the presence of IDDM (as a categorical covariate, p<0.03), but not
to the HbA1c level (p=0.76). Thus, the leftward shift in this relationship in the IDDM
patients remained significant after controlling for the HbA1c level. Except for possible
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Table 3. Urinary and plasma measurements of cortisol, aldosterone, ACTH and PRA.
Control IDDM patients     Change with
Subjects Normal Ualb.V    Micro Ualb.V    ACE inhibition
(n=8) (n=8) (n=8)    (n=7)
Urine
  Free cortisol  68.3±29.1 35.1±11.1 61.0±30.4     8.6(-53.8 to 71.1)
a b
   (pmol/min)
  Free aldosterone  0.83±0.44 0.72±0.42 1.26±0.65       -0.72(-1.28 to -0.17)
b c
   (pmol/min)
  Aldosterone 21.5±15.9 17.3±7.6 26.5±15.5 -16.5(-30.7 to -23)
c
  glucuronide (pmol/min)
Plasma
  Cortisol (nmol/l) 381±119 401±154 551±117   39(-73 to 152)
a,b
  ACTH (pmol/l)  5.5±4.2  7.5±3.5  7.5±4.2  7.1(-5.5 to 19.7)
  Aldosterone  0.45±0.27 0.64±0.42 0.55±0.32     -0.17(-0.58 to -0.01)
d
   (nmol/l)
PRA (ng/l.s) 0.30±0.22 0.32±0.20 0.40±0.38    0.52(0.02 to 1.82)
d
Data are the mean±SD or changes in the mean (95% confidence interval). Ualb.V: urinary albumin
excretion.    p<0.01 vs. control subjects and   p<0.05 vs. normoalbuminuric IDDM;   p<0.02 and
a b c
 p<0.05 vs without ACE inhibition 
d
Table 2. Urinary excretion of steroid metabolites in the study subjects
Control IDDM patients Change with
Subjects Normal Ualb.V   Micro Ualb.V  ACE inhibition
(n=8) (n=8) (n=8)   (n=7)
THF (nmol/min)  4.2±1.4  3.1±1.0  3.0±1.3 0.5(-1.3 to 2.2)
a a
Allo-THF (nmol/l)    3.4±1.0  1.7±0.9  1.3±0.7 0.3(-0.4 to 0.9)
b b
THE (nmol/min)  7.5±2.2  5.8±1.6  5.3±2.7 1.3(-1.4 to 4.0)
a a
THF+allo-THF+THE 15.1±4.1 10.6±1.6  9.6±4.4 2.0(-2.9 to 7.0)
a b
(nmol/min)
THF+allo-THF/THE 1.02±0.14 0.82±0.19 0.86±0.15     -0.08(-0.19 to 0.0)
a a c
(µmol/µmol)
Allo-THF/THF 0.86±0.26 0.55±0.19 0.46±0.21     0.04(-0.08 to 0.16)
a b
(µmol/µmol)
A/E (µmol/µmol) 1.35±0.39 1.04±0.34 0.91±0.36    -0.04(-0.23 to 0.14)
a
Data are the mean±SD or changes in the mean (95% confidence interval). Ualb.V: uirnary albumin
excretion rate. Allo-THF/THF and A/E reflect 5"/5$-reduction of C-21 and C-19 steroids,
respectively.   p<0.01 and   p<0.01 vs. control subjects;   p<0.05 vs without ACE inhibition 
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Figure 1.Relationships among HbA1c, urinary allo-THF (A), urinary THF+allo-THF/THE (B), urinary
allo-THF/THF (C), and urinary A/E (D). ! Control subjects, Q normoalbuminuric and Q
microalbuminuric IDDM patients. A: r=-069, p<0.001: B: r=-0.58, p<0.01; C: r=-0.61, p<0.01; D: r=-
0.59, p<0.01 (in the combined groups).
blood pressure with initial blood volume and with the urinary cortisol to cortisone me-
tabolite ratio in the control group (n=8, r=0.63 and r=0.63, p<0.10 for both), no further
interrelationships between blood pressure, initial blood volume, BMI, HbA1c, steroid
metabolites and aldosterone could be demonstrated.
In the microalbuminuric IDDM group ACE-inhibition treatment resulted in a fall in
systolic and diastolic blood pressure, whereas overnight Ualb.V and creatinine clearance
did not change significantly (Table 1). Mean HbA1c and fasting blood glucose levels
remained unaltered (Table 1). Overnight urinary sodium excretion rose by 42 (95%CI, 18
to 66) µmol/min from 69±41 to 111±47µmol/min at this second evaluation (p<0.02). As0.5 0.7 1.1 1.5 0.9 1.3
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presented in Table 2 the absolute urinary excretion of THF, allo-THF and THE did not
change significantly, but there was a modest further decrease in the cortisol to cortisone
metabolite ratio. No changes were observed with respect to the allo-THF/THF ratio and
the A/E ratio. Urinary and plasma cortisol, as well as plasma ACTH did not change
significantly following ACE-inhibition treatment (Table 3). As expected, urinary and
plasma aldosterone decreased and PRA increased after administration of the ACE-inhibi-
tor (Table 3).
Figure 2.Relationships 
between the  urinary cortisol 
to cortisone metabolite ratio
(THF+allo-THF/THE) and 
initial blood volume an index
of blood volume.! Control
subjects (r=0.77,p<0.05;
n=8), Q normo- and Q micro-
albuminuric IDDM patients 
(r=0.56, p<0.05; n=13).
The regression line is shifted 
to the left in the IDDM 
patients (p<0.03, by analysis 
of covariance).
Discussion
The lower urinary excretion of tetrahydro metabolites of cortisol and cortisone in
normo- and microalbuminuric IDDM patients strongly suggest that the diabetic state
influences cortisol metabolism via an impaired reduction of glucocorticoids. It was also
found that the urinary allo-THF/THF ratio as well as the A/E ratio was lower,
indicating that the proportion of 5"/5ß reduced corticoids of both the C-21
(glucocorticoids) and the C-19 (adrenal androgens) series was decreased. In addition, the
urinary cortisol to cortisone metabolite ratio was lower in IDDM. Since this metabolite
ratio reflects the set-point of overall direction of the 11ß-HSD-catalysed cortisol to
cortisone interconversion [5-8], the present findings support the notion that IDDM is
associated with an imbalance in 11ß-HSD activity. Opposite changes in the urinary allo-
THF/THF ratio and in the cortisol to cortisone metabolite ratio have been demonstrated
in type 1 AME syndrome and after ingestion of licorice, conditions associated with
impaired dehydrogenase activity of 11ß-HSD [5-8,28,29].
It is uncertain whether the presently observed lower urinary excretion of
tetrahydro metabolites of glucocorticoids reflects decreased cortisol secretion in IDDM,
since urine was collected overnight and cortisol production rate was not measured.
Previous studies have shown mild hypercortisolaemia in IDDM and a diminishedChapter 11 144
activation of the hypothalamic-pituitary adrenal axis is unlikely [17-19]. Fasting plasma
cortisol was indeed higher in the microalbuminuric IDDM patients. Overnight urinary
free cortisol excretion was within normal limits in both IDDM groups, albeit that its
level was lower in normoalbuminuric patients compared to controls. Obviously, diabetes
mellitus is associated with multiple alterations in the regulation of cortisol metabolism
and further study is indicated to document their exact nature.
5" and 5ß reductases as well as 11ß-HSD are widely distributed enzymes
[4,27,30]. In rat liver 5" reductase is found in the endoplasmatic reticulum, whereas 5ß
reductase is a cytosolic enzyme [30]. Both reductases require NADPH as a cofactor and
are capable of metabolising different classes of steroids, including C-21 and C-19 com-
pounds [27]. 11ß-HSD is predominantly concentrated in the microsomal cell fraction and
thus far two functional isoforms have been identified [4,31]. 11ß-HSD , isolated from 1
a variety of tissues including liver and vascular smooth muscle, exhibits both
dehydrogenase and reductase activity and catalyses the dehydrogenation of cortisol to
cortisone as well as the reduction of cortisone to cortisol. The direction of the reaction
is dependent on the availability of its cofactor NADP /NADPH, the ambient
+
cortisol/cortisone concentration and the glycosylation status of the protein [4]. 11ß-
HSD  is present in placenta and in the distal nephron. This isoform only shows 2
dehydrogenase activity and requires NAD  as a cofactor [4,32-34]. In rat kidney both
+
NADP  and NAD  availability affect dehydrogenase activity of 11ß-HSD, suggesting
+ +
the expression of both isoforms [31]. In human renal tissue the 11ß-HSD  isoform is 2
preferentially expressed and 11ß-HSD activity is largely NAD -dependent [33,34].
+
Experimental studies have demonstrated a diabetes-induced accumulation of NADP  and
+
NADH in the cytosolic cell compartment as a result of increased reduction of glucose to
sorbitol and oxidation of sorbitol to fructose via the sorbitol pathway [35]. The present
study showed inverse correlations of urinary allo-THF, the allo-THF/THF and the A/E
ratio as well as THF+allo-THF/ THE ratio with the HbA1c level. These relationships
would fit the hypothesis that chronic hyperglycemia induces a decrease in intracellular
NADPH which impairs apparent 5"/5ß reductase activity. The data might also support
the concept that a higher NADP /NADPH ratio enhances dehydrogenase activity and
+
inhibits reductase activity of 11ß-HSD , but it seems very improbable that a lower 1
NAD /NADH stimulates dehydrogenase activity of 11ß-HSD . In the interpretation of
+
2
the current results it should be noted that the urinary  THF+allo-THF/THE ratio is only
an index of the overall in vivo direction of the cortisol to cortisone interconversion.
Therefore, it is not possible to direct the imbalance in 11ß-HSD activity to a specific
tissue or to a specific isoform.
In IDDM patients without nephropathy extracellular volume tends to be increased,
whereas plasma volume is normal or elevated [9-15]. We found that initial blood volume
was elevated in the normoalbuminuric IDDM group, but our technique which estimates
upper arm segmental blood volume cannot be easily compared with other methods to
measure whole body extravascular and blood volume. In both the control group and the
combined diabetic groups a positive correlation was found between the urinary cortisol
to cortisone metabolite ratio and initial blood volume. Of note, the regression line was
significantly shifted leftwards in the diabetic patients, thus essentially excluding that theCortisol metabolism in IDDM 145
overall change in 11ß-HSD activity is primarily responsible for an abnormal fluid and
sodium retention in IDDM. 11ß-HSD could also play a role in blood pressure regulation
[36]. Inhibition of dehydrogenase activity of 11ß-HSD enhances the vasoconstrictor
potency of cortisol and impaired cortisol to cortisone conversion is a salient feature in
a subgroup of patients with essential hypertension [37,38]. The similar decrease in the
urinary cortisol to cortisone metabolite ratio in the microalbuminuric compared to the
normoalbuminuric IDDM group makes it unlikely, however, that the blood pressure rise
associated with incipient nephropathy is related to altered dehydrogenase activity of 11ß-
HSD.
Plasma aldosterone as well as urinary free aldosterone and aldosterone-glucuronide
excretion were unchanged in the IDDM groups compared to control subjects. Normal
to low levels of circulating aldosterone have been previously shown in heterogeneous
groups of diabetic patients [15,39] and in IDDM patients irrespective of  the presence
of microalbuminuria [14], whereas discrepant data have been reported with respect to
PRA and plasma active renin [11-15,40,41]. Our data support the contention that
circulating aldosterone might be insufficiently suppressed in relation to the altered
volume homeostasis, although it is not likely that the sodium and fluid retention in
IDDM is caused by a stimulated plasma aldosterone per se [14,15]. 
During ACE-inhibition therapy urinary and plasma cortisol remained unchanged,
in agreement with data in healthy subjects [42]. ACE-inhibition resulted in a modest
further lowering of the cortisol to cortisone metabolite ratio, without an effect on the
proportion of 5"/5ß reduced corticoids. Since the HbA1c level was unaltered, this effect
was not attributable to a change in metabolic control. In the rat, ACE-inhibitor adminis-
tration stimulates 11ß-HSD activity in renal tissue and this influence is partly antago-
nized by angiotensin II [20]. The presently observed moderate decrease in urinary
cortisol to cortisone metabolite ratio is in keeping with enhanced dehydrogenase activity
of 11ß-HSD in vivo. It is possible that, in addition to inhibition of angiotensin II and
aldosterone, stimulation of 11ß-HSD could contribute to the saliuretic effect of ACE-
inhibition treatment [20]. Indeed, urinary sodium excretion was increased during treat-
ment, but our study design does not allow a conclusion with respect to the responsible
mechanism.
In conclusion, IDDM patients show multiple abnormalities in urinary corticoid
metabolite excretion, suggestive of impaired corticoid reduction and altered 11ß-HSD
activity. It seems very unlikely that a change in 11ß-HSD activity is primarily responsi-
ble for the sodium and fluid retention in IDDM. Since ACE-inhibition resulted in a
further decrease in the urinary cortisol to cortisone metabolite ratio, an additional
mechanism of action of this treatment might be provided by an effect on 11ß-HSD
activity.
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Addendum
Scheme representing metabolic pathways of cortisol.CHAPTER 12
SUMMARY AND CONCLUSIONS
Chapter 1 outlines the epidemiology, the functional stages, the pathogenesis and
therapeutic aspects of renal disease in patients with insulin-dependent diabetes mellitus
(IDDM). Several aspects of the pathogenesis of diabetic nephropathy (DN) are more
extensively overviewed in sections on the influence of norepinephrine (NE) and the
growth hormone-insulin-like growth factor-I (GH-IGF-I) axis on renal function. Both
substances belong to hormonal systems that control renal haemodynamics in opposite
ways:  NE causes renal vasoconstriction, the GH-IGF-I-axis induces renal vasodilatation.
Since the early stages of diabetic renal involvement are characterised by an imbalance in
glomerular vasodilation and vasoconstriction, the possible role of these humoral systems
in diabetic nephropathy (DN) is discussed. The role of 11$-hydroxysteroid dehydrogena-
se (11$-HSD) in protecting the mineralocorticoid receptor from activation by cortisol is
briefly recapitulated in the context of abnormalities in sodium and volume homeostasis in
IDDM.
Effects of NE on renal protein handling and renal haemodynamics. 
In chapter 2, the relationships between plasma NE and the rise in albuminuria after
a fixed exercise test is evaluated in normo-and microalbuminuric IDDM patients and
healthy subjects. Physical exercise provides a strong sympathetic stimulus and can lead to
an increase in urinary albumin excretion. NE is both a neurotransmitter and a hormonally
active substance spilled over from the sympathetic nervous system. Plasma NE levels
may influence renal function by vasoconstriction mediated via "-adrenoceptors, which
have been located along glomerular arterioles. The albuminuric response after exercise is
thought to result from an enhanced glomerular passage of macromolecules in
conjunction with  rises in systemic blood pressure and alterations in renal
haemodynamics.
Moderate strenuous exercise was found to induce an exaggerated rise in
albuminuria in both IDDM groups, in keeping with earlier reports. Blood pressure rose
to higher levels in the microalbuminuric IDDM patients. The rise in plasma NE levels
was significantly greater in normo- and microalbuminuric IDDM patients than in
healthy subjects. Multiple regression analyses revealed that both elevations in blood
pressure and stimulated plasma NE levels independently contributed to the albuminuric
response. 
Exercise and exogenous NE induce comparable renal haemodynamic changes in
humans. Both are associated with a decrease in effective renal plasma flow (ERPF)
without much change in glomerular filtration rate (GFR). Consequently, filtration
fraction rises which suggests a change in pressure profile along glomerular vessels, in
favour of an increase in intraglomerular pressure. Indeed, in experimental studies NE
increases intraglomerular pressure. Thus, the relationship between changes in plasma
NE concentrations and changes in albuminuria during exercise support the hypothesisChapter 12 150
that NE is involved in the albuminuric response by a renal haemodynamic mechanism,
like a rise intraglomerular pressure. The observations also suggest that an enhanced
catecholamine response may contribute to an exaggerated rise in albuminuria in micro-
albuminuric IDDM patients. From these experiments no conclusion can be drawn wheth-
er an altered renal vascular responsiveness to NE in IDDM is involved in this
phenomenon. 
In chapter 3, the possible relationships between circulatory NE levels and renal
haemodynamic parameters are investigated in normo- and microalbuminuric IDDM
patients and in healthy subjects. Both GFR and ERPF were higher in IDDM patients
compared to healthy subjects. GFR and ERPF were found to be inversely correlated with
venous plasma NE levels. No differences were observed in the relationships between
plasma NE and ERPF between the IDDM and healthy subjects. The slightly lower plasma
NE levels in the IDDM patients could thus contribute to the elevations in ERPF. GFR
was negatively related to plasma NE and positively with the presence of IDDM. This sup-
ports the notion that concomitant vasodilating mechanisms play a role in the elevations of
GFR in IDDM patients. These results suggest that circulatory NE is a determinant of
renal haemodynamics both in IDDM patients and healthy subjects.
In chapter 4, a randomized, placebo controlled NE infusion experiment is under-
taken in matched groups of normo- and microalbuminuric IDDM patients and healthy
subjects. Microproteinuria, renal and systemic haemodynamic responses were measured
during stepwise exogenous NE infusions at individually determined NE threshold, 20%
pressor and pressor doses. The study addressed the following questions. First, does -
exogenous NE induce a microproteinuric response? Second, is there a difference in
microproteinuric response in normo- and microalbuminuric IDDM patients and healthy
subjects? Third, what are the determinants of such a microproteinuric response? Fourth,
are there differences in renal haemodynamic NE- responsiveness between these groups?
Exogenous NE was found to increase microproteinuria in conjunction with a rise in
systemic blood pressure and renal vasoconstriction in all groups. NE increased urinary
albumin and IgG excretion, but no effect was seen on urinary $2-microglobulin
excretion. This indicates that NE increases glomerular protein leakage. Furthermore, the
absolute microproteinuric response was more pronounced in microalbuminuric IDDM pa-
tients than in normoalbuminuric IDDM patients and healthy subjects. Multiple regression
analysis showed that the increase in microproteinuria was not only related to the rise in
systemic blood pressure induced by the NE infusions, but also to the increase in plasma
NE level itself. The renal haemodynamic NE responsiveness (i.e. a fall in ERPF and rise
in filtration fraction) was similar in the groups.
This study is the first to demonstrate that a vasopressor agent causes an increase in
microproteinuria. These results disagree with previous studies using angiotensin II. Our
findings support the hypothesis that an intrarenal mechanism contributes to the NE-
induced increase in microproteinuria, and demonstrate that a low dose of NE causes
glomerular vasoconstriction. This is in accord with the role of circulatory NE in the
albuminuric response following exercise, and with the relationship of plasma NE with
renal haemodynamics as outlined  in the preceding chapters. The enhanced micro-
proteinuric response in microalbuminuric IDDM is likely to be the result of a glomerularSummary and conclusions 151
permselectivity defect. Plasma NE rises during strenuous daily life activities and this may
contribute to the perpetuation of microproteinuria. Proteinuria itself is a determinant of
future loss of renal function, although it is still unknown if this also holds true for the
microalbuminuric phase of diabetic renal disease. It can, therefore, be argued that
protection against the renal NE effects may be of clinical benefit.
In chapter 5, the possibility that treatment with the ACE-inhibitor, enalapril,
attenuates systemic and renal haemodynamic NE responsiveness in microalbuminuric
IDDM is investigated. Such an effect would be of particular relevance in micro-
albuminuric IDDM patients, since systemic NE responsiveness has been found to be
exaggerated, and strict blood pressure control has been shown to prevent or delay pro-
gression of albuminuria in these patients. 
Enalapril was found to lower systemic blood pressure and overnight urinary
albumin excretion, and to increase ERPF. The blood pressure lowering effect of enalapril
disappeared with NE pressor infusion. The overall mean increase in blood pressure in
response to NE was even higher with than without enalapril. ERPF remained elevated
during NE infusion with enalapril treatment, and the NE-induced fall in ERPF was
unaltered by enalapril. Urinary albumin excretion was similar during the NE infusions
before and after enalapril treatment. These results are in keeping with earlier reports in
patients with non insulin-dependent diabetes mellitus, but contrast with findings in
patients with essential hypertension. The lack of effect of ACE inhibition treatment on
the systemic and renal effects of NE may have clinical implications for the
design of renoprotective strategies in IDDM patients.
In chapter 6, the possibility that low dose dopamine infusion counteracts NE-
induced renal vasoconstriction is investigated. Although low dose dopamine is widely
used to attenuate the decrease in renal haemodynamics during NE infusion therapy, this
effect has not been proven in humans. Dopamine (4 µg/kg per min) was added to
incremental doses of NE in normotensive healthy subjects. This dose of dopamine was
shown to prevent the fall in ERPF during NE infusion. Dopamine also attenuated the rise
in blood pressure, enlarged pulse pressure, blunted the fall in heart rate, and induced a
large natriuretic response. Thus, dopamine is indeed able to oppose NE-induced renal
vasoconstriction. They also indicate that dopamine influences systemic haemodynamics
during NE infusion. Further studies are warranted to confirm these findings in critically
ill patients, and to establish whether low dose dopamine infusion is able to improve their
clinical outcome. The latter is of particular relevance since a recent study reported
disappointing effects of low dose dopamine on prevention of renal failure in this patient
category.
Renal effect of the GH-IGF-I-system 
In chapter 7, it is investigated whether abnormal GH and IGF-I levels influence
urinary albumin excretion. GH deficient patients, patients with (un)treated acromegaly
and healthy subjects were compared. Urinary albumin excretion rate was shown to be
elevated in acromegalic patients and tended to be reduced in GH deficient patients as
compared to healthy subjects. Moreover, GH and IGF-1 lowering by treatment with theChapter 12 152
somatostatin analogue, octreotide, reduced albuminuria in the acromegalic patients. The
level of albuminuria was positively correlated with the GH and IGF-I level. These
findings support the notion that the GH-IGF-I system is involved in urinary protein
excretion. Since renal insufficiency is uncommon in acromegaly, it is unlikely that GH
and IGF-I elevations alone predispose to clinically important glomerular damage.
In chapter 8, baseline and amino acid-stimulated GFR and ERPF are compared in
GH deficient, acromegalic and normo- and hyperfiltering IDDM patients as well as in
healthy subjects. Moreover, the possible relationship between plasma IGF-I levels and
renal haemodynamics were evaluated across these groups.
Baseline GFR and ERPF were shown to covary with GH status: the lowest values
were found in the GH deficient patients followed by higher levels in the healthy subjects,
treated and untreated acromegalic patients. The amino acid-induced increase in GFR and
ERPF was enhanced in the GH deficient patients and was abolished in the acromegalic
and hyperfiltering IDDM patients. Taken all groups together, an inverse relationship was
found between baseline GFR and ERPF and the amino acid-induced increment in GFR
and ERPF. This indicates the renal reserve filtration capacity is exhausted in glomerular
hyperfiltration, and suggest that hyperfiltering IDDM and acromegalic patients share
comparable renal haemodynamic abnormalities.
The plasma level of IGF-I was a determinant of GFR and ERPF across the GH
deficient, acromegalic and healthy subjects, but not in the IDDM groups. The latter does
not exclude a role of abnormalities in the GH-IGF-I system in glomerular hyperfiltration
associated with IDDM. Enhanced glomerular IGF-I accumulation due to increased IGF-I
receptor expression, alterations in local production of IGF-binding proteins and in IGF-
binding protein 3 protease activity, could affect renal haemodynamics in IDDM.
Obviously, IGF-I infusion experiments are required to evaluate whether renal
haemodynamic sensitivity to IGF-I is enhanced in IDDM. The very limited availability
to clinical use of IGF-I currently does not enable us to carry out such experiments.
In chapter 9, an exercise test is used to stimulate GH physiologically in IDDM
patients with a normal and elevated GFR. GFR and ERPF were measured under stand-
ardised conditions, and IDDM patients with glomerular hyperfiltration (GFR>130 ml/min
per 1.73m ) were individually matched with IDDM patients with a normal GFR (90 to
2
130 ml/min per 1.73m ). Kidney size was measured by ultrasonography. The circulatory
2
levels of glucagon and GH were determined on a separate day in the fasting state and
after exercise. 
The mean levels of these hormones were not significantly different in the hyper-
and normofiltering IDDM patients. However, multiple regression analysis showed that
exercise-stimulated GH levels, circulatory plasma glucagon as well as HbA1c were
significantly related to renal haemodynamic parameters and kidney size. These findings
support the hypothesis that stimulated levels of GH and circulating glucagon contribute to
glomerular hyperfiltration in IDDM. In contrast, previous studies showed that diurnal GH
and glucagon profiles were not different in normo- and hyperfiltering IDDM patients.
These discrepancies may due to the lack of use of stimulated GH levels in those studies,
and to the definition of glomerular hyperfiltration. Summary and conclusions 153
From the studies described in the chapters 7,8 and 9, we conclude that the GH-IGF-
I system plays a role in renal haemodynamics and in glomerular protein handling in
various disease states in humans, including GH deficiency and GH excess, as well as in
IDDM. From a therapeutic point of view, it will be of interest to determine whether
somatostatin analogues prevent progression of albuminuria and loss of renal function in
IDDM patients. Such intervention could have a place as an adjunct to or as an alternative
for blood pressure lowering therapy. The availability to clinical use of long acting
somatostatin analogues will facilitate the evaluation of such treatment.
Urinary IgG excretion in normoalbuminuric IDDM 
Chapter 10 describes the artefacts that can be encountered when urinary IgG is
measured at low concentrations. It has been reported that urinary IgG excretion is in-
creased in normoalbuminuric IDDM patients, but this phenomenon in not well under-
stood. In normo- and microalbuminuric IDDM patients and healthy subjects, urinary IgG
was measured in samples that were kept frozen for 2 to 4 weeks. Urinary IgG excretion
was higher both in normo- and microalbuminuric IDDM patients compared to healthy
subjects. Furthermore in IDDM patients, the IgG clearance divided by the albumin clear-
ance was found to be higher in urine collections that contained glucose as compared to
samples without glucose. This raised the possibility that glucose influences urinary IgG
concentration, possibly by a preserving effect of glucose during storage. 
In a laboratory experiment, the effects various storage procedures were evaluated in
urine samples with different amounts of protein. Urinary IgG declined when samples
were frozen for several weeks without precautions. The best results were obtained when
urine was stored frozen with addition of bovine serum albumin, phosphate buffer and
high concentrations of glucose. These results indicate that glucose in urinary specimens
of IDDM patients can in fact prevent the decrease in IgG, and may thus explain the
apparently higher urinary IgG excretion in normoalbuminuric IDDM patients when
unprocessed urine is stored frozen before assay. This study indicates that precautions
should be taken when urinary IgG cannot be measured immediately.
Sodium and volume homeostasis in IDDM and the role of 11$-HSD
In chapter 11, urinary cortisol and cortisone metabolites are evaluated in normo-
and microalbuminuric IDDM patients and in healthy subjects. The primary objective was
to establish whether possible abnormalities in cortisol metabolism as a consequence of an
altered 11$-HSD enzyme activity, are involved in the abnormal sodium and fluid
retention in IDDM patients. 11$-HDS catalyses the interconversion of cortisol and its
inactive metabolite, cortisone, and thereby protects the mineralocorticoid receptor from
being activated by cortisol. A change in the so-called cortisol-cortisone shuttle towards
cortisol could lead to sodium retention and volume expansion in IDDM. Alternatively, a
change towards cortisone could attenuate sodium retention. 
Lower urinary excretion rates of cortisol and cortisone metabolites were found in
normo- and microalbuminuric IDDM patients suggesting that the diabetic state influ-
ences cortisol metabolism via an impaired reduction of glucocorticoids. Furthermore,
the urinary cortisol to cortisone metabolite ratio was lower in IDDM. This indicatesChapter 12 154
that the set-point of overall direction of the 11ß-HSD catalysed cortisol to cortisone
inter-conversion is shifted towards cortisone. In the IDDM patients, the urinary cortisol
to cortisone metabolite ratio was inversely related to the HbA1c level. A positive
relation between the urinary cortisol to cortisone metabolite ratio and initial blood
volume, as a measure of whole body extravascular and blood volume, was found both
in healthy subjects and in IDDM patients. Interestingly, the regression line was between
these parameters was shifted leftwards in the IDDM patients. This indeed suggests that
the cortisol to cortisone ratio is a determinant of volume homeostasis, but essentially
excludes the possibility that the an abnormal 11ß-HSD activity is primarily responsible
for an abnormal fluid and sodium retention in IDDM. Finally in microalbuminuric
IDDM patients, ACE-inhibition treatment was shown to induce a modest further lower-
ing of the cortisol to cortisone metabolite ratio. 
These results raise the possibility that altered cofactor availability as consequence
of chronic hyperglycaemia influences glucocorticoid reduction and 11$-HSD activity in
humans. Improved metabolic control could induce a backward shift of the cortisol-
cortisone shuttle towards cortisol in IDDM patients, which would accentuate volume
and sodium homeostasis. Moreover, this study suggests that stimulation of 11$-HDS
activity may be an additional mechanism whereby ACE inhibitors promote saliuresis.SAMENVATTING 
Inleiding. 
In hoofdstuk 1 worden het voorkomen, de stadia, de theorieën over het ontstaan en de
behandelingsmethoden van diabetische nierziekte (nefropathie) besproken. Naar schatting
treedt nefropathie op bij 30% van de patiënten met van insuline-afhankelijke diabetische
mellitus (IADM). Diabetische nefropathie wordt gekenmerkt door een verhoogde eiwi-
tuitscheiding in de urine (proteïnurie) van meer dan 0.5 gram per dag  en een geleidelijk
verlies van nierfunctie. Nefropathie is een ernstige complicatie van diabetes mellitus,
omdat naar verloop van tijd terminaal nierfunctieverlies kan optreden, zodat nierfunctie
vervangende behandeling met dialyse of transplantatie noodzakelijk wordt. Daarnaast is
gebleken dat IADM patiënten met proteïnurie een sterk verhoogd risico hebben op hart-
en vaatziekten. Verbeterde behandelingsmethoden kunnen het beloop van de nefropathie
gunstig beïnvloeden. Met name agressieve bloeddrukverlaging vermindert de snelheid
van het nierfunctieverlies en heeft naar alle waarschijnlijkheid de vermindering van het
overlijden ten gevolge van hart- en vaatziekten tot gevolg.
Het identificeren van patiënten met een verhoogde kans op het ontwikkelen van een
diabetische nefropathie is mogelijk gemaakt door de introductie van gevoelige
laboratoriummethoden waarmee lage concentraties van eiwit, albumine, in de urine
gemeten kunnen worden. Onder normale omstandigheden passeert een kleine hoeveelheid
albumine het glomerulaire filter in de nieren. De glomerulus is de kleinste functionele
eenheid van de nier. Hier wordt de urine gevormd uit het bloed dat onder druk gefilterd
wordt over een poreuze membraan, de glomerulaire basaal membraan. De glomerulaire
basaal membraan vormt een effectieve barrière tegen verlies van grote eiwitten, zoals
albumine. Gebleken is dat  bij IADM patiënten een geringe verhoging van de albumine
uitscheiding in de urine (microalbuminurie) van prognostische betekenis is voor het later
ontwikkelen van nefropathie. Deze verhoogde doorlaatbaarheid van albumine kan wijzen
op vroege veranderingen in het filtratie proces ten gevolge van een hogere filtratie druk
in de glomeruli en veranderingen in de glomerulaire basaal membraan.
Het ontstaan van diabetische nefropathie is waarschijnlijk multifactorieel bepaald.
Men veronderstelt dat veranderingen in de bloedsomloop door het lichaam en de nieren
(haemodynamische factoren) en veranderingen in de stofwisseling (metabole factoren) bij
IADM patiënten bijdragen aan het ontstaan van diabetische nefropathie. Immers, zowel
hoge bloeddruk als onvoldoende diabetes regulatie zijn risicofactoren voor het ontstaan
van deze complicatie. Daarnaast spelen erfelijke factoren een rol bij de predispositie voor
diabetische nefropathie.
Het is thans nog niet mogelijk om het ontwikkelen van diabetische nefropathie te
voorkomen. Onderzoek naar factoren, die een rol spelen bij het ontstaan van diabetische
nefropathie, is van belang om de behandelingsmogelijkheden te kunnen optimaliseren. In
dit proefschrift is getracht meer inzicht te krijgen in de werking van noradrenaline (NA)
en de groeihormoon (GH)-insulin-like growth factor-I (IGF-I)-as  op de nieren. NA is
een niervaatvernauwende stof (renale vasoconstrictor) die de doorstroming in de nier
vermindert en de filtratiedruk kan verhogen. GH veroorzaakt indirect niervaatverwijding
(renale vasodilatatie) door stimulatie van IGF-I synthese. De vroege veranderingen in de
nierfunctie bij IADM patiënten worden gekenmerkt door een dysbalans tussen vasodilatie156
van de vaten die de glomerulus van bloed voorzien (preglomerulaire arteriolen) en
vasoconstrictie van de vaten die het bloed afvoeren (postglomerulaire arteriolen). Deze
veranderingen leiden waarschijnlijk tot een toegenomen filtratiedruk. Een apart hoofdstuk
is gewijd aan methoden om urine ingevroren te bewaren alvorens kleine hoeveelheden
eiwit, in casu immunoglobuline-G, te bepalen. In een ander hoofdstuk wordt de rol van
de balans tussen de hormonen, cortisol en cortison, bij zoutretentie en volume expansie
bij IADM patiënten belicht.
Effecten van noradrenaline op de nierdoorbloeding en het eiwit verlies in de urine.
NA is de neurotransmitter van het sympathische zenuwstelsel, die vrijkomt uit de
zenuwvezels. NA lekt voor een deel naar de circulatie. Dit circulerende NA is als vaso-
actieve stof werkzaam. NA veroorzaakt vasoconstrictie na binding aan zogenaamde "-
adrenerge receptoren . In de nieren zijn "-adrenerge receptoren gelokaliseerd in de vaten
van de glomerulaire arteriolen. Deze bepalen in belangrijke mate de nierdoorstroming en
reguleren de filtratiedruk. Fysieke inspanning stimuleert het sympathische zenuwstelsel
en kan een stijging van de albuminurie veroorzaken. Deze toename van albuminurie na
fysieke inspanning wordt toegeschreven aan een verhoogde glomerulaire passage voor
grote moleculen, in combinatie met een stijging van de systemische bloeddruk en glome-
rulaire filtratiedruk.
In hoofstuk 2 is onderzocht of een stijging van de plasma NA spiegel bijdraagt aan een
toename van het eiwitverlies in de urine tijdens een gestandaardiseerde fietstest. Bestu-
deerd werden IADM patiënten met normo- en microalbuminurie (normale en licht ver-
hoogde albumine excretie in de urine) en controle personen. Fysieke inspanning indu-
ceerde een duidelijke en meer uitgesproken toename van de albuminurie bij de microal-
buminurische IADM patiënten dan de controle personen. In de micro-albuminurische
IADM patiënten werden hogere bloeddrukken bereikt. In beide IADM groepen steeg de
plasma NA spiegel tot hogere waarden dan bij de controle personen. Zowel de stijging in
de bloeddruk als de toename van de NA spiegels correleerden met de toename van albu-
minurie. Deze bevinding suggereert dat NA via een renaal haemo-dynamisch mechanis-
me bijdraagt aan de stijging van albuminurie als gevolg van inspanning. De hogere NA
spiegels bij de IADM patiënten zouden op deze wijze de versterkte albuminurische
respons in IADM patiënten kunnen verklaren. Dit wordt gesteund door eerder onderzoek
waaruit bleek dat NA infusie en fysieke inspanning een gelijkwaardige daling van de nier
doorstroming veroorzaken. Een dergelijke daling kan gepaard gaan met een hogere
glomerulaire filtratiedruk en kan leiden tot een stijging van albuminurie. Een NA infusie
experiment zou deze hypothese kunnen bevestigen.
In hoofdstuk 3 werd de mogelijke relatie tussen het in het bloed aanwezig NA en
renale haemodynamische parameters, zoals de klaring (glomerulaire filtratie rate: GFR)
en de nierdoorbloeding (effectieve renale plasma flow: ERPF), geëvalueerd in normo- en
microalbuminurische IADM patiënten en controle personen. De GFR en de ERPF werden
bepaald met standaard infusie methoden. De in rust afgenomen plasma NA spiegel was
iets lager bij de IADM patiënten dan bij de controle personen. De IADM patiënten
hadden een hogere GFR en ERPF dan de controle personen, wijzend op glomerulaire
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plasma NA spiegel. Tussen de IADM en de controle personen bleek geen verschil in deze
relatie te bestaan. Dus de lagere plasma NA spiegels zouden kunnen bijdragen aan een
verhoogde ERPF bij IADM patiënten. De GFR was eveneens negatief gecorreleerd met
de plasma NA concentratie. Bovendien bleek dat IADM patiënten een hogere GFR
hadden, onafhankelijk van de plasma NA spiegel. Dit impliceert dat additionele vasodila-
terende mechanismen, naast de invloed van een lagere NA spiegel, een rol spelen bij de
verhoogde GFR bij IADM patiënten. 
Hoofdstuk 4 geeft de resultaten weer van een gerandomiseerde, placebo gecontroleerde
NA infusie studie bij gematchte normo- en microalbuminurische IADM patiënten en niet-
diabetische controle personen. Dit onderzoek werd uitgevoerd om de volgende vragen te
beantwoorden. Ten eerste, kan NA toediening een toename van de eiwituitscheiding in de
urine (microproteïnurie) induceren bij de mens? Ten tweede, zijn er verschillen in een
door NA-geïnduceerde microproteïnurische respons tussen normo- en microalbuminuri-
sche IADM patiënten en controle personen? Ten derde, wat zijn de determinanten van
een door NA-geïnduceerde toename van microproteïnurie? Ten vierde, bestaan er ver-
schillen in de renale haemodynamiek tijdens NA infusie tussen de onderzochte groepen?
In dit onderzoek werden de microproteïnurie (uitscheiding van albumine en
immunoglobuline-G), de systemische en de renale haemodynamiek gemeten tijdens 3
opeenvolgende NA infusie doses, die respectievelijk een bloeddrukstijging van 0, 4 en 20
mmHg veroorzaakten. De NA infusie dosis werd per deelnemer van te voren bepaald. 
De systemische bloeddruk gevoeligheid voor NA was toegenomen bij beide groepen
IADM patiënten, zoals eerder is gerapporteerd voor heterogene groepen diabetes
patiënten. NA, gegeven in een dosis die de bloeddruk met 20 mmHg deed stijgen, veroor-
zaakte een toename van de microproteïnurie in combinatie met renale vasoconstrictie in
alle onderzochte groepen. NA verhoogde zowel de uitscheiding van albumine als
immunoglobuline-G, maar niet van $2-microglobuline. Dit impliceert dat NA de glome-
rulaire passage van eiwitten doet toenemen. In absolute zin was de toename van de mi-
croproteïnurie groter in de microalbuminurische IADM patiënten ten opzichte van de
normoalbuminurische IADM patiënten en controle personen. Multipele regressie analyse
toonde aan dat de stijging van de bloeddruk en de toename van de plasma NA spiegels
onafhankelijk bijdroegen aan de door NA geïnduceerde toename van microproteïnurie.
NA veroorzaakte een uitgesproken daling van de ERPF en stijging van de filtratie fractie
(het quotiënt van GFR en ERPF), maar had geen effect op de GFR. De relatie tussen de
plasma NA spiegel en de veranderingen in renale haemodynamiek verschilden niet tussen
de onderzochte groepen.
Bovengenoemde studie is het eerste acute infusie experiment dat een toename van
microproteïnurie als reactie op de vasopressor, NA,  aantoont. In eerdere, niet met place-
bo gecontroleerde, studies met de vasopressor, angiotensine II, werd een dergelijk effect
op de microproteïnurie niet gevonden. Onze resultaten geven steun aan de hypothese dat
NA via een renaal mechanisme de glomerulaire eiwitlekkage in de nieren doet toenemen.
Dit is in overeenstemming met de in de voorgaande hoofdstukken  veronderstelde rol van
circulerende plasma NA op de toename van albuminurie bij fysieke inspanning, en de
beschreven relatie met renaal haemodynamische parameters. De versterkte
microproteïnurische respons bij de microalbuminurische IADM patiënten  is
waarschijnlijk het gevolg van een preëxistent permeabiliteitsdefect van de glomerulaire158
basaal membraan. Plasma NA spiegels stijgen tijdens dagelijkse inspanningen en zouden
aldus kunnen bijdragen aan eiwitlekkage. De aanwezigheid van proteïnurie wordt als een
ongunstige indicator beschouwd voor toekomstig nierfunctieverlies, alhoewel het niet
zeker is of dit ook geldt voor de microalbuminurische fase  van diabetische nefropathie.
Desalniettemin zou bescherming van de nier tegen renale NA effecten van klinische
belang kunnen zijn bij microalbuminurische IADM patiënten. 
In hoofdstuk 5 is onderzocht of behandeling met een angiotensine-converting enzyme
(ACE) remmer de NA-geïnduceerde stijging van de bloeddruk en renale vasoconstrictie
beïnvloed bij IADM patiënten met microalbuminurie. Bij patiënten met essentiële hyper-
tensie is gebleken dat ACE-remmers inderdaad de door NA-geïnduceerde stijging van de
bloeddruk verminderen, hetgeen als een additioneel werkingmechanisme van deze medi-
camenten kan worden gezien. Een studie bij gezonde vrijwilligers heeft bovendien
aangetoond dat dit ook geldt voor de door NA-geïnduceerde ERPF daling. Zeven micro-
albuminurische IADM patiënten werden voor en 6 weken na behandeling met de ACE-
remmer, enalapril, onderzocht. Conform de verwachting trad er tijdens enalapril behande-
ling een daling op van de bloeddruk en de albuminurie, en bleek de ERPF te zijn toege-
nomen. De bloeddrukstijging onder invloed van NA was echter meer uitgesproken tijdens
enalapril behandeling. De ERPF daling en de albuminurie tijdens NA infusie werd niet
door enalapril beïnvloed. Deze bevindingen suggereren dat enalapril onvoldoende be-
scherming biedt tegen systemische en renale NA effecten. 
In hoofdstuk 6 is onderzocht in hoeverre intraveneus toegediend dopamine in staat is
het renale vasoconstrictieve effect van NA infusie te antagoneren. Dopamine wordt veel
toegepast om bij haemodynamisch instabiele patiënten de nierfunctie te ondersteunen
tijdens NA behandeling. Bij 7 gezonde vrijwilligers werd in gerandomiseerde volgorde
dopamine en placebo toegevoegd aan 3 verschillende NA infusie doses. Dopamine bleek
de door NA-geïnduceerde ERPF daling zeer effectief te antagoneren. Er was een minder
uitgesproken bloeddruk stijging en een sterke toename van de zout uitscheiding na toe-
voeging van dopamine aan de NA infusen. Deze studie bevestigt de veronderstelling dat
lage dosis dopamine bij de mens de vasoconstrictieve effecten van NA in de nier tegeng-
aat. Of dit ook geldt voor instabiele patiënten zal nader onderzocht moeten worden. De
verminderde door NA-geïnduceerde bloeddrukstijging en de toegenomen zoutexcretie
onder invloed van dopamine kunnen bij haemodynamisch instabiele patiënten echter
minder gewenst zijn.
Effecten van groeihormoon en insulin-like growth factor-I op de nier.
De GH-IGF-I-as wordt bij de mens beschouwd als een determinant van de nierfunctie.
Exogeen toegediend GH en IGF-I stimuleren zowel de GFR als de ERPF. Het effect van
de GH-IGF-I-as op microproteïnurie is niet goed bekend. In hoofdstuk 7 is onderzocht of
de albumine uitscheidingssnelheid in de urine gerelateerd is aan GH en IGF-I spiegels in
het bloed. In deze studie werden patiënten met GH deficiëntie, patiënten met
(on)behandelde acromegalie ten gevolge van een GH producerend hypofyse adenoom en
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bij de patiënten met acromegalie en was iets lager bij de patiënten met GH deficiëntie ten
opzichte van de controle personen. Bij de acromegalie
patiënten resulteerde medicamenteuze verlaging van de GH en IGF-I spiegels met octreo-
tide in een daling van de albumine uitscheidingssnelheid. Er bestond een positieve relatie
tussen de GH en IGF-I spiegels en de albumine uitscheidingssnelheid, onafhankelijk van
de kreatinine klaring. Deze bevindingen bevestigen dier experimentele studies dat ver-
hoogde GH en IGF-I spiegels microproteïnurie kunnen induceren, en zijn in overstem-
ming met de toename van albuminurie na IGF-I infusie bij gezonde vrijwilligers.
In hoofdstuk 8 werden de parameters voor de nierfunctie (GFR en ERPF) basaal en na
stimulatie door middel van aminozuren infusie gemeten. Vergeleken werden GH defici-
ente patiënten, (on)behandelde acromegalie patiënten, IADM patiënten met een normale
en een verhoogde GFR (normo- versus hyperfiltratie) en gezonde controle personen. Ook
werden de IGF-I spiegels in relatie tot de gemeten nierfunctieparameters vergeleken. 
De basale GFR en ERPF waarden correspondeerden met de mate van GH secretie: de
laagste GFR en ERPF waarden werden gevonden bij de GH deficiënte patiënten, gevolgd
door een hogere GFR en ERPF bij de controle personen, behandelde en onbehandelde
acromegalie patiënten. Er bleek in alle groepen een inverse relatie te bestaan tussen de
hoogte van de basale GFR en ERPF en de toename van GFR en ERPF na stimulatie met
aminozuren infusie. De GFR en ERPF waren bij de acromegalie en hyperfiltrerende
IADM patiënten niet meer stimuleerbaar. De GFR en ERPF correleerden met de plasma
IGF-I spiegel bij de GH deficiënte patiënten, (on)behandelde acromegalie patiënten en de
controle personen, maar niet bij de IADM patiënten. 
Een verhoogde GFR (glomerulaire hyperfiltratie) is een fenomeen dat bij IADM en
acromegalie wordt gevonden. Bij patiënten met acromegalie is deze het gevolg van de
hoge GH en IGF-I spiegels, maar de rol van de GH-IGF-I-as bij diabetische glomerulaire
hyperfiltratie is niet duidelijk. De afwezige GFR en ERPF respons na aminozuren infusie
suggereert dat de renale reserve capaciteit bij glomerulaire hyperfiltratie maximaal benut
is. Deze opmerkelijke overeenkomst tussen de acromegalie en hyperfiltrerende IADM
patiënten werd echter niet weerspiegeld in een verhoogde plasma IGF-I concentratie bij
de hyperfiltrerende IADM patiënten. Bij diabetische ratten is accumulatie van IGF-I in de
nier aangetoond. Men veronderstelt dat toegenomen renale IGF-I receptor activiteit en
verandering in lokale productie van IGF-I bindende eiwitten hieraan ten grondslag liggen.
Op een dergelijke wijze zou de GH-IGF-I-as een rol kunnen spelen bij glomerulaire
hyperfiltratie bij IADM patiënten, ondanks het feit dat de plasma IGF-I spiegel niet
verhoogd is. Deze veronderstelling zou bij IADM patiënten met een IGF-I infusie experi-
ment onderzocht kunnen worden. De beperkte beschikbaarheid van IGF-I maakt een
dergelijke studie momenteel niet mogelijk.
In hoofdstuk 9 werden de door inspanning gestimuleerde GH en glucagon spiegels
geëvalueerd in IADM patiënten met normale en verhoogde GFR. Glucagon heeft evenals
GH een vasodilaterende werking op de nier. Glucagon spiegels zijn dikwijls verhoogd bij
IADM patiënten. Onderzocht werd of deze hormonen zouden kunnen bijdragen aan de
verhoging van GFR, ERPF en niergrootte bij IADM patiënten. Door middel van gestand-
aardiseerde GFR en ERPF metingen werden IADM patiënten met glomerulaire hyperfil-
tratie geselecteerd. Deze werden individueel gematcht met normo-filtrerende IADM160
patiënten.
De gemiddelde concentratie van deze hormonen was niet significant verschillend
tussen de normo- en hyperfiltrerende IADM patiënten. Echter, multipele regressie analy-
se toonde dat de door inspanning gestimuleerde GH spiegel, de glucagon concentratie en
het HbA1c gehalte als maat voor diabetes regulatie, positief correleerden met de GFR,
ERPF en niergrootte.
Een eerdere studie toonde geen verschillen aan in dag profielen van deze hormonen bij
normo- en hyperfiltrerende IADM patiënten. Overeenkomstig onze studie is ook gevon-
den dat de GH afgifte na GH-releasing hormoon toediening verhoogd is bij hyperfiltre-
rende ten opzichte van normofiltrerende IADM patiënten. Deze bevindingen suggereren
dat GH en glucagon een rol kunnen spelen bij glomerulaire hyperfiltratie in IADM
patiënten. 
Uit de hoofdstukken 7, 8 en 9 wordt geconcludeerd dat de GH-IGF-I-as de renale
haemodynamiek en proteïnurie beïnvloedt bij diverse patiënten categorieën, waaronder
GH deficiëntie, acromegalie en IADM. Vanuit een therapeutisch  perspectief, bestaat de
vraag of somatostatine analogen de progressie van albuminurie en nierfunctieverlies bij
IADM patiënten zouden kunnen tegengaan. Een dergelijke interventie met GH en IGF-I
concentratie verlagende middelen zou mogelijk een waardevolle aanvulling kunnen zijn
op bloeddruk verlagende behandeling. Met het beschikbaar komen van langwerkende
somatostatine analogen zal dit binnen afzienbare tijd onderzocht kunnen worden.
Het effect van glucose op de immunoglobuline-G concentratie in de urine.
Het immunoglobuline-G is een groter eiwit dan albumine. Het meten van de
immunoglobuline-G uitscheidingsnelheid in de urine verschaft informatie over de veran-
deringen in de poriën grootte van het glomerulaire basaal membraan. Bij normoalbumi-
nurische IADM patiënten is gerapporteerd dat ook immunoglobuline-G  in ver-hoogde
mate wordt uitgescheiden. Deze bevinding is onbegrepen omdat de poriën-grootte van de
glomerulaire basaal membraan bij deze patiënten geacht wordt onveranderd te zijn.
In hoofdstuk 10 vonden ook wij dat normoalbuminurische IADM patiënten een ver-
hoogde mate van immunoglobuline-G excretie in de urine hadden ten opzichte van
controle personen. Tevens bleek de immunoglobuline-G uitscheiding hoger te zijn in
urine verzamelingen van IADM patiënten die glucose bevatten dan in die van patiënten
zonder glucosurie. Aangezien het immunoglobuline-G gehalte in de urine kan
verminderen bij het bewaren van de monsters bij -20 C gedurende enkele weken, veron-
0
derstelden wij dat de aanwezigheid van glucose mogelijk een conserverend effect op het
immunoglobuline-G had. In een laboratorium experiment werd deze hypothese getoetst.
Getest werden diverse bewaarregimes op de houdbaarheid van immuno-globuline-G in
urine monsters van niet-diabetes patiënten met een verschillende mate van proteïnurie. De
immunoglobuline-G concentratie daalde in de monsters die onbehandeld bij -20 C waren
0
ingevroren. Daarentegen bleek een voorbehandeling met fosfaatbuffer, koeienalbumine
en glucose te beschermen tegen het verlies van immuno-globuline-G. Het minste verlies
na 12 weken invriezen bij -20 C werd gevonden bij die urine monsters, waaraan een hoge
0
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van glucose in de urine van IADM patiënten preserverend werkt op het urine
immunoglobuline-G gehalte, wanneer urine verzamelingen zonder voorzorgsmaatregelen
worden bewaard bij -20 C. Een dergelijk effect leidt tot de een schijnbare verhoging van
0
de immunoglobuline-G uitscheiding bij normoalbuminurische IADM patiënten ten
opzichte van niet diabetische personen. Er dienen dus voorzorgsmaatregelen getroffen te
worden wanneer de urine immunoglobuline-G bepaling niet onmiddellijk kan worden
uitgevoerd.
De rol van 11$ $-hydroxysteroid dehydrogenase bij de water- en zouthuishouding bij
IADM patiënten.
In hoofdstuk 11 is onderzocht of veranderingen in het metabolisme van
glucocorticoïden, met name van de activiteit van het enzym 11$-hydroxysteroid
dehydrogenase (11$-HSD), een rol spelen in de toegenomen water en zout retentie bij
IADM patiënten. Hiertoe werden de metabole afbraakproducten van cortisol en cortison
in de urine gemeten bij normo- en microalbuminurische IADM patiënten en controle
personen. De verhouding in de metaboliet uitscheiding werd als maat gebruikt voor de
11$-HSD enzym activiteit. Dit enzym catalyseert de inter conversie tussen cortisol en het
metabool inactieve, cortison, en beschermt de mineralocorticoïde receptor tegen active-
ring door cortisol. Een verschuiving in het cortisol-cortison evenwicht richting cortisol
zou bij IADM patiënten kunnen bijdragen aan de toegenomen zoutretentie en volumebel-
asting. Omgekeerd zou een verandering in de richting van cortison hiertegen beschermen.
Bij normo- en microalbuminurische IADM patiënten werd een lagere excretie van
cortisol en cortison metabolieten in de urine gevonden in vergelijking met de controle
personen. Dit wijst erop dat de reductie van glucocorticoïden tot tetrahydrometabolieten
bij IADM patiënten gestoord is. De urine cortisol/cortison metaboliet ratio was lager in
de IADM groepen. Dit impliceert een verschuiving in het evenwicht tussen cortisol en
cortison ten gunste van cortison. Bij IADM patiënten bleek een inverse relatie tussen het
HbA1c gehalte en de urine cortisol/cortison metaboliet ratio te bestaan. Zowel bij IADM
patiënten als bij de controle personen was de urine cortisol/cortison metaboliet ratio
positief gerelateerd met het via een impedantie techniek gemeten extravasculaire- en
bloedvolume. Deze relatie was in de IADM groepen naar links verschoven. Dit
suggereert dat de 11$HSD activiteit zoals weerspiegelt in de urine cortisol/cortison
metaboliet ratio, een determinant is van volume homeostase. De linksverschuiving in
deze relatie bij de IADM patiënten maakt het echter onwaarschijnlijk dat een veranderde
11$-HSD activiteit verantwoordelijk is voor de toegenomen zoutretentie en volume
expansie. De behandeling van de microalbuminurische IADM patiënten met een ACE-
remmer induceerde een verdere verlaging van de urine cortisol/cortison metaboliet ratio.
Op basis van deze resultaten wordt de hypothese naar voren gebracht dat de gestoorde
reductie van glucocorticoïden en de 11$-HSD gemediëerde verschuiving in het corti-
sol/cortison evenwicht bij IADM patiënten het gevolg kan zijn van een veranderde
cofactor beschikbaarheid ten gevolge van chronische hyperglycaemie. De bevindingen
suggereren ook dat verbeterde metabole controle tot een verandering in het 
evenwicht van cortisol/cortison ten gunste van cortisol kan leiden en aldus de zoutretentie
en volume expansie bij IADM patiënten kan doen toenemen. De stimulatie van 11$-HSDNederlandstalige samenvatting  163
door ACE-remmers suggereert een additioneel werkingsmechanisme waardoor deze
farmaca zoutexcretie kunnen bevorderen.Information on the author  163
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